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Abstract 
Platelets (thrombocytes) mediate clot formation following vessel injury.  Inherited 
thrombocytopenias, characterised by platelet counts below 150 x 109 L-1, have  
variable bleeding severity.  
Whole exome sequencing of two cousins with severe thrombocytopenia  
identified a shared single-codon deletion in ANKRD18A.   ANKRD18A’s function 
is unknown.  We hypothesise that this mutation in ANKRD18A is the aetiology of 
these children’s thrombocytopenia. 
Despite limited patients’ blood, quantitative real-time polymerase chain reaction  
demonstrated reduced ANKRD18A mRNA levels in patient leukocytes compared 
to controls.  Patients’ platelets demonstrated decreased activity when stimulated 
with adenosine diphosphate, collagen related peptide and the synthetic peptide 
SFLLRN, which mimics the N-terminal sequence of protease activated receptors.  
Electron microscopy demonstrated macrothrombocytopenia.  
To assist characterisation studies, a recombinant fragment of ANKRD18A, the 
ankyrin repeat domain, was purified to generate a polyclonal antibody, α-25277. 
Experiments demonstrated possible specificity of α-25277.  Cellular functions of 
ANKRD18A remain unclear, yet the availability of α-25277, once better 
characterised, will be instrumental in demonstrating the potential link between 
ANKRD18A and the observed thrombocytopenia.  Another in-house antibody, α-
21234, may also be effective.  Antibody specificity can be proven by 
immunoblotting lysates of cells, where ANKRD18A is silenced by RNAi.  Should 
both antibodies not be specific, generating a monoclonal antibody is requisite.  
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1. Introduction 
1.1. Platelet physiology  
Human platelets, derived from its precursor, the megakaryocyte (Mk), are discoid 
shaped hematopoetic anucleated cellular fragments that are 1 to 3 µm in 
diameter.  Platelets play important roles in hemostasis, wound healing, 
angiogenesis, inflammation and innate immunity (Machlus and Italiano 2013).  
The platelet’s role as the initial mediator in hemostasis following vascular injury 
was first elucidated by Giulio Bizzozero in 1881 (Coller 2011).  Because of this 
initial discovery of the platelet’s function by Bizzozero and because patients have 
presented with bleeding diatheses secondary to thrombocytopenia (low platelet 
counts), diseases have been identified and ascribed to platelet abnormalities.  In 
healthy individuals the physiological concentration range for platelets is (150 - 
400) × 109 /L.  As the sentinels of vascular integrity, platelets normally circulate in 
the vasculature not interacting with unimpaired inner surfaces of vessels 
(Ruggeri and Mendolicchio 2007).  However, when vessels are injured, a series 
of events occur to form a hemostatic plug: platelet adhesion, platelet aggregation 
and thrombus formation (Figure 1.1).  
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1.1.1. Platelet Activation 
Following vessel injury, endothelial cells are damaged, exposing extracellular 
matrices which allow platelets to quickly adhere to exposed adhesive 
macromolecules [von Willebrand factor (vWF) and collagen] of the extracellular 
matrix.  This critical adhesion step of hemostasis occurs under conditions of high 
shear rates such that this interaction needs to be strengthened using platelet 
receptors GPIb/V/IX, which binds vWF and GPVI, which binds collagen. The 
copy numbers of GPIb/V/IX are estimated at ~50,000 per platelet and the copy 
numbers of GPVI are ~4000-6000 per platelet.  GPVI, which is non-covalently 
coupled with the Fc Receptor γ (FcRγ) chain, when cross-linked by its ligand, 
initiates signalling utilising the immunoreceptor tyrosine-based activation motif 
(ITAM) located in the cytoplasmic region of FcRγ. The ITAMs are tyrosine 
phosphorylated by Src kinases Fyn and Lyn resulting in the recruitment of the 
tyrosine kinase Syk to bind the ITAMS via its SH2 domains, leading to Syk 
activation which initiates the phosphorylation and activation of downstream 
proteins such as the transmembrane adapter linker protein, LAT, (linker for 
activated T-cells) and SLP-76 (Src homology 2 domain-containing leukocyte 
phosphoprotein of 76 kDa).  This signalling cascade is further activated involving 
proteins such as PLCγ2, PKC and the release of Ca+2 stored in the endoplasmic 
reticulum (Stegner, Haining et al. 2014), (Li, Delaney et al. 2010).  Elevated 
levels of Ca+2 lead to the Ca+2 dependent association of GPIIb and GPIIIa 
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resulting in the activated platelet membrane receptor complex, GPIIb/IIIa, which 
binds fibrinogen (Figure 1.2).   
 
 
 
Figure 1.1 - Platelet activation at sites of vascular injury.  ECM, extracellular 
matrix; fg, fibrinogen. (Offermanns 2006) 
 
 
The copy numbers of GPIIb/IIIa per platelet is estimated at 80,000 to 100,000.  
Induction of the signalling cascade also activates GPIa/IIa (copy numbers 
estimated at 2,000-4,000 per platelet), which also binds collagen.  The adhesion 
of platelets to the damaged vessel wall thus brings about the formation of a 
platelet monolayer.  Following adhesion, platelet aggregation occurs, whereby 
more platelets are recruited from the circulation and utilising GPIIb/IIIa mediated 
aggregation, a platelet plug forms.   
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Figure 1.2 - Signalling pathways of 3 major platelet adhesion receptors:  
GPIb-IX-V, GPVI and GPIIb/IIIa (integrin αIIbβ3).  sGC, soluble guanylyl 
cyclase; eNOS, endothelial nitric oxide synthase (Li, Delaney et al. 2010). 
 
 
 
The recruitment of more platelets is brought about by a number of locally 
generated mediators such as thrombin (which is produced on the surface of 
activated platelets), ADP (released from dense bodies of activated platelets) and 
thromboxane A2 (TXA2), which is formed by a series of metabolic reactions:  
   
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platelet membrane phospholipids are converted to arachodonic acid (AA) 
followed by AA conversion to prostaglandin H2 (PGH2), using the COX-1 enzyme; 
and finally PGH2, is converted to TXA2 using thromboxane synthase (Figure 1.5).   
All three mediators activate platelets via G-protein coupled receptors (ADP 
receptors P2Y12 and P2Y1 coupled to G proteins Gi and Gq, respectively; thrombin 
receptors PAR1 and PAR4 coupled to G proteins G13 and Gq and thromboxane 
receptors coupled to G proteins G13 and Gq), which act through their signalling  
pathways to facilitate the formation and release of more of the same mediators.  
This positive-feedback mechanism amplifies the initial adhesion step so that 
there is quick activation and recruitment of platelets to an area of injury to form a 
thrombus (Figure 1.3) (Li, Delaney et al. 2010), (Offermanns 2006). 
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Figure 1.3 - Platelet G protein coupled receptors’ signalling.  PGI2, 
prostacyclin; PI, prostacyclin receptor; 5HT, serotonin;  SFK, Src family kinases;  
PI3K, phosphoinositide 3-kinase;  PDE3, phophodiesterase-3;  NOS, nitric oxide 
synthase;  NO, nitric oxide;  sGC, soluble guanylate cyclase;  PKG, 
phosphokinase G;  MAPK, mitogen-activated protein kinases;  PLA2, 
phospholipase A2;  IP3, inositol triphosphate;  DAG, diacyl glycerol;  
CalDAGGEF1, calcium and DAG-regulated guanine nucleotide exchange factor 
1;  PKC, phosphokinase C;  RIAM, Rap1-GTP-interacting adapter molecule; 
GEF, guanine nucleotide exchange factor;  AC, adenylate cyclase;  TXA2, 
thromboxane;  ADP, adenosine diphosphate  (Li, Delaney et al. 2010).    
 
 
   
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The initial platelet response to activators such as ADP, thromboxane (TxA2) and 
thrombin is a change of its shape from discoid to spherical.  The concentrations 
of agonist required for this shape change are much lower than that needed for 
degranulation and aggregation.  Shape change is a rapid process whereby the 
platelet cytoskeleton is reorganised:  new actin filaments are laid down to form 
the submembranous actin filament network; filopodia are extended; actomyosin-
based contractile processes are stimulated, resulting in the centralisation of 
dense and α granules and finally, the circumferential microtubule coil 
depolymerizes (Offermanns 2006).   
 
Following shape change, platelets accumulate to form multiple platelet/platelet 
interactions (platelet aggregation) to form a platelet plug.  Platelet aggregation is 
carried out by GPIIb/IIIa, which binds various extracellular ligands including 
dimeric fibrinogen and multimeric vWF.  The structures of fibrinogen and vWF 
allow them to cross-bridge platelets to form platelet aggregates (Offermanns 
2006).   
 
Although the signalling cascade of ADP, TxA2 and thrombin has not yet been 
definitely clarified, what is currently known is that signalling following platelet 
activation with these three ligands induces the intracellular domains of GPIIb/IIIa 
to rapidly convert into an active conformation (inside-out signalling), which lead to 
the activation of the ligand binding function of GPIIb/IIIa and the initiation of the 
“outside-in” signalling.  Results of “outside-in” signalling lead to platelet 
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spreading, more granule secretion, stabilisation of platelet adhesion and 
aggregation and clot retraction.  For aggregation to be rapid and efficient, the 
activation of all three of the heterotrimeric G protein coupled receptors, Gq, G13 
and Gi is required (Offermanns 2006), (Li, Delaney et al. 2010).  Clot retraction is 
the decrease in size of a blood clot after several days; its purpose is to bring 
together the edges of the blood vessel wall, which has been damaged.  Clot 
retraction is dependent on the presence of platelets because clot retraction is 
regulated by signalling pathways utilised by receptors found on platelets: the 
thrombin receptor and GPIIb/IIIa (Kasahara, Kaneda et al. 2013).  
 
To amplify platelet activation, platelets need to secrete its α granule and dense 
body contents as well as lysosomal contents, which serve to act on the vessel 
wall as well as other circulating hematopoietic cells.  Contents of α granules 
include growth factors, chemokines, adhesive molecules and coagulation factors.  
Dense body granules include ATP, ADP and serotonin (Offermanns 2006). 
 
A physiological process that complements as well as influences platelet 
activation is the activation of the coagulation cascade (Figure 1.4).  Secretion of 
platelet α-granules contributes to the pro-coagulant activity of platelets by 
providing additional coagulant factors such as Factor V, VIII and I (fibrinogen).  
“Strong” platelet activation (prolonged increases in intracellular [Ca++] leads to 
phosphatidylserine exposure on the outer membrane of platelets (Offermanns 
2006).  Phosphatidyserine provides binding sites for plasma protein complexes 
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such as factor VIIIa-IXa (tenase) and factor Va–Xa (prothrombinase), which are 
needed to convert prothrombin to thrombin (factor IIa) (Zwaal, Comfurius et al. 
2004).  The coagulation cascade assists in stabilising the clot since thrombin 
converts soluble fibrinogen to insoluble fibrin strands, which are cross-linked by 
factor XIII to form a stabilised blood clot (Undas and Ariens 2011).  
 
 
Figure 1.4 - Schematic diagram of the coagulation cascade (Illustration from 
epomedicine.com) 
 
Dissolution of blot clots to maintain a patent vasculature is dependent on 
fibrinolysis (Figure 1.5).  Under normal physiological conditions, coagulation and 
fibrinolysis are finely regulated.  The major fibrinolytic protease is plasmin, which 
is formed by the conversion of the circulating plasma zymogen, plasminogen 
(PLG), by both activators: tPA (tissue PLG activator, produced by endothelial 
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cells) and uPA (urokinase, produced by renal epithelial cells, 
monocytes/macrophages and endothelial cells).  It appears that tPA is the major 
intravascular activator of PLG.  There are currently no human examples of 
complete deficiencies of tPA or/and uPA.  However, evaluations of tPA and uPA 
deficient (single and doubly deficient) mice indicate that both are not required for 
normal fertility and embryologic development but are vital for clot lysis in the adult 
mice (Cesarman-Maus and Hajjar 2005, Rijken and Lijnen 2009).   
 
 
Figure 1.5 - Simplified schematic diagram of the fibrinolytic system.  t-PA, 
tissue plasminogen activator; u-PA, urokinase plasminogen activator; PAI-1, 
plasminogen activator inhibitor-1; α2-AP, α2-antiplasmin; TAF1, thrombin-
activatable fibrinolysis inhibitor.  Blue denotes stimulation and red denotes 
inhibition (Rijken and Lijnen 2009). 
 
Utilising a positive feedback mechanism, plasmin cleaves both tPA and uPA, 
transforming them from single chains to active two-chain polypeptides.  Plamin’s 
major substrate, fibrin, regulates its own degradation by binding both PLG and 
tPA on its surface to localise and enhance plasmin generation.  tPA is dependent 
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on the presence of fibrin to increase its efficiency in generating plasmin.  Once 
plasmin is formed, it is rapidly inhibited by its major inhibitor, α2-plasmin inhibitor 
and its lesser inhibitor, α2-macroglobulin, unless it remains bound to fibrin or to its 
cell surface receptors (Cesarman-Maus and Hajjar 2005).    
 
Once it’s formed, plasmin cleaves fibrin to generate soluble degradation 
products.  It also exposes carboxy-terminal lysine residues on fibrin, which 
provide further binding sites for tPA and PLG, leading to enhanced plasmin 
generation and fibrin removal.  Binding of the lysine residues can be blocked by 
lysine analogues as well as by TAF1 (thrombin-activatable fibrinolysis inhibitor).   
TAF1 is activated by thrombin to remove carboxy-terminal lysine residues, thus 
decreasing plasmin generation to stabilise a fibrin thrombin and providing a 
counter regulatory mechanism to fibrinolysis.  Fibrin dissolution is also regulated 
by PLG inhibitors such as PAI-1 (PLG activator inhibitor-1) and plasmin inhibitors 
such as α2-PI (α2-plasmin inhibitor).  Plasmin when bound to fibrin has its lysine 
binding sites occupied and is protected from α2-PI.  TAFI, however, can decrease 
this protection by deleting the lysine residues on fibrin to prevent plasmin binding 
(Rijken and Lijnen 2009).  
 
Plasmin degradation of fibrin produces a number of molecular products.  When 
fibrin, cross-linked by factor XIII, is degraded by plasmin, fragments called D-
dimers are released.  Other fibrin breakdown products are also formed which 
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may inhibit platelet function, potentiate bradykinin’s hypotensive effects and 
affect chemotaxis and immune modulation (Hajjar 2003).  
1.1.2. Platelet inactivation 
Platelet activation is inhibited by the vasoactive hormones nitric oxide (NO) 
(Palmer, Ashton et al. 1988) and prostacyclin (PGI2) (Moncada, Gryglewski et al. 
1976), both of which are produced by the endothelium.  The endothelium covers 
the inner surface of the vasculature, serving not only as a structural barrier 
against circulating elements in the blood, but is also an endocrine organ, 
releasing various hormones such as NO and PGI2, which act on the circulatory 
system.  In healthy blood vessels, the endothelium constitutively produces the 
enzymes nitric oxide synthase (NOSIII) and cyclo-oxygenase (COX-1), which 
catalyse the formation of NO and PGI2.  Both NO and PGI2 function to vasodilate 
vessels and inhibit platelet aggregation.  On blood vessels, the actions of NO and 
PGI2 are additive whereas in platelets, they are synergistic.  NO mediates its 
actions mainly by activating intracellular guanylyl cyclase, leading to the 
formation of cGMP.  Prostacyclin, in contrast, mediates its actions via cell surface 
receptors (IP) and/or intracellular receptors peroxisome proliferator-activated 
receptors (PPAR)β.  In diseased (i.e. occluded) vessels, vascular smooth muscle 
cells produce inducible forms of NOSII and COX-2, which produce substantial 
amounts of NO, PGI2 and prostaglandin E2 (Mitchell, Ali et al. 2008).  
Nitric oxide synthesis arises from the catalysis of L-arginine, a non-essential 
amino acid, and oxygen, using the enzyme NOSIII.  Byproducts of the reaction 
are L-Citrulline and H2O.  NOS exists as three isoforms, NOSI, NOSII and NOSIII 
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(Fedorov, Hartmann et al. 2003).  It is NOSIII which is mainly found in endothelial 
cells, where it is a membrane-bound, constitutively expressed homodimer 
requiring calcium to activate it (Forstermann, Schmidt et al. 1991).  Calcium is 
required for calmodulin binding, which together associate with NOSIII, to regulate 
its activity.  Other modifications of NOSIII include post-translational lipid 
modifications, protein-protein interactions, and protein phosphorylation (Sessa 
2004).  Once synthesised in the endothelial cell, NO diffuses out of the cell via 
the luminal side to affect platelet and other vascular cellular functions and via the 
abluminal side to affect smooth muscle function.  For platelets, NO inhibits 
adhesion and aggregation; for smooth muscle cells, NO inhibits vasoconstriction 
and vascular remodelling and smooth muscle cell proliferation.  The mechanism 
by which platelets and smooth muscle cells are principally affected is through the   
activation of cytosolic soluble guanylyl cyclase by NO, which leads to an increase 
in intracellular cGMP, which activates protein kinase G, resulting in reduced 
intracellular calcium and reduction in cell activation (Hanafy, Krumenacker et al. 
2001).  Prostacyclin synthesis initiates at the endothelial membrane where 
phospholipase A2 (PLA2) releases arachadonic acid (AA) from membrane-bound 
lipids with the assistance of calcium (Mitchell and Warner 1999) (Figure 1.6).  
AA, once liberated, can be metabolised further with cyclo-oxygenase (COX), 
which exists as two isoforms, COX-1 and COX-2.  COX-1 is the major isoform in 
healthy endothelial cells and is constitutively expressed (Mitchell, Lucas et al. 
2006).  The second step in prostacyclin synthesis involves two enzymatic 
reactions utilising cyclo-oxygenase: an oxygenase step converting AA to 
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prostaglandin G2 (PGG2) and a peroxidase step converting PGG2 to 
prostaglandin H2 (PGH2).  PGH2 serves as a substrate for a number of 
subsequent prostaglandin synthase enzymes, including prostacyclin synthetase 
(PGIS) and thromboxane synthase.  In endothelial cell, COX-1 and PGIS 
predominate, resulting in prostacyclin being the major product made.  However, 
in platelets, COX-1 also predominates, but thromboxane synthase is the major 
prostaglandin synthase enzyme present, resulting in thromboxane being the 
predominant product made (Needleman, Moncada et al. 1976).  
 
 
Figure 1.6 - Schematic diagram of eicosanoid (prostaglandins and related 
compounds) synthesis (Illustration from www.tankonyvtar.hu). 
 
Prostacyclin binds to two receptor types: the cell surface prostacyclin (IP) 
receptor and the nuclear receptor PPARβ (peroxisome proliferator-activated       
receptor β).  IP receptors, thought to be the predominant surface receptors for 
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prostacyclins, are seven trans-membrane spanning G-protein coupled receptors, 
which are ubiquitous throughout the body but are especially enriched on platelets 
and smooth muscle cells (Stitham, Arehart et al. 2007), (Mitchell, Ali et al. 2008).  
Activation of IP receptors by prostacyclin leads to G-protein mediated activation 
of adenylate cyclase, leading to formation of cAMP, which phosphorylate PKA 
(Figure 1.3).  Phosphorylated PKA leads to a decrease in calcium in cells such 
as platelets and smooth muscle cells (Schwarz, Walter et al. 2001). 
 
It is still unclear how PPARβ plays a role in preventing platelet aggregation since 
PPAR receptors affect function at the level of gene transcription and platelets 
have no nuclei.  Studies have indicated that specific PPARβ agonists inhibit 
platelet aggregation independent of IP receptors; and, PPARβ agonists can also 
act in synergy with IP receptor agonists to inhibit platelet aggregation, suggesting 
that IP and PPARβ receptors have separate but complementary signalling 
pathways (Ali, Davidson et al. 2006). 
 
In conclusion, following vessel injury, exposure of extracellular matrices allows 
platelet receptors to bind adhesive macromolecules collagen, (vWF and 
fibrinogen), thus laying down the initial monolayer of platelets.  Further activation 
of platelets from local mediators such as thrombin, ADP and thromboxane lead to 
platelet aggregation and clot formation, which is stabilised by certain members of 
of the coagulation cascade (I, V, VIII, and XIII).   To counteract the activation of 
platelets are the vasoactive hormones NO and prostacyclin, which are co-
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released by the endothelium, acting in synergy to inhibit platelet aggregation and 
vasoconstriction of the vasculature.  They mediate these effects via the second 
messengers cGMP and cAMP respectively (Mitchell, Ali et al. 2008).  
 
                  
1.2. DNA Sequencing 
Modern day DNA sequencing, termed dideoxy DNA sequencing, is based on the 
sequencing method developed by Dr. Fred Sanger in the 1970’s.  This enzymatic 
sequencing method depends on random inhibition of DNA chain elongation.   
The DNA to be sequenced needs to be single-stranded thus serving as a 
template for the construction of a new complementary DNA strand in vitro using a 
DNA polymerase.  The newly synthesized DNA strands are of various lengths, 
which are then separated by size on a slab polyacrylamide gel.   The sequencing 
reaction occurs via four parallel reactions, each of which contains the four dNTPs 
(dATP, dCTP, dGTP, and dTTP) plus a small amount of one of the four 
analogous dideoxynucleotides (ddNTPs), which are a base-specific chain 
terminators.  Structurally, ddNTPs are nearly identical to dNTPs except that they 
lack a hydroxyl group at the 3’ carbon position (Figure 1.7A).  Dideoxynucleotides  
can be incorporated into a DNA chain, but cannot join in the phosphodiester 
bonding at its 3’ carbon with other dNTPs because its 3’ carbon lacks a hydroxyl 
group.  Therefore, once a ddNTP has been added to a DNA chain, it causes the 
termination of DNA chain elongation (Figure 1.7B).   In order to visualise the 
elongated DNA chains, one of the four dNTPs or the primer is labelled with 35S or 
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32P, thus labelling the DNA.   The dNTPs’ concentrations are in excess compared 
to the concentrations of the ddNTPs, creating a competition between a specific 
ddNTP and its dNTP counterpart for inclusion in the lengthening DNA chain.   
 
 
A.  
 
B. 
 
 
Figure 1.7 - Nucleic acid structures and DNA chain elongation.  (A) 
Molecular structures of dideoxyribonucleotide and deoxyribonucleotide  (B) 
Example of DNA chain elongation. (Illustrations from www.ubooks.pub– panel A, 
and binf.snipcademy.com– panel B).    
 
 
 
DNA chain termination will occur randomly at any one of the four nucleotide 
bases.  Since the sequencing sample is a population of identical DNA molecules, 
each of the four base-specific reactions will be a collection of labelled DNA 
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fragments of different lengths.  In each base-specific reaction, DNA fragments 
will have a common 5’ end and variable 3’ ends because of the random insertion 
of ddNTPs.  Each base-specific reaction will be loaded onto a high urea 
concentration denaturing polyacrylamide gel to size-fractionate the DNA 
fragments.  Even fragments differing by only one nucleotide can be separated.  
Once electrophoresis is completed, the gel is dried and exposed to X-ray film to 
allow visualisation of the DNA fragments.  DNA sequence is determined by using 
the naked eye to read from the shortest fragment (bottom of film) to the longest 
fragment (top of film) (Strachan 2011).  
 
To improve the efficiency of dideoxy DNA sequencing, automated DNA 
sequencing machines, which sequence fluorescently labelled DNA, were 
introduced in the 1980’s.  Four different fluorescent dyes, each with a different 
emission wavelength, were used; thus, permitting all four reactions to be loaded 
into a single sample well on a polyacrylamide gel.  During the running of the gel, 
DNA fragments passed by a laser, which excited the fluorescent dyes and a 
monitor detected and recorded the fluorescence signals.  This generated an 
intensity profile for each of the four different fluorophores as well as electronically 
storing the information.   Automated sequencing was subsequently made more 
efficient by introducing capillary sequencing instruments in 1999.  For these 
instruments, rather than having DNA samples on a slab gel, samples were 
instead injected into long and very thin (0.1 mm diameter) capillary tubes 
containing polyacrylamide gel (Strachan 2011).  The use of capillary tubes 
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eliminated many rate-limiting steps in the sequencing protocol.  Also, run times 
could be accelerated because heat is more rapidly dissipated using capillary 
tubes vs. glass plates which were used for slab gels.  Each capillary sequencing 
instrument was able to detect 500-600 bases from each of 96 reactions in about 
10 hours, producing around 115 kbp per day (24 hour unattended operation) 
(Mardis 2011).  These instruments ultimately became the principal data-
generating workhorses used for the human and mouse genome projects in 
2001/2002 (Mardis 2013).   
1.2.1. Next Generation Sequencing  
The automated Sanger method of DNA sequencing is considered a “first-
generation” technology, and subsequent newer methods of sequencing, arriving 
in 2005, came to be referred to as “next-generation sequencing” (NGS) or 
“massively parallel” sequencing (Metzker 2010, Mardis 2011).  The major 
advantages offered by NGS are the enormous amount of data which can be 
generated at a much cheaper cost (Metzker 2010).  Unlike the past, where there 
was only one company which manufactured the capillary sequencing instruments 
(Applied Biosystems), there are now many commercially available NGS 
instruments, resulting in fierce competition among the manufactures to provide 
better sequencing platforms.  These platforms aim to increase the amount of 
sequence output per run, to increase read lengths (the number of nucleotides per 
sequence read), to improve base-calling accuracy and to decrease costs (Mardis 
2011) (Figure 1.8).  
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Figure 1.8 - Changes in the various sequencing instrument read outputs, 
timeline of newly introduced sequencing instruments and major 
sequencing projects over the past decade.  Top, data output per run plotted 
on logarithmic scale.  Middle, introduction year of various NGS sequencing 
platforms.  Bottom, timeline of the major sequencing projects which have been 
completed. (Mardis 2011) 
 
 
Table 1.1 - Comparison of NGS platforms (Mardis 2011) 
 
increase the amount of sequence output per run, to increase read lengths
(the number of nucleotides per sequence read), to lower costs, and to
improve base-calling accuracy for their instruments. Much like a buyer
of a new car, genome centres have taken each new ‘massively parallel’
(see below) instrument for a ‘test drive’ to explore their performance and
to understand their strengths and weaknesses in terms of data quality,
associated production processes, and actual cost to operate. (This last
includes personnel, consumables, additional instrumentation to operate,
amortized equipment rate, and informatics infrastructure.) Their collective
efforts to vet each new technology and report their findings by scientific
presentations, press releases, word of mouth, and peer-reviewed manu-
scripts have effectively fuelled the rivalry and competition among the
instrument vendors and have resulted, not surprisingly, in both winners
and losers in this commercial sector.
This so-called ‘massively parallel’ sequencing technology differs sig-
nificantly from Sanger capillary sequencing. Although each instrument
is distinctly different in its specifics, as detailed in several reviews10,11 (see
also Table 1), all massively parallel devices share certain attributes, as
follows. First, the initial preparatory steps are fewer and simpler to
perform than for Sanger sequencing. Instead of a bacterial cloning step
followed by DNA isolation, massively parallel sequencing begins with
the production of a library formed by ligating platform-specific syn-
thetic DNAs (adapters) onto the ends of the fragment population to
be sequenced. Second, all platforms require the library fragments to be
amplified on a solid surface (either a glass slide or a microbead) by a
polymerase-mediated reaction that produces many copies of each single
library fragment. Amplification is needed so that the ensuing sequen-
cing reactions produce sufficient signal for detection by the instrument’s
optical system. However, this step also provides a source of sequencing
error that is perpetuated through the downstream processes, because
polymerases are never 100% accurate. Third, these instruments perform
sequencing reactions as an orchestrated series of repeating steps that are
performed and detected automatically. The specifics of the DNA
sequencing reaction are different for each platform, emphasizing
the amazing range of innovation in chemistry, molecular biology and
engineering required to produce sequence information from hundreds
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Although each of the NGS instruments is different in certain specific ways (Table 
1.1), they also share certain aspects, which are characteristic of massively 
parallel sequencing, making it different from Sanger sequencing.  Firstly, for 
NGS, there are fewer initial DNA preparatory steps.  Rather than performing a 
bacterial cloning step followed by DNA purification, which is required for Sanger 
sequencing, for NGS, DNA is fragmented and a library is produced by ligating 
specific synthetic DNAs (adapters) to the ends of the DNA fragments to be 
sequenced.  Secondly, the library fragments are amplified on a solid surface 
(glass slide or microbead) by a DNA polymerase reaction.  Amplification by PCR, 
forming template clusters, is required so that subsequent sequencing reactions 
will produce enough signal for detection by the optical system.  However, the 
downside to this step is that it introduces sequencing errors, which will be carried 
to the analysis step.  Immobilisation of the template onto a solid surface allows 
the template to be spatially separated so that millions of sequencing reactions 
can be performed simultaneously (Metzker 2010).  Thirdly, the sequencing 
reactions are a series of repeating steps that are performed and detected 
automatically.  Each different NGS instrument has its own DNA sequencing 
reaction (Table 1.1).  Regardless of the specifics, these sequencing reactions are 
notable for the fact that they occur in a nucleotide–by-nucleotide stepwise 
fashion rather than by separation and detection of previously produced 
sequencing reaction products, as seen in Sanger sequencing.  Therefore, in 
NGS, the sequencing instruments perform sequencing and detection 
simultaneously rather than as distinct processes.  Also, during each sequencing 
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run, thousands to millions of fragments are sequenced, creating enormous data 
sets.  Fourthly, for NGS, sequence information can be obtained from both ends 
of the DNA fragments being sequenced.  One can either sequence both ends of 
linear fragments (paired end sequencing) or from both ends of previously 
circularised fragments (mate pair sequencing) (Figure 1.9).  Paired end 
sequencing libraries, requiring little DNA, consist of DNA fragments less than 1 
kb, are not complicated to make, making it the method most often used to 
prepare the template for human genome sequencing.  For paired-end 
sequencing, the linear fragment has adapter sequences with different priming 
sites for each adapter.  Sequence begins from an adapter priming site of a 
fragment followed by the sequencing from the opposite adapter priming site.  
These sequences are then paired during the alignment step of data analysis.  
Having two sequences of the same region provides more certainty of placement 
than having only one end read of the same length.  Mate pair libraries, made 
from DNA fragments greater than 1 kb, require much more DNA because of the 
low yield of circularisation of large DNA molecules.  The library for mate-pair 
sequencing is constructed by circularising a fragment around a single adapter so 
that both fragment ends ligate to the adapter ends (Figure 1.9).  The fragment is 
then linearized by type IIS endonuclease digestion or by nick translation to 
produce a linear fragment with both ends of the original fragment and a central 
adapter.  The central adapter is biotinylated, allowing for capture and purification 
using streptavidin magnetic beads.  The linear fragments again have unique 
adapters ligated to their ends and sequencing begins from one adapter site 
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followed by sequencing from the adapter of the other pair.  Ultimately, the 
resulting sequences are longer than the sequences from the paired-end 
sequencing.  Often, both sequencing approaches are used together to sequence 
genomes with difficult sequences (repetitive regions) or when attempting de novo 
sequencing.  Mate-pair sequences provide longer reads (up to 20 kb is possible) 
while paired-end sequences allow, through its shorter sequences, the assembly 
of difficult to sequence regions; paired-end sequences provide additional detail to 
the sequencing scaffold provided by the mate-pair reads.  Finally, read lengths 
generated from NGS are much shorter than those generated from Sanger 
sequencing.   Unfortunately, these short reads will also contain sequencing 
errors, which is indistinguishable from a variant (Sims, Sudbery et al. 2014).  For 
Sanger sequencing, read length is determined by a combination of gel-related 
factors:  percentage of the polyacrylamide gel, the length and thickness of the 
gel, time spent running the gel and the electrophoresis conditions.      In NGS, 
read length is a function of the signal to noise ratio.  Each NGS instrument has its 
own source of noise, which creates certain types of sequencing errors; this 
interplay between noise and error types gives rise to the term “error model,” 
which is specific to each instrument (Table 1.1).  Noise adds up during the 
sequencing process and ultimately leads to decreased read length because the 
signal from nucleotide base incorporation is outcompeted by incorrect signals 
resulting from noise such as incorrect or out-of-phase incorporation events, 
residual signals from prior reactions or reactants and other sources of noise 
(Mardis 2013).  To determine what the read lengths and error types are for an 
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instrument, one needs to sequence a reference set of genes or a genome and 
compare the results with a high quality reference gene set or genome.   Doing 
this will allow one to determine the different types of errors (substitution, insertion 
or deletion errors) as well as the error model (random vs. systemic errors).   
Overall, the more a sequence is examined following alignment with a high-quality 
reference sequence, the better the chance of identifying the error models and 
coverage biases and their contributing sources (Mardis 2013).  Difficulties raised 
by short reads arise during the analysis step.  Although short reads can be 
assembled like Sanger sequencing reads (which is based on shared sequences), 
the fact that there are fewer numbers of shared sequences due to the shorter 
read lengths makes it difficult to assemble the overall length of contiguous 
sequences.  This limitation is compounded when the genome to be sequenced is 
large and complex.  Thus, because high quality reference genomes exist for 
many organisms, using NGS reads for sequence read alignment is a better 
approach for data analysis (Mardis 2013).   Specific algorithms have been 
devised for short read alignments and there is a score- based metric that 
indicates a sequence’s best fit in the genome.  Sequences with mostly repetitive 
content score lowest because of the uncertainty of their validity (Li, Ruan et al. 
2008).   To overcome error problems, the number of sequencing reads (depth of 
coverage) can be increased (Sims, Sudbery et al. 2014).  Also, more accurate 
reads can be obtained by sequencing from both ends of each library fragment 
using paired-end sequencing and/or mate-pair sequencing (as outlined above) 
(Metzker 2010, Mardis 2013). 
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In conclusion, NGS has revolutionised DNA sequencing by massively increasing 
data production while significantly lowering the cost of sequencing; however, 
there are drawbacks to NGS.  These include the presence of polymerase errors 
during library construction early on in the sequencing process, resulting in 
nucleotide bases wrongly appearing as variants in the sequenced genome; the 
occurrence of preferential amplification of certain fragments in the library 
population, making them appear to be more abundant relative to other fragments; 
and finally, the dilution of DNA modifications, such as different types of 
methylation, during the amplification process.  Also, because of the massive 
amount of data generated by NGS, burdens are placed on research centres for 
the storage of the sequences.  And, there are data analysis challenges as well, 
due to the increased quantity of data, the extreme short reads and the different 
error profiles of each read type (Mardis 2011).     
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Figure 1.9 - Comparison of fragment library construction for (a) mate-end 
vs. (b) mate-pair sequencing.  “A” signifies adaptor and “SP” signifies specific 
primer (Mardis 2013). 
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In order to overcome some of the above shortcomings of NGS, instrument 
detectors were subsequently devised which could, as accurately as possible, 
sense very low levels of signal produced from unamplified individual DNA 
molecules as they are being sequenced.  This form of sequencing, termed 
single-molecule sequencing, has been labelled “third-generation” sequencing.  
This newest form of sequencing produces sequences faster than NGS (20,000 
times faster) and at lower costs as well.   Read lengths are quite long (>1000 bp) 
but there is an overall higher error rate.  An example of this platform is the 
instrument by Pacific Biosciences, Inc., which involves sequencing-by-synthesis 
whereby synthesis occurs in real-time, thus making the sequencing reactions 
extremely fast.  This platform has also been shown to successfully sequence as 
well as detect specific methyl residues known to be on DNA residues serving a 
regulatory role.  The error model for single-molecule sequencing consist mainly 
of insertion and deletion errors plus a small percentage of substitution errors.  To 
offset the high error rate seen with single-molecule sequencing of an individual 
read, multiple reads of the same molecule are required so that there is an overall 
higher consensus read accuracy for the molecule (Mardis 2013).   
1.2.2. Exome Sequencing 
Despite the huge technological progress that has been made in DNA 
sequencing, it is still too expensive to sequence a whole genome to enough 
depth to identify variants that affect phenotypic expression (Warr, Robert et al. 
2015).  Most read lengths from NGS are short and contain errors, which look no 
different from a variant.  To overcome this conundrum, the number of sequencing 
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reads can be increased: a read containing a 1% error rate when sequenced 
identically 8 times, will result in a strongly supported identification of a variant 
associated with an error rate of 10-16 (Schatz, Delcher et al. 2010).  Thus, 
increased depth (the average number of times a nucleotide is sequenced in a 
collection of random raw sequences) of short reads can be used to overcome the 
inadequacies of NGS but incurs greater costs secondary to increased number of 
sequencing runs, to increased number of analytical inspections of cumbersome 
captured image files, and for the storage of the large number of sequences 
(Mamanova, Coffey et al. 2010, Sims, Sudbery et al. 2014).   
 
One method to bypass the continued costliness of NGS is to perform targeted 
sequencing.  This “target-enrichment” strategy is based on the capture of specific 
regions of the genome from a DNA sample followed by massively parallel 
sequencing of the targets.  Exome sequencing targets all the exons of the protein 
coding genes in the genome (encompassing ~1% of the human genome), and 
may also target functional non-protein coding elements such as microRNA, long 
intergenic noncoding RNA and other RNA molecules as well as specific 
candidate loci (Warr, Robert et al. 2015); (Mamanova, Coffey et al. 2010).  
Exome sequencing has proven to be an efficient way to identify variants and 
genes responsible for Mendelian disorders; it is faster than conventional 
approaches and it can surplanting conventional approaches which have failed to 
identify the culprit gene (Bamshad, Ng et al. 2011).  Traditional methods of 
identifying rare Mendelian disorders can be hampered by having only small 
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number of cases or families to study, reduced penetrance (the proportion of 
persons with a specific phenotype among people with the genotype), locus 
heterogeneity (having phenotypically similar characteristics despite having 
mutations at different genetic loci) and reduced reproductive fitness.  However, 
there are drawbacks with exome sequencing as well.  One major concern is that 
it is still unclear exactly which sequences in the human genome are protein 
coding.  Initial exome sequencing efforts used as its targeted DNA, genes that 
were identified by the Consensus Coding Sequence (CCDS) Project, a highly 
reputable compilation, although not complete.  Currently, all commercial kits 
target at a minimum, genes identified in the RefSeq collection (an open-access 
compilation of annotated and curated DNA and RNA nucleotide sequences) and 
even hypothetical proteins as well.  Other limitations of exome sequencing 
include capture probe efficiency – some sequences are not even targeted by the 
probes offered; sequencing of all templates are not equally efficient thus 
sequences can not all be aligned to the reference genome, and it is still unclear 
whether other sequences such as promoters, microRNA and ultra-conserved 
elements (genome subsequences, which seem to have high levels of sequence 
constraint) should be sequenced as well (Bamshad, Ng et al. 2011).        
    
There are mainly two different methods of exome capture: solution-based and 
array-based.  The initial preparation steps for solution-based and array-based 
whole exome sequencing (WES) are similar: the DNA is fragmented and 
oligonucleotide probes (baits) are used to hybridize to selective target areas of 
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the genome.  In solution-based methods, use of biotinylated oligonucleotide 
probes to selectively bind targeted regions of the genome followed by “pull-down” 
with streptavidin metal beads is used.  Non-targetted regions of the genome, 
which do not bind to the probes, are washed away and targeted regions bound to 
the metal beads are amplified, enriching the sample for the targeted region of the 
genome (Warr, Robert et al. 2015). For the array-based method, oligonucleotide 
probes, rather than being biotinylated are bound to a high-density microarray.  
The array-based method was the original method used in WES but has since 
been replaced by the solution-based method.  Benefits of the solution-based 
method include less DNA needed for the process, the number of probes it can 
use is not limited by what can be accommodated on the microarray, and no 
additional equipment or time is required to process the microarray (Warr, Robert 
et al. 2015). 
 
Similar to NGS platforms, exome capture platforms evolve quickly.  Basically, 
each version differs mainly in the region of the genome which it targets; however, 
84% of the targeted region still overlap (Chilamakuri, Lorenz et al. 2014).  There 
are three major companies that provide exome capture platforms: NimbleGen, 
Agilent, and Illumina (Table 1.2).  We chose to use the Agilent’s SureSelect 
Human All Exon Kit, which of the three kits, is the only one to use RNA probes; 
the probes used are longer than those found in other kits (114-126 bp) and the 
targeted sequences are adjacent to one another rather than overlapping (Clark, 
Chen et al. 2011).  Advantages of the Agilent exome capture kits are that it is 
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good at identifying insertions and deletion (indels) because longer probes allow 
for larger mismatches (Clark, Chen et al. 2011, Bodi, Perera et al. 2013, 
Chilamakuri, Lorenz et al. 2014); it produces fewer duplicate reads when 
compared to NimbleGen (Sulonen, Ellonen et al. 2011) and it has a greater 
alignment rate and fewer PCR duplicates than NimbleGen (Bodi, Perera et al. 
2013).  Disadvantages with the Agilent kit include fewer high-quality reads 
(Sulonen, Ellonen et al. 2011) and less uniform coverage (Bodi, Perera et al. 
2013).  However, the Agilent kit can detect the most SNPs and small indels with 
more depth of coverage (Clark, Chen et al. 2011).  Overall, all three kits have 
high levels of targeting efficiency and cover a very large part of what we know of 
the exome.  Which kit to chose for an experiment depends on the question one 
wishes to answer because the kits differ somewhat in their target choice, bait 
(oligonucleotide) lengths, bait density and molecule used for capture (Warr, 
Robert et al. 2015).   
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Table 1.2 – Summary of differences between various exome sequencing 
platforms (Warr, Robert et al. 2015). 
 
Clinical application of WES was first successfully used to identify a rare disease 
in a child presenting with severe symptoms suggestive of inflammatory bowel 
disease; however, definite diagnosis could not be made despite comprehensive 
clinical evaluation.  Following WES, analysis identified a novel hemizygous 
missense mutation in the gene, X-linked inhibitor of apoptosis, whereby a 
cysteine residue had been replaced with a tyrosine.  Further functional assays 
confirmed deficiency of the protein, X-linked inhibitor of apoptosis, and the 
diagnosis of X-linked lymphoproliferative disease 2 was made, although the child 
exhibited inflammatory bowel-like symptoms, which had never been associated 
with X-linked lymphoproliferative disease 2.  Based on this diagnosis, the child 
received an allogenic bone marrow transplant because the recommended 
treatment for X-linked lymphoproliferative disease 2 is a bone marrow transplant 
NimbleGen’s SeqCap EZ Exome Library has the greatest bait den-
sity of any of the platforms and uses short (552105 bp), overlapping
baits to cover the target region (Clark et al. 2011). This approach has
been found to be an efﬁcient method for enrichment with the least
amount of sequencing needed to cover the target region and sensi-
tively detect variants (Clark et al. 2011) and also has a high level of
speciﬁcity, showing fewer off-target reads than other platforms (Clark
et al. 2011; Sulonen et al. 2011). Importantly, this bait design has been
found to show greater genotype sensitivity and more uniformity of
coverage in difﬁcult to sequence regions, such as areas of high GC
content, than the other platforms (Asan et al. 2011; Sulonen et al.
2011; Bodi et al. 2013).
Agilent’s SureSelect Human All Exon Kit is the only platform to
use RNA probes, with the other platforms opting for DNA probes.
The baits used are longer than those used in NimbleGen’s platform
(1142126 bp) and the corresponding target sequences are adjacent to
one another rather than overlapping (Clark et al. 2011). This design
has been found to be good at identifying insertions and deletions
(indels), because longer baits can tolerate larger mismatches (Clark
et al. 2011; Bodi et al. 2013; Chilamakuri et al. 2014); it has been
suggested that this also may reduce reference allele bias at hetero-
zygous sites compared with other bait designs; however, in practice
the allele bias has been similar to other platforms (Asan et al. 2011;
Hedges et al. 2011). The platform has been found to produce fewer
duplicate reads than NimbleGen but also fewer high-quality reads
(Sulonen et al. 2011). Bodi et al. (2013) found that Agilent had
a greater alignment rate and fewer PCR duplicates than NimbleGen
but also had less uniform coverage.
Illumina’s TruSeq Exome Enrichment Kit uses 95-bp probes that
leave small gaps in the target region, with paired end reads extending
outside the bait sequence during sequencing to ﬁll the gap. This design
has been found to have a high percentage of off-target enrichment
(Clark et al. 2011), which reduces its target efﬁciency compared with
the other platforms. This kit detects more single-nucleotide variants in
the untranslated regions (UTRs) than the other platforms (Clark et al.
2011), although comparisons of performance with NimbleGen and
Agilent’s “+UTR” kits have yet to be performed. Following ﬁltering
for duplicates, multiple mappers, improper pairs, and off-target reads,
Chilamakuri et al. (2014) found that this platform retained fewer reads
(54.8%) than NimbleGen (66%) or Agilent (71.7%). At high read
counts (.50M), this platform outperformed Agilent’s SureSelect in
downstream identiﬁcation of indels (Clark et l. 2011).
Illumina’s Nextera Rapid Capture Exome and Expanded Exome
kits are similar to the TruSeq kit in their probe design. They differ
from the other kits in that they use transposomes t fragment the
genomic DNA, whereas the other platforms use ultrasonication. These
kits have not been extensively compared with the other platforms,
with only Chilamakuri et al. (2014) having included Nextera in a com-
parison study. At the time of the study there was only one Nextera kit,
which was the Expanded Exome version: the kit with the larger target
region of the two. The Expanded Exome kit shares a target region with
the TruSeq kit, which includes UTRs and miRNAs. Chilamakuri et al.
(2014) found that the Nextera kit had increased coverage of high GC
content areas as the result of altered bias in the transposome technol-
ogy used during fragmentation, decreasing its overall uniformity;
however, recent changes to the protocol in the new versions may have
improved this. They also found that out of all platforms tested, the
Nextera platform retained the fewest reads after ﬁltering for dupli-
cates, multiple mappers, improper pairs, and off-target reads, at
40.1%.
Chilamakuri et al. (2014) compared the target regions of the hu-
man kits from three providers (NimbleGen SeqCap EZ v3.0 – 64.1Mb;
Agilent SureSelect V4 – 51.1Mb; and Illumina TruSeq and Illumina
Nextera original version and protocol – 62.08 Mb). Despite the fact
that all of the platforms are targeting the human exome, there is
surprisingly little overlap between the three designs, with just 26.2 Mb
covered by all three target regions. NimbleGen’s and Agilent’s cov-
erage are more similar to one another than either are to Illumina’s;
n Table 1 Summary of the differences between the solution-based, exome-sequencing platforms
NimbleGen’s SeqCap
EZ Exome Library
Agilent’s Sure Select
Human All Exon Kit
Illumina’s TruSeq
Exome Enrichment Kit
Illumina’s Nextera Rapid
Capture Exome Kit
Probe size, bpa 552105 1142126 95 95
Probe type DNA RNA DNA DNA
Coverage strategy High-density, overlapping
probes
Adjacent probes Gaps between probes Gaps between probes
Fragmentation method Ultrasonication Ultrasonication Ultrasonication Transposomes
Target region size
(human), Mbb
64 50 62 62
Reads remaining
after ﬁlteringc
66% 71.7% 54.8% 40.1%
Major strengths (i) High sensitivity and
speciﬁcity
(i) Better coverage
of indels
(i) Good coverage of
UTRs and miRNAs
(i) Good coverage of
UTRs and miRNAs
(ii) Most uniform coverage
in difﬁcult regions
(ii) High alignment rate
(iii) Fewer duplicate reads
than other platforms
Major weaknesses (i) More duplicate reads
than Agilent
(i) Fewer high-quality
reads than NimbleGen
(i) High off-target
enrichment
(i) High off-target enrichment
(ii) Lower alignment rate
than Agilent
(ii) Coverage bias for high
GC content areas reducing
uniformity
Nonhuman supported Yes Yes No No
UTR, untranslated region; miRNA, microRNA.
a
As described in Clark et al. (2011), NimbleGen SeqCap EZ v2.0, Agilent SureSelect Human All Exon 50Mb, Illumina TruSeq Exome Enrichment.
b
For NimbleGen SeqCap EZ v3.0, Agilent SureSelect V5, and Illumina TruSeq and Illumina Nextera original versions.
c
Filtering for duplicates, multiple mappers, improper pairs, and off-target reads, data from Chilamakuri et al. (2014) .
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to prevent the development of a lethal ailment, hemophagocytic 
lymphohistiocytosis.  Following his bone marrow transplant, the child’s 
gastrointestinal symptoms resolved.  The child had inflammatory bowel-like 
symptoms due to loss of tolerance to the bacteria in his gastrointestinal tract 
(Worthey, Mayer et al. 2011, Warr, Robert et al. 2015). 
 
Since the initial success of using WES to diagnose the above rare Mendelian 
disorder, exome sequencing has been used to diagnose novel Mendelian 
diseases as well as identify novel variants for diseases with known phenotypes.  
Furthermore, exome sequencing can assist physicians in diagnosing patients 
who have not yet exhibited the full spectrum of symptoms and it can be used for 
prenatal diagnoses (Sassi, Guerreiro et al. 2014, Warr, Robert et al. 2015).  
Benefits of early diagnosis and finding the causal variant include correct 
treatment, alleviation of further invasive testing, better prognostic advise and 
eligibility for benefits and clinical trials (Iglesias, Anyane-Yeboa et al. 2014, Warr, 
Robert et al. 2015). 
 
It is assumed that with time, as the cost of sequencing decreases, the 
enthusiasm for WES will wane because scientist want more comprehensive 
sequences.  It is thought that currently, WES is used more often than whole 
genome sequencing (WGS) because it enriches for the coding region of the 
genome, which is more easily interpretable, and is less costly, allowing for 
greater numbers of samples to be sequenced and analysed.  WGS 
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encompasses most of the genome, but it requires a larger amount of sequencing 
to achieve the same amount of coverage as WES.   However, when comparing 
the performances of WES to WGS, one sees that there are certain advantages to 
WES.  Because WES can achieve higher coverage due to target-enriched 
sequencing over specific regions of the genome, WES is able to pick up regions 
of genome missed by WGS.  Thus, exome sequencing, because of greater base 
coverage due to enrichment, can identify variants not identified using WGS.  
Also, WES can be used to clarify or validate reads from WGS where there has 
been low depth of coverage (Bamshad, Ng et al. 2011).   
 
                                     
1.3. Platelet Disorders 
Among the diseases which are manifested by platelet-related bleeding are 
inherited thrombocytopenias (IT). ITs result from genetic defects affecting the 
biogenesis of platelets from its precursor, the megakaryocyte (Mk).  In ITs, 
defects in platelet structure or function results in thrombocytopenia which can 
then lead to haemorrhaging, which can range from mild to life-threatening, 
regardless of platelet count; however, the severity of thrombocytopenia (defined 
as platelet counts of less than 150 × 109/L) does not positively correlate with the 
severity of bleeding (Nurden and Nurden 2011).  Also, the clinical expression of 
the same bleeding disorder can vary from one patient to the next.  This lack of 
correlation and consistency and the lack of understanding of why this is so, 
further underscores the fact that we still have much to learn concerning platelets: 
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the biology underlying platelet biogenesis, the structures and interactions of 
platelet proteins, and the receptors and signalling pathways used by platelets for 
activation/aggregation.  
 
Until the end of the century, only a few ITs were known and they were identified 
because of severe haemorrhaging episodes.  Thus, diseases labelled as 
inherited thrombocytopenias were few in number and not clearly characterized 
until around 15 years ago (Noris and Balduini 2015).  Since then, knowledge 
concerning ITs has burgeoned because of the application of next generation 
sequencing (NGS) to identify new genes that cause ITs.  NGS, which parallelizes 
the DNA sequencing process, produces thousands of sequence variants 
concurrently, allowing sequencing to be faster, more efficient, and less 
expensive.  This has facilitated the sequencing of large numbers of patients’ DNA 
to identify new genes as well as new variants of known genes that are associated 
with diseases resulting in thrombocytopenia.  The recruitment and 
characterisation of large series of patients equipped with genetic information 
along with large coordinated international collaborations have assisted in 
identifying and characterising the increased number of novel disorders in recent 
years.  Fourteen newly identified genes have been identified since 2010 - 
increasing the total number of well-characterised genes attributed to IT to 25.  
Currently, hereditary thrombocytopenia is thought to affect at least 2.7 per 
100,000 individuals (Balduini and Noris 2016).  However, it is believed that these 
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genes account for only around 50% of patients with IT, suggesting that there are 
still many more genes that need to be identified (Balduini, Pecci et al. 2012). 
 
The best known IT prior to the usage of NGS was the biallelic form of Bernard-
Soulier syndrome (BSS), which is characterised at birth with recurrent life-
threatening haemorrhaging (Balduini and Noris 2016).  Other ITs with severe 
bleeding tendencies include Wiscott-Aldrich syndrome (WAS), congenital 
amegakaryocytic thrombocytopenia (CAMT), and gray platelet syndrome (GPS).  
In the past, spontaneous haemorrhaging and prevention of hemorrhages and 
attainment of hemostasis after a large bleed following injury was always a major 
concern (Noris and Balduini 2015).  Nowadays, most patients diagnosed with 
these “newer” ITs have only mild or moderate thromobocytopenia with little to no 
bleeding diathesis (Balduini and Noris 2016).  Excessive bleeding may only 
become evident when the patient is appropriately challenged with surgery, 
childbirth, menstruation, or injury (Watson, Lowe et al. 2013).  Platelet 
abnormalities are only suspected and diagnosed when the patient presents with 
a disproportionate amount of bruising for the severity of injury, with bruising not 
associated with trauma, or excessive bleeding at mucocutaneous membranes 
(Cox, Price et al. 2011).  This “pattern” of bleeding i.e. petechiae, bruising at non-
contact areas of the body, or mucosal bleeding such as gingival bleeding, 
nosebleeds and menorrhagia, allows the clinician to differentiate platelet 
disorders from other coagulation defects such as haemophilia and type III von 
Willebrand disease (vWD), where hemorrhaging are more severe and are 
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located in joint spaces, soft tissues, and muscles (van Ommen and Peters 2012).  
Although patients with “newer” ITs do not have as severe bleeding risks, they 
nonetheless are predisposed to other risks because such ITs are associated with 
systemic diseases: renal failure due to glomerulopathies, hematologic 
malignancies, skeletal defects, immunodeficiency, etc. which can be fatal (Noris 
and Balduini 2015).  Now, because the vast majority of patients with hereditary 
thrombocytopenia have mild to no bleeding risks, the diagnosis of 
thrombocytopenia is often made incidentally in adult life and at times with the 
misdiagnosis of immune-mediated thrombocytopenia, known as Immune 
thrombocytopenic purpura (ITP).  ITP is an autoimmune disorder caused by auto-
antibodies (IgG) in ~60% of cases to GPIIb/IIIa or GPIb/IX.  Patients are 
thrombocytopenic but have normal bone marrow morphology and no other 
known cause for the decreased platelet counts.   Misdiagnosis can result in futile 
and dangerous therapies such as splenectomy or intravenous steroids (Balduini, 
Savoia et al. 2013).   
 
Studying inherited platelet disorders is important because it can assist in 
identifying and providing the correct diagnosis. It will additionally assist in the 
further understanding and clarification of platelet development and biology.  Such 
studies can ultimately lead to discovery of treatments for ITs, treatments for 
thrombocytopenias due to causes other than genetic mutations as well as for 
treatments of diseases caused by coagulopathies.  Also, because many of the 
newly identified ITs are part of a syndrome with other associated pathologies, 
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identification of the genetic defect will assist in appropriate medical follow-up and 
care when the other diseases develop (Balduini and Noris 2016).  
1.4. Platelet Biogenesis and Inherited Thrombocytopenias 
The production of platelets involves two phases. The first phase involves Mk 
differentiation, which takes days to be completed – there is an enormous amount 
of nuclear proliferation and enlargement of the Mk cytoplasm so that cytoskeletal 
proteins, platelet-specific granules and sufficient membrane are present for 
platelet formation.  The second phase lasts relatively quickly – completion is 
within hours.  In the second phase, Mks remodel their cytoplasm to form 
proplatelets and then preplatelets, which subsequently are shed into the blood 
stream as platelets (Machlus and Italiano 2013).  In humans, it takes about 5 
days for Mks to undergo polyploidization, mature and release platelets (Odell, 
Jackson et al. 1970).  Once in the blood stream, human platelets survive for 7 to 
10 days (Jackson and Edwards 1977).       
 
Platelets, despite being anuclear, have unique receptors, a highly organized 
cytoskeleton and specialized secretory granules (Thon and Italiano 2010).  They 
originate from Mks, which are the largest (50 to 100 µm) yet one of the rarest of 
cells in the bone marrow (Nakeff and Maat 1974).  For the assembly and release 
of platelets into the blood stream, Mks need to become polyploid by the process 
of endomytosis, which involves cycles of DNA replication without cell division 
(Figure 1.10).  Endomitosis in Mks is similar to other cell cycles: G1, S and G2 
phases are followed by mitosis during which anaphase chromosomes separate 
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and cleavage furrow formation begins; however, in Mks the nuclei do not 
completely separate and cleavage furrows regress before cytokinesis is 
completed.  Because there is no cleavage, nuclei of Mks are multilobulated with 
a polyploid nucleus (Geddis 2010).  
 
 .   
 
Figure 1.10 - Schematic diagram of endomitosis (Geddis 2010). 
 
 
After nuclear polyploidization, Mk maturation commence whereby they migrate 
from their osteoblastic niches to their vascular niches in the bone marrow to form 
pseudopodia, which contain the majority of the Mk’s cytoplasm in long narrow 
processes called proplatelets.   A Mk can have between 10 to 20 proplatelets. 
Mks extrude their nucleus (Machlus and Italiano 2013) and proplatelets develop 
tandemly placed platelet-like swellings that are connected by thin cytoplasmic 
bridges (Italiano, Lecine et al. 1999).  In the sinusoidal blood vessels of the bone 
marrow, bar-bell shaped proplatelets form, and are released.  Proplatelets 
interconvert to preplatelets and eventually, platelets form when bar-bell shaped 
proplatelets undergo fission (Machlus and Italiano 2013).    
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Polyploidy is a distinctive feature of mature Mks.   It has been proposed that Mk 
polyploidization serves to amplify functional genes in order to simplify the 
massive production of lipids and proteins needed to form the extensive 
invaginated membrane system (IMS) (Zimmet and Ravid 2000).  The IMS, the 
hallmark of a mature Mk cytoplasm, is a large complicated membrane network of 
cisternae and tubules that is continuous with the Mk plasma membrane.  It 
occupies the entire megakaryocytic cytoplasm except for a narrow area at the 
periphery.  The IMS is thought to serve as the source of membrane needed to 
form proplatelets (Schulze, Korpal et al. 2006).  During the development of 
platelets, their granule and organelle contents are transported from the Mk cell 
body as streams of individual particles (Italiano, Lecine et al. 1999).  Alpha 
granules, the most abundant organelle in platelets (Machlus, Thon et al. 2014), 
are made in the Golgi apparatus of Mks and consist of endogenous proteins as 
well as proteins from the extracellular environment. Alpha granule contents 
include von Willebrand factor, fibrinogen, fibronectin, thrombospondin, platelet 
factor 4, transforming growth factor β, platelet derived growth factor, and insulin-
like growth factor.  Dense granule contents include ADP/ATP, Ca2+, histamine, 
and serotonin.  These granules will eventually be transferred to the newly made 
platelets (Whiteheart 2011).  
 
Mks are derived from hematopoietic stem cells (HSC) (Figure 1.11), which 
differentiate in the osteoblast to more committed progenitors: the common 
myeloid progenitor (CMP) and the megakaryocyte-erythroid progenitor  (MEP).  
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MEPs develop into cells that belong to the megakaryocyte and erythrocyte 
lineages (Kaushansky 2008).   
 
 
Figure 1.11 – Schematic diagram of platelet development (Geddis 2010). 
 
 
Thrombopoietin is a glycoprotein produced by the liver and kidney and it 
functions to regulate the production of platelets.  The commitment of HSCs to 
Mks is initiated by the binding of thrombopoietin (TPO) to its Mk specific receptor, 
c-Mpl, a homologue of the oncogene, v-Mpl.  Both HSCs and Mks express c-Mpl.  
TPO and c-Mpl are essential for HSC and megakaryocyte growth and 
differentiation.  Ligation of TPO with c-Mpl results in the cytoplasmic protein 
tyrosine kinase, Janus kinase 2 (Jak2), to bind to c-Mpl and become activated.    
Based on crystallographic data of the erythropoietin receptor, it is believed that c-
Mpl, in the unbound state, is a homodimer.  However, upon binding to TPO, the 
C-terminal ends of c-Mpl are brought closer together, allowing Jak2 molecules, 
which are bound to the receptor, to activate each other through trans-
autophosphorylation (Witthuhn, Quelle et al. 1993).  Jak2 phosphorylates itself at 
multiple tyrosines as well as phosphorylating c-Mpl, which provides docking sites 
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for SH2 domain containing proteins.  Jak2 activation leads to activation of 
multiple downstream proteins: signal transducer and activator of transcription 
(STAT), mitogen-activated protein kinase (MAPK) and phosphoinositol-3 kinase 
(PI3K).  There is also negative regulation of TPO signalling to prevent 
thrombocythemia or leukemia.  Proteins involved in the negative signalling 
pathways include the suppressor of cytokine signalling (SOCS) family and Lnk, 
an adaptor protein, both of which inhibit Jak signalling (Geddis 2010).  Mk growth 
and differentiation requires multiple growth factors, the most important being 
TPO.  This is exemplified in c-Mpl and Tpo-null mice, which are 
thrombocytopenic and have reduced HSCs and progenitors of all lineages 
(Geddis 2010). Also, transcription factors such a RUNX1, GATA1, FLI-1 and 
ETV6 form complex networks regulating the differentiation of Mks (Dore and 
Crispino 2011).  
 
Many different genes control each of the phases of megakaryocyte and platelet 
development.     A causal variant occurring in any of these genes may result in 
thrombocytopenia.  When a disease-causing variant is present in the genes 
involved in the proliferative phase of megakaropoiesis, where proliferation of 
promegaloblasts is affected, there is absent or reduced number of Mks in the 
bone marrow.   When genes involved in the maturation phase are affected, the 
number of Mks can be normal or increased but Mks are immature i.e. small with 
hypolobulated nucleus and sometimes with reduced alpha granules.   When Mk 
production is normal, thrombocytopenia is due to defective proplatelet formation 
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or abnormally increased platelet removal (Johnson, Fletcher et al. 2016, Savoia 
2016). Some examples of genes with disease-causing variants which affect each 
of the stages of platelet development include THPO/MPL and HOXA11 affecting 
Mk production; RUNX1, FLI1, ETV6, GATA1 affecting Mk maturation; and MYH9, 
WAS, GP1BA, GP1BB, GP9, ITGA2B and ITGB3 affecting platelet production 
and development (Figure 1.12 and Table 1.3). 
 
1.4.1. Inherited Thrombocytopenias caused by genes affecting Mk 
production 
 
 
 
Figure 1.12 - Schematic diagram of the different stages of platelet 
development associated with the genes which can mutate at each stage.  
Above each stage are the different genes which can be mutated to cause an 
inherited thrombocytopenia.  THPO is the gene for TPO (Savoia 2016).        
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THPO and MPL are essential genes in the production of platelets.  Many different 
causal variants inherited in a homozygous or heterozygous manner have been 
identified in these two genes.  Loss of function variants of the MPL gene result in 
congenital amegakaryocytic thrombocytopenia (CAMT).  Patients with CAMT, an 
autosomal recessive disease, have a high risk of life-threatening hemorrhages 
and progress within the first years of life to develop bone marrow aplasia which 
can result in death unless bone marrow transplants are performed (Balduini, 
Pecci et al. 2012).  Forty-one different disease-causing variants, found along the 
entire MPL gene, have been identified (Balduini, Pecci et al. 2012).  The 
functional consequences resulting from the variants have not all been completely 
identified.  However, it appears that patients with complete loss of function of the 
MPL gene have permanently low platelet counts whereas presence of any 
residual MPL function will result in improvement of thrombocytopenia after the 
first year of life (Ballmaier and Germeshausen 2011).  However, the currently 
reported MPL variants explain only 60% of the CAMT cases, suggesting that 
CAMT might be caused by other genes not yet identified (Ballmaier and 
Germeshausen 2011).   
 
In regards to the THPO gene, there is a gain of function variant resulting in 
increased platelet production (Wiestner, Schlemper et al. 1998), as well as a loss 
of function variant of the THPO gene (p.R38C) which reduces binding affinity of 
TPO to MPL.  An example of this gain of function variant is the disease 
hereditary thrombocythemia, which is transmitted in an autosomal dominant 
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fashion.  TPO is persistently elevated in the afflicted individuals studied.  The 
mutation that was identified was a G to C transversion at the splice donor site of 
intron 3 of THPO. This mutation leads to mRNAs with shortened 5’UTR resulting 
in more efficiently translated mRNA and thus systemic overproduction of TPO 
(Wiestner, Schlemper et al. 1998). Homozygous patients with the loss of function 
variant develop aplastic anemia, whereas heterozygous patients have mild 
thrombocytopenia (Dasouki, Rafi et al. 2013).   Another example of causal gene 
variants that affect megakaryocyte production involves the gene HOXA11, a 
transcription factor with an unknown role in hematopoiesis but which encodes for 
a homeobox protein that regulates gene expression, morphogenesis and 
differentiation.  Pathological variants of the HOXA11 gene result in an autosomal 
dominant IT named radio-ulnar synostosis with amegakaryocytic 
thrombocytopenia (RUSAT).   Patients with RUSAT present with proximal fusion 
of the radius and ulna (resulting in difficulty with supination and pronation of 
forearm) plus thrombocytopenia caused by absent or reduced number of 
megakaryocytes in the bone marrow which also may become aplastic.  The initial 
patients which presented with RUSAT were two unrelated families which were 
nonconsanguineous and of different ethnic backgrounds.  Both fathers and 
affected children had radio-ulnar synostosis but only three of the four affected 
children had symptomatic thrombocytopenia since birth. Utilising Sanger 
sequencing, the mutation was identified as a single base-pair deletion in the 
highly conserved homeodomain, located at exon 2 of HOXA11.  The point 
mutation is located at a critical DNA binding site whereby the mutation causes a 
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nonsense mutation because there is a translational frameshift resulting in a 
premature stop. There appears to be no HOXA11 mRNA expression as 
determined by RT-PCR in platelets, megakaryocytic cell lines or TPO-induced 
CD34+ umbilical cord stem cells.  It is postulated that the patients that were 
studied developed amegakaryocytic thrombocytopenia secondary to alterations 
in the interaction of HOXA11 or its protein with other genes that play an important 
role in megakaryocytic differentiation during the specific embryonic stage 
important for hematopoiesis (Thompson and Nguyen 2000).   HOX genes’ 
function in normal hematopoiesis has been has extensively been studied using 
gene expression analysis, targeted genetic insertion and deletion studies in 
hematopoietic stem cells (HSC) and early hematopoietic progenitors of murine 
models and cell lines.    However, it should be realised that targeted genetic 
deletion studies are difficult to interpret given the functional redundancy of HOX 
genes. Highly expressed in most primitive HSCs and progenitors, HOX genes’ 
expression is virtually absent in CD34- cells, which are differentiated bone 
marrow cells (Alharbi, Pettengell et al. 2013).  Examples of “knock-down” studies 
include those for HOXA9, the most widely expressed HOX family member, 
HOXA5 and HOXA7:  HOXA9-/- mice are very deficient in myeloid and lymphoid 
cells (Magnusson, Brun et al. 2007); HOX5A-/- mice have an increase in erythroid 
progenitors and a decrease in myelomonocytic cells (Crooks, Fuller et al. 1999) 
and HOX7A-/- mice demonstrate a decrease in megakaryocytic/erythroid 
progenitors resulting in reticulocytosis and thrombocytopenia (So, Karsunky et al. 
2004).  To date, HOX11A-/- mice have been generated whereby skeletal 
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deformities were analysed but haematological abnormalities were not mentioned 
(Small and Potter 1993).   
1.4.2. Inherited Thrombocytopenias caused by genes affecting Mk 
maturation 
The next stage of megakaryopoiesis where genetic causal variants can affect the 
production of platelets is during megakaryocyte maturation.  Most of the genes 
which are currently known and which are affected at this stage, encode for 
transcription factors such as GATA1, FLI1, RUNX1 and ETV6.  GATA1 encodes 
for a zinc finger transcription factor found in megakaryocytic/erythroid progenitors 
and controls megakaryocytic and erythroid development.  GATA1, which binds 
cofactor FOG1, has two zinc fingers, a C-terminal one which binds DNA avidly 
and an N-terminal one which stabilizes DNA binding.  GATA1 variants can cause 
an X-linked macrothrombocytopenia with decreased α-granule content, whereby 
Mks are immature.  GATA1 variants may also cause dyserythropoietic anemia or 
β-thalasemia.  GATA1 also interacts with other transcription factors such as FLI1 
(Millikan, Balamohan et al. 2011).  FLI1 and ETV6 both belong to the same ETS 
family of transcription factors, which is characterized by the following structure: at 
the N-terminus is a pointed (PNT) domain, which dimerizes and interacts with 
other transcription factors; a central inhibitory domain; and, at the C-terminus, the 
DNA-binding domain (ETS).  Disease-causing variants in the ETV6 gene result in 
autosomal dominant thrombocytopenia, an elevated erythrocyte mean 
corpuscular volume (MCV) and B cell precursor acute lymphoblastic leukemia 
(ALL).  Mks are immature i.e. small and hypolobulated with abnormal red cell 
precursors (Noetzli, Lo et al. 2015).  FLI1 interacts with GATA1 as well as with 
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RUNX1 to regulate many genes needed for terminal megakaryocytic maturation 
(Huang, Yu et al. 2009).  FLI1 when deleted at its chromosomal region, 11q24.3, 
results in Jacobsen syndrome, which, when thrombocytopenia is also present, is 
named Paris-Trousseau syndrome.  The Mks of these patients are small with low 
ploidy but platelets are large i.e. macrothrombocytopenic with giant α-granules 
(Bluteau, Glembotsky et al. 2012).  RUNX1, which belongs to the family of genes 
called core binding factor α2 (CBF-α), is heterodimeric because it complexes with 
core binding factor β (CBF-β).  CBF-β doesn’t directly bind DNA but increases 
the DNA binding ability of the RUNX1-CBF-β complex and makes it more stable.  
Mutations of RUNX1 result in the disease called familial platelet disorder with 
propensity to acute myelogenous leukemia (FPD-AML) (Savoia 2016).   Patients 
with FPD-AML have moderate thrombocytopenia with decreased α-granules, 
small, increased number of Mks and a predisposition to develop myelodysplastic 
syndromes or acute myeloid leukemia (AML) (Savoia 2016).  One of the genes to 
which RUNX1 binds is the 5’UTR of ANKRD26, thereby inhibiting ANKRD26 
transcription.  Causal variants that occur at the 5’UTR of ANKRD26 prevent 
RUNX1 binding and result in the autosomal dominant disease, ANKRD26-related 
thrombocytopenia (ANKRD-RT or THC2).     Patients with ANKRD-RT have an 
increased number of megakaryocytes, which are small with hypolobulated nuclei 
and have in their cytoplasm, particulate structures (PaCS) which are made of 
proteasome complexes and polyubiquinated proteins (Necchi, Balduini et al. 
2013).  Patients with ANKRD26-RT are also predisposed to developing 
haematological malignancies, especially AML (Noris, Favier et al. 2013).     
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Targetted disruption of the ANKRD26 gene in mice results in hyperphagia, 
obesity and gigantism, all of which are caused by defects in the primary cilia 
found in regions of the brain which control apetite and energy homeostasis (Bera, 
Liu et al. 2008, Acs, Bauer et al. 2015).   The molecular mechanism for 
adipogenesis is attributed to increased activation of ERK and mTOR signalling 
pathways (Fei, Bera et al. 2011).  Analyses of ANKRD26-/- mice did not 
demonstrate   altered haematological cell counts.  However, a study of 11 Italian 
and French pedigrees with THC2 revealed no dramatic changes in 
megakaryocyte differentiation but a defect in proplatelet development, as seen in 
electron micrographs of THC2 patient megakaryocytes derived from purified 
blood CD34+ cells treated with TPO and SCF (Stem cell factor).  Correction of 
this defect in proplatelet development was accomplished by using a MEK 
inhibitor. The mechanism postulated to explain this defect is the persistant 
activation of the MAPK/ERK1/2 pathway, which was seen using THC2 patient-
derived megakaryocytes when compared to controls. (Bluteau, Balduini et al. 
2014).  
1.4.3. Inherited Thrombocytopenias caused by genes affecting 
platelet production and development 
The next group of ITs result from defective proplatelet formation or release.  
Examples of diseases from this group include MYH9-RD, Wiskott-Aldrich 
syndrome (WAS), Bernard Soulier Syndrome (BSS), and Glanzmann 
thrombasthenia (GT).  MYH9-RD, one of the most commonly identified ITs, is 
caused by causal variants in the MYH9 gene, which encodes for the heavy chain 
of non-muscle myosin IIA in non-muscle cells (Balduini, Pecci et al. 2011).  Non-
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muscle myosin IIA’s protein structure consists of an amino terminal globular head 
followed by a coiled coil domain and a non-helical tail at the carboxy terminus, 
which dimerizes and associates with two pairs of light chains.  The heavy chain 
of non-muscle myosin IIA is expressed throughout hematopoiesis and normally 
contributes to cytokinesis, membrane rigidity, and contraction of matrix.  The 
proposed mechanistic cause for macrothrombocytopenia is the lack of heavy 
chain non-muscle myosin IIA reactivation in terminal platelet formation.  When 
proplatelets squeeze through the sinusoidal blood vessels, it is shear, which 
divides the proplatelets to form preplatelets.   Fluid stress activates heavy chain 
non-muscle myosin IIA, which accumulates at stressed sites to cause 
fragmentation of preplatelets to form platelets.  When heavy chain non-muscle 
myosin IIA mutates, it doesn’t aggregate, but is diffuse, preventing preplatelets 
from fragmenting and thus forming normal sized platelets (Spinler, Shin et al. 
2015).  Patients with MYH9-RD are macrothrombocytopenic at birth and have 
neutrophils, which contain cytoplasmic aggregates of wild-type and mutated 
myosin-9 (Savoia, De Rocco et al. 2010).  Later in life, the majority of patients 
with MYH9-RD develop sensorineural hearing loss, presenile cataracts, chronic 
or intermittent elevated liver enzymes, and glomerulonephritis which can 
progress to endstage renal failure (Pecci, Biino et al. 2012).  
 
WAS and X-linked thrombocytopenia (XLT) are both caused by causal variants 
located on the gene for Wiskott-Aldrich syndrome protein (WASp).  WASp is 
located on the X chromosome, is expressed in hematopoietic cells and functions 
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to regulate the actin cytoskeleton.  Males with WAS have multiple medical 
problems: moderate to severe congenital microthrombocytopenia; eczema; 
severe immune compromise with risks for developing lymphoproliferative 
disorders.  Thrombocytopenia is due to inefficient platelet release into the blood 
stream as well as increased clearance of platelets from the circulation (Balduini, 
Pecci et al. 2012).  Almost 150 different mutated alleles have been described for 
WAS: the most common being missense and splice-site mutations, short 
deletions and nonsense mutations (Pai and Notarangelo 2010).  Loss-of-function 
variants usually result in WAS whereas variants which allow expression of the 
WASp, however small, results in XLT.    There is a strong correlation between 
severity of WAS variants and the phenotypic expression of WAS/XLT (Massaad, 
Ramesh et al. 2013).     
 
 
Figure 1.13 - Structural domain organisation of Wiskott-Aldrich Syndrome 
protein (WASp).  WH2(WASP-homology-2; also called verprolin-homology), 
C(cofilin-homology or connector), A(acidic region), PP(polyproline domain), 
GBD(GTPase binding domain), B(basic domain), WH1(WASP-homology-1 
domain) (Goley and Welch 2006). 
 
 
WASp (Figure 1.13) is a class I nucleation promoting factor.  It is needed for 
actin-related protein 2/3 (ARP2/3) complex activation because the ARP2/3 
complex (the nucleator) itself has no catalytic activity.  The ARP2/3 complex is a 
Chapter One Introduction 
 
 
71 
 
major participant in cellular actin polymerization, forming branched-actin-filament 
networks in the actin cytoskeleton (Goley and Welch 2006).  
 
The key member of the actin cytoskeleton is the monomeric globular (G) actin, 
an ATPase, which can assemble itself to form filamentous (F) actin.  Actin 
polymerisation is tightly coupled to ATP hydrolysis, which controls the kinetics in 
the assembly and disassembly of actin and its binding with interacting proteins 
(Pollard and Borisy 2003).  The formation of a new actin filament is termed 
nucleation.  Spontaneous nucleation is possible but kinetically laborious so for a 
cell to be efficient it has factors, which can accelerate or bypass nucleation to 
allow for more effective assembly of actin.  There are three classes of proteins 
called nucleators, which can initiate actin polymerisation: the actin-related protein 
2/3 (ARP2/3) complex, the formins and spire.  Each nucleator initiates nucleation 
by a particular method.  The ARP2/3 complex is believed to mimic an actin dimer 
or trimer and serves as a template for the initiation of a new actin filament which 
branches off an existing filament to generate y-branched actin networks (Goley 
and Welch 2006). The ARP2/3 complex consists of seven polypeptides of which 
two, ARP2 and ARP3, are actin-related proteins of the ARP2 and ALP3 
subfamilies.  Other subunits of the complex include ARPC1, ARPC2, ARPC3, 
ARPC4 and ARPC5.  By itself, the ARP2/3 complex has no biochemical activity; 
but, when bound to a nucleation promoting factor (NPF), it will be activated to 
begin formation of a new filament (daughter) that branches off from an existing 
filament (mother) at a 70° branch angle (Mullins, Heuser et al. 1998, Amann, 
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2001 #152).  Termed autocatalytic branching or dendritic branching, this coupling 
of nucleation and branching is the functional essence of the ARP2/3 complex in 
the cell.   
 
Nucleation promoting factor (NPF) proteins are made up of two groups, class I 
and class II, based on how they activate the ARP2/3 complex and their effect on 
the y-branching reaction (Goley and Welch 2006).  There are a diverse array of 
class I and II NPF proteins with different overall domain structures.  For class I 
members, of which WASp (Figure 1.12) is one, the only common domain shared 
by all, is the WCA domain, which consists of a WASP-homology-2 (WH2 or 
verprolin-homology) domain that binds G-actin and a central (C or cofilin-
homology) domain and an acidic (A) region, which together (CA) binds the 
ARP2/3 complex (Marchand, Kaiser et al. 2001, Chereau, Kerff et al. 2005).  A 
model for how class I NPF functions involves the acidic region binding to the 
ARP2/3 complex which allows the central region to initiate activating 
conformational changes in the complex and the WH2 and central regions to bind 
and present actin monomers to the ARP2/3 complex to facilitate the formation of 
a nucleus for the polymerization of the daughter filament (Panchal, Kaiser et al. 
2003).  Class I NPFs are activated by a number of factors, the most studied 
being the Rho-family GTPases, CDC42 and Rac, which bind the GBD domain 
(Bompard and Caron 2004).  
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Actin polymerization is required for multiple vital cellular processes such as cell 
migration, phagocytosis, endocytosis, vesicle trafficking and cytokinesis.  
However, the nucleation promoting factor required for each of the cellular 
processes vary.  Phagocytosis is the process whereby large (greater than 0.5 µm 
in diameter) items such as bacteria are engulfed.   Cells such as phagocytes 
utilise actin polymerization to negotiate the plasma membrane around the 
bacteria’s surface.  The only NFP which is used for phagocytosis is WASp, which 
is expressed in hematopoietic cells in mammals (Castellano, Le Clainche et al. 
2001).  The internalisation of small particles (endocytosis) also requires actin 
polymerisation; however, the precise role that the ARP2/3 complex and WASp 
play in this process which includes invagination of the membrane, pinching off 
vesicles, or driving vesicles away from the plasma membrane, remains to be 
clarified (Kaksonen, Sun et al. 2003).  WASp may also play a role in adhesion 
and in podosome formation (Goley and Welch 2006).  
 
The GPIb/IX/V complex consists of glycoproteins (GP) Ibα, GPIbβ, GPIX, and 
GPV, which associate in a ratio of 2:4:2:1 in the endoplasmic reticulum (ER) of 
Mks and platelets before migrating to the membrane (Luo, Mo et al. 2007).  
Platelets require this complex to bind and aggregate on the exposed endothelium 
of damaged blood vessels.  GPIbα binds von Willebrand factor (vWF).   GPIbα, 
GPIbβ and GPIX are needed for the correct assembly of the complex in the ER.  
More than 50 different causal variants have been identified in GPIBA, GPIBB and 
GP9 (Lopez, Andrews et al. 1998).  Variants that decrease the expression of the 
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GPIb/IX/V complex or its ability to bind vWF result in the biallelic (recessive form) 
or the monoallelic (dominant variant) form of Bernard-Soulier syndrome (BSS).  
Patients with biallelic BSS have moderate macrothrombocytopenia but a severe 
bleeding diathesis.  The GPIb/IX/V complex on platelets is severely reduced to 
undetectable and when patient platelets are tested for aggregation using 
ristocetin, there is none to barely any aggregation.  Generally, the monoallelic 
form of BSS is clinically less severe: patient platelet counts are only slightly 
decreased, bleeding risk is mild or absent and ristocetin-induced aggregation is 
normal or slightly abnormal.  Ristocetin is an antibiotic, which was previously 
clinically used to treat Staphylococcal infections but was discontinued because of 
its side effects in patients: thrombocytopenia and platelet aggregation.  Why 
ristocetin causes platelet aggregation is hypothesized to be due to its phenolic 
groups, which bind platelets, reducing the platelets negative surface charge.  
Normally, the platelets’ net negative charge leads to repulsion and prevents 
bridging by vWF via GPIb.  When ristocetin, which is positively charged, is 
added, it binds via its phenolic groups to platelets (probably at protein-associated 
free carboxy groups on the platelets), reducing the platelets’ net negative charge, 
allowing for closer platelet interaction, which then allows for the vWF to bridge 
between platelets, causing agglutination (Coller and Gralnick 1977). 
 
There are also variants on GP1BA which increases the affinity of GPIbα for VWF 
resulting in macrothrombocytopenia - this is called platelet type von Willebrand 
disease (Savoia, Kunishima et al. 2014).  Another important receptor found on 
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platelet and MK cell surfaces is the GPIIb-IIIa complex, which when exposed, 
has a binding site for fibrinogen.  When its genes, ITGA2B and ITGB3, which 
encode for the two integrin subunits of the receptor, αIIb and β3, have biallelic 
pathological variants, Glanzmann thrombasthenia (GT) develops.  GT is an 
autosomal recessive disease whereby platelets are functionally abnormal but 
phenotypically normal: platelets cannot aggregate but are of normal size and 
number (Gresele, Falcinelli et al. 2009).  However, there is also an autosomal 
dominant form of macrothrombocytopenia whereby gain of function variants are 
found in either the αIIb or β3 subunit resulting in constitutive activation of the 
GPIIb-IIIa complex; however, there is no platelet aggregation defect (Kashiwagi, 
Kunishima et al. 2013). 
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Disease (abbreviation) Frequency* 
/spontaneous 
bleeding 
Inheri-
tance 
Gene 
(chromosome 
location) 
Other features 
Normally sized platelets 
Congenital   amegakaryocytic 
thrombocytopenia (CAMT) 
+++/yes AR MPL (1p34) Always evolves into bone marrow 
aplasia in infancy.   
Amegakaryocytic thrombocytopenia 
with radio-ulnar synostosis  
(RUSAT or CTRUS) 
+/yes AD HOXA11  
(7p15-14) 
Radio-ulnar synostosis ± other defects. 
Possible evolution into  
Aplastic anemia. 
Familial platelet disorder and 
predisposition to acute 
myelogenous leukemia (FPD/AML) 
++/no AD RUNX1 (21q22) High risk of developing leukemia or 
myelodysplastic syndrome. 
 
ANKRD26-related thrombocytpenia  
(THC2 or ANKRD26-RD) 
++/no AD ANKRD26 
(10p2) 
Risk of developing acute myelogenous 
leukemia 
Large platelets 
GATA1-related disease (GATA-RD) ++/yes XL GATA1 (Xp11) Hemolytic anemia, possible 
unbalanced globin chain synthesis, 
possible congenital erythropoietic 
porphyria 
Paris-Trousseau thrombocytopenia 
(TCPT), Jacobsen syndrome (JBS) 
++++/yes AD FLI1 (11q24.3) Cardiac and facial defects, 
developmental delay ± other defects 
MYH9-related disease (MYH9-RD) ++++/no AD MYH9  
(22q12-13) 
Cataracts, nephropathy, and/or 
deafness 
Platelet-type vWD (VWDP)  ++++/yes AD GP1BA (17p13) Platelet count goes down under stress 
Bernard-Soulier syndrome (BSS) 
  Biallelic 
    Monoallelic 
+++/no  
AR 
AD 
 
GP1BA (17p13) 
GP1BB 
(22q11), GP9 
(3q21) 
 
Giant platelets 
 
Large platelets 
Glanzmann thrombasthenia (GT) +/no AD ITGA2B 
(17q21.31) 
ITGB3 
(17q21.32) 
Platelet anisotropy 
Small platelets 
Wiskott-Aldrich syndrome (WAS) 
  
X-linked thrombocytopenia (XLT) 
++++/yes XL WAS (Xp11) Severe immunodeficiency leading to 
death in infancy. 
Mild immunodeficiency 
Table 1.3 - Overview of inherited thrombocytopenias (confer section 1.3). 
Frequencies are indicated as follows:  *++++, >100 families reported; +++, >50 
families reported; ++, > 10 families reported; +, < 10 families reported.  AD, 
autosomal dominant; AR, autosomal recessive; XL, X-linked. (Balduini and 
Savoia 2012, Balduini, Savoia et al. 2013). 
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1.5. Identification of genes responsible for inherited 
thrombocytopenias  
The genetic causal variants identified in ITs usually involve a single gene that 
follows a Mendelian pattern of inheritance.  Of the Mendelian diseases that have 
been studied, the majority are caused by rare mutations that affect the function of 
the protein; around 85% of disease-causing mutations are found in exomes (the 
coding regions of the genome) or in canonical splice sites (Choi, Scholl et al. 
2009).  The human genome has around 180,000 exons so exomes constitute 
only approximately 1.5% of the human genome.  As a result, using whole exome 
sequencing (WES) to identify rare Mendelian mutations is a more efficient and 
cost-effective approach to studying Mendelian disorders than whole genome 
sequencing.  Exome sequencing allows targeted sequencing of predefined 
regions at high depth, thus reducing the complexity of the genomic analyses as 
well as reducing storage costs.  Reduced costs allow more samples to be 
sequenced and thus enable larger population based comparison (Schneeberger 
2014).  Other benefits of exome sequencing include the ability to identify genes 
in certain instances when conventional approaches have failed.  For instance, 
linkage studies cannot be done on extremely rare diseases because there are 
not enough participants for a statistically powerful study.  Linkage studies also 
cannot identify sporadic mutations, genetic heterogeneity (causal variants that 
are located on different genes) nor phenotypic heterogeneity (diverse 
presentation of the disease leading to uncertain diagnosis) (Ku, Naidoo et al. 
2011).  However, WES has limitations as well (Schneeberger 2014):  if causal 
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variants are located in regulatory regions (introns), they will be missed by WES; 
genetic markers can only be genotyped if they are in the targeted regions and 
WES requires enrichment kits and information about targeted regions.   
 
Similar to other genetic analyses, once candidate genes and variants are 
identified by WES, further functional studies are required to confirm that the 
coded protein does what is hypothesised and that the causal variants identified 
are deleterious.   
 
Although the number of patients which have been identified with ITs have 
increased, absolute numbers remain small, making it difficult to find patients to 
study.    In the past, genetic studies of IT focused on candidate gene sequencing 
with whole exome sequencing of individual cases when a causative gene wasn’t 
obvious (Zhang, Churpek et al. 2015).  For the past 8 years our laboratory has 
undertaken a collaborative and more large scale approach to identifying and 
studying ITs.  Called the genotyping and platelet phenotyping (GAPP) study, this 
has involved recruiting patients with suspected IT or sustained thrombocytopenia 
from over 25 Haemophilia Comprehensive Care Centres across the UK.  Before 
patients enter the study, they’ve had clinical and genetic studies to rule out 
known platelet disorders: GT, BSS, WAS, MYH9-RD, and ITP as well as known 
non-platelet disorders such as vWD and inherited coagulation factor deficiencies.  
Once patients have entered the study, their platelets undergo several functional 
assays to characterize the platelets before having their genomic DNA sequenced 
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using WES.  The diagnosis of platelet disorders therefore involves a two-prong 
approach - platelet phenotyping plus WES.   
 
Normally, the definitive diagnosis of a platelet disorder is determined by using 
light transmission aggregometry (LTA), the gold standard method (Born 1962), to 
analyze platelet rich plasma (PRP) for any defects in platelet aggregation.   This 
is accomplished by using a streamlined panel of platelet agonists at specified 
concentrations (Dawood, Lowe et al. 2012).  Assessment of platelet dense 
granule ATP release, using lumi-aggregometry provides additional information 
regarding platelet secretion disorders.   However, in thrombocytopenic patients, 
because lumi-aggregometry is unreliable for platelet counts below 150 x 109/L, a 
flow cytometry assay, developed in our laboratory, is performed (Dawood, Wilde 
et al. 2007).  Using the flow cytometer, thrombocytopenic patients’ PRP are 
stimulated with the following agonists to check for the presence and functionality 
of the following receptors as well as their signalling pathways:  ADP (3 and 
30µM) - P2Y12 receptor, Gi signalling; collagen related peptide (CRP, 0.3 and 
3µg/ml) - GPVI receptor and signalling and PAR-1 peptide (10 and 100µM) - 
protease-activated receptor, Gq signalling.  Also checked by flow cytometry is 
membrane expression for P-selectin, a marker of α and dense granule release 
and fluorescent fibrinogen binding, a marker of integrin activation.  
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1.6. A family with severe thrombocytopenia  
This project involves the characterization of a novel protein, ANKRD18A (Ankyrin 
Repeat Domain 18A). The corresponding gene, ANKRD18A was identified 
following the sequencing of the exomes of two cousins from a consanguineous 
family (Figure 1.14).  The proband (patient who is the starting point for a genetic 
study), patient II:5,  was entered in this study at age 3 because of a platelet count 
of 3x109/L.  Phenotypically, he had developmental delay and skull abnormalities 
because at birth he developed bilateral intraventricular hemorrhages requiring 
insertion and several revisions of a ventriculo-peritonal shunt. He received HLA 
matched platelet transfusions every 1-2 weeks for the first six to twelve months of 
life.  His baseline platelet count remained at approximately 10x109/L.  There were 
no abnormalities in the rest of his full blood count.  He had a bone marrow 
aspirate and trephine (a hole saw used in surgery to remove a circle of tissue) 
which was normocellular with normal megakaryocyte numbers and morphology 
and normal cytogenetics.  His cousin, II:3, is the only sibling with a platelet 
abnormality in her immediate family. She has a baseline platelet count of (15 – 
20) × 109/L, but requires weekly HLA matched platelet transfusions to prevent 
epistaxis and hematomas, which have been severe enough to necessitate 
hospitalization.  Both the proband and his cousin had normal coagulation 
parameters and there were no identifiable anti-platelet auto-antibodies or HLA 
antibodies (Initial clinical work-up of both patients were performed by Dr. 
Jayashree Motwani and Dr. Mike Williams at Birmingham Children’s Hospital).  
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Figure 1.14 - Pedigree of patients affected by ANKRD18A-linked severe 
thrombocytopenia.  Shaded square is the male patient (II:5) with the 
homozygous non-frameshift deletion of ANKRD18A (p.801-801).  Shaded circle 
(II:3) is his cousin. Double lines linking I:1 with I:2 and I:3 with I:4 signify a first 
cousin union (analysis performed by N. Morgan). 
 
1.6.1. A genetic variant in ANKRD18A correlates with severe 
thrombocytopenia  
To determine the genetic defect underlying the thrombocytopenia seen in these 
two patients, exome sequencing was performed using the SureSelect human 
AllExon 50Mb kit (Agilent Technologies) and sequenced on the Hi Seq 2000 
(Illumina) with 100 bp paired-end reads.  Because Patient II:5 and II:3 were 
cousins born from consanguineous relationships derived from a single 
consanguineous kindred, analysis was focussed on identifying a shared 
homozygous variant  secondary to the recessive segregation of the disease.  
Patient II:5 had 24,293 variations and his cousin, patient II:3, had 23,943.  
Comparing these variants with the 1000 Genomes project database and our in-
house database, which was composed of >250 exomes at the time, 83 
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homozygous novel variants were identified for patient II:5 and 77 for patient II:3.  
Of these variants, only 2 homozygous non-synonymous variants [FRMPD1 
(p.A509V) and GNE (p.G447R)] and 1 non-frameshift deletion [ANKRD18A 
(p.E799-799 del)] were found in both patients on chromosome 9p13.3.  All three 
variants are located within a tightly linked region of homozygosity on 
chromosome 9.  Information from Sanger sequencing was used to verify these 
mutations as well as to perform segregation analysis among immediate family 
members (Figure 1.15).  The 2 non-synonymous variants were found in the 
genes FRMPD1 (A509V) and GNE (G447R).  FRMPD1 encodes for a FERM and 
PDZ domain containing protein which functions to regulate the subcellular 
localization of activator G-protein signalling 3 (An, Blumer et al. 2008).  It is 
weakly expressed in hematopoietic cells; and, the alanine that is mutated in 
FRMPD1 is not conserved in different species, suggesting that the alanine 
residue is insignificant.  Also, most recently, the variant in FRMPD1 has been 
observed to occur at a frequency of 0.0003708, implicating that this low-
frequency variant is unlikely to be pathogenic. GNE encodes for UDP-N-
acetylglucosamine 2-epimerase, a bifunctional enzyme which catalyses the initial 
two steps in the biosynthesis of N-acetylneuraminic acid (sialic acid).  Its 
structural domain organisation reveals an epimerase domain at its amino 
terminus and a kinase domain at its carboxy terminus (Stasche, Hinderlich et al. 
1997, Eisenberg, Avidan et al. 2001, Tong, Tempel et al. 2009). Mutagenesis 
and enzymatic activity studies have established that the activities of the 
epimerase and kinase domains are interrelated and that mutations in either one 
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of the domains will affect the activities of both domains (Penner, Mantey et al. 
2006).  Sialic acids are monosaccharides, which are expressed on the cell 
surfaces of all eukaryotic hematopoietic cells.    
 
 
Figure 1.15 - Segregation analysis of the exome candidates in family 
members.  The 3 variants (in the genes GNE, FRMPD1 and ANKRD18A) were 
shared by both children and were located within a region of homozygosity on 
chromosome 9p13.3.  Double lines linking parents signify first cousin unions. 
(analysis performed by N. Morgan) 
 
 
Heterozygous variants (autosomal dominant) located in the epimerase domain of 
the GNE gene results in sialuria, which is an overexcretion of sialic acid in the 
urine.  Homozygous and compound heterozygous (both alleles are mutated at 
different locations) variants located in either the epimerase or the kinase domain 
result in a group of neuromuscular disorders called hereditary inclusion body 
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myopathies (HIBM), which are characterized by adult-onset, slowly progressive, 
distal and proximal muscle weakness.  Muscle biopsies from these patients 
demonstrate rimmed vacuoles and filamentous inclusions.  Initial identification of 
the genetic aetiology of HIBM by Eisenberg et. al. (Eisenberg, Avidan et al. 2001) 
studied 47 Middle Eastern Jewish families and one family from the countries 
India, Georgia and the Bahamas. All the patients from the Jewish families had a 
homozygous M712T missense mutation in the kinase domain of the protein 
whereas the family from India had a V696M and C303X compound heterozygous 
missense mutation in the kinase and epimerase domain, respectively; the family 
from Georgia had a G576E and A631T compound heterozygous missense 
mutation, both in the kinase domain; and the family from the Bahamas had a 
R246Q and D225N compound heterozygous missense mutation, both in the 
epimerase domain.  However, in this study no mention was made regarding the 
patients’ hematopoietic profiles (Eisenberg, Avidan et al. 2001).   
 
Since the initiation of this project, there have since appeared two separate 
reports of two sets of siblings, of nonconsanguineous parents, who developed 
myopathies during late adolescence.  Interestingly, these patients also had 
thrombocytopenia since birth: platelet counts ranged from 1.1 – 40 × 109/L.  
Genetic analyses of one of the sets of siblings, who are Japanese, had a 
compound heterozygous V603L and G739 missense mutation, both in the kinase 
domain.  For the other set of siblings, who are Chinese, genetic analyses 
demonstrated both siblings having a compound heterozygous T217H missense 
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and D515Q frameshift mutation, the former in the epimerase domain and the 
latter in the kinase domain (Izumi, Niihori et al. 2014, Zhen, Guo et al. 2014).   
 
Variants in the GNE gene are suggested to have a role in causing 
thrombocytopenia.  Sialic acid is known to play a role in platelet function: it is 
located in the platelet membrane and is involved in glycosylation.  Several 
groups have shown that platelets, when lacking sialic acid, are removed from the 
circulation, resulting in shortened platelet lifespan and thrombocytopenia 
(Sorensen, Rumjantseva et al. 2009). 
 
The homozygous non-synonymous variant in the GNE gene (p.G447R) of these 
two patients, II:5 and II:3, is located in the kinase domain.  Despite these findings 
regarding the GNE gene, it is still possible that the genetic defect which is 
causing the thrombocytopenia in Patients II:5 and II:3 is due to the homozygous 
non-frameshift deletion of the amino acid glutamic acid 801 in the  gene 
ANKRD18A.  It is hypothesised that the mutation in ANKRD18A is the causal 
variant because neither patient suffered from sialuria nor any myopathies.  
ANKRD18A (Ankyrin Repeat Domain 18A) encodes a protein, which is 
expressed only in primates (Figure 1.17), and is weakly expressed in cells of 
hematopoietic lineage (Figure 6.1).  Currently functionally uncharacterized, it 
encodes for a 992-residue, multi-domain protein of 116kD.  Speculatively, 
ANKRD18A has three distinct regions of homology to proteins of known structure 
as determined by fold prediction using threading (Phyre2, HHpred).  The amino 
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terminal region (residues 1-260 or 35-235, as determined by two different fold 
prediction algorithms) consists of 9 ankyrin-like repeats, followed by a coiled coil 
region that appears to resemble the structures of tropomyosin (residues 470-780) 
and at the carboxy terminus, the colicin IA (residues 529-942) homology domain 
(Figure 1.16).  The homozygous non-frameshift deletion of the last of a trio of 
glutamic acid residues in ANKRD18A (p.E801del) is located in the colicin IA 
homology domain. The carboxy terminal domain of ANKRD18A has only a very 
limited homology to colicin IA.  
 
 
Figure 1.16 - Linear domain organisation of ANKRD18A derived from 
bioinformatical sequence analysis.   Domains (or regions of homology) have 
been identified with the fold prediction server HHpred using the sequence of 
ANKRD18A (isoform 2). ANKRD18A isoform 1 has a 63-amino acid insertion, 
between the ankyrin repeat domain and the tropomyosin homology region. 
Threading suggests that, compared to isoform 2, isoform 1 (1054 residues) has a 
more extended ankyrin repeat domain, comprising 11 repeats instead of 9 in the 
shorter isoform 2 (992 residues). The approximate position of the in-frame 
deletion mutation (pGlu801del) is indicated. 
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Colicin IAs are E. coli bacteriocidic proteins formed by its plasmids.  Colicins are 
transmembrane proteins that form channels to depolarize the bacterial cellular 
cytoplasmic membrane, resulting in the depletion of cellular energy and the killing 
of bacteria.  Colicins are released by E. coli to reduce competition from other 
bacterial strains.  Colicin IA has three domains: an amino-terminal translocation 
domains which functions to allow movement across the outer membrane and 
periplasmic space; the receptor–binding domain and the carboxy-terminal 
channel-forming domain which functions to form channels in the cytoplasmic 
domain (Gouaux 1997, Stroud, Reiling et al. 1998).  The sequence identity over 
the homologous region between ANKRD18A and colicin IA is very low (9% 
identity) but the prediction has a high confidence level (98%).  The homology 
extends over the coiled-coiled region of colicin IA, including the receptor binding 
region but excludes the channel-forming domain.  In the fold prediction, the 
ANKRD18A Δ801 deletion mutation maps to a small helix in the receptor-binding 
region of colicin IA.  Because of the very low level of sequence identity between 
the two proteins, a prediction of what effect the analogous deletion would have 
on colicin IA is not possible. (Wiener, Freymann et al. 1997).  
 
NKRD18A is specific to primates (Figure 1.17) and is a member of the POTE 
(expressed in Prostate, Ovary, Testis and placenta) family of genes, of which 
ANKRD26 is the ancestral gene (Figure 1.17).  Causal variants located at 
multiple sites in the 5’-UTR of ANKRD26 have been shown to cause an 
autosomal dominant form of thrombocytopenia (ANKRD-RT or THC2), which 
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have been identified in multiple families in Italy (Noris, Perrotta et al. 2011).  
ANKRD18A and ANRKD26 share 44% identity at the amino acid sequence level.   
There is yet another POTE protein named ANKRD18B (also located on 
chromosome 9), which is 93%-identical to ANKRD18A at the amino acid 
sequence level (Figure S3).  The three glutamic acid residues, which are in 
ANKRD18A (residues 797-799) are also present in ANKRD18B (residues 870-
873).  The MLEEEVL sequence motif, which encompasses the three consecutive 
Glu residues (Δ801, third Glu residue mutated in patient ANKRD18A), is 
conserved in Pan troglodytes (chimpanzee) and partially conserved in Nomascus 
leucogenys (gibbon; third Glu residue missing) (Figure S4).  It is absent in 
gorillas, because the gorilla orthologue of ANKRD18A (760 amino acids) is 
truncated at the C-terminus relative to the human sequence (Figure S 4).  
 
ANKRD18A is specific to primates and is a member of the POTE gene family, 
which encompasses 13 known paralogs (Hahn, Bera et al. 2006).  Several POTE 
paralogs have been implicated in apoptosis and cytoskeletal regulation.  For 
instance, the POTE paralogs, POTE2α-actin and POTE2γ-C, which have an 
actin retrogene, were shown to induce apoptosis when transiently transfected 
into HeLA cells (Liu, Bera et al. 2009).  POTE proteins RAI14 and UACA share 
the linear domain organisation of ANKRD26 and other POTE proteins.  RAI14 is 
ubiquitously expressed and has thread-like projections in the cytoplasm that are 
POTE actin fusion proteins. The mouse orthologue of RAI14 is associated with 
cortical actin cytoskeletal structures in the terminal web and is also seen in 
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intestinal epithelial cell-cell adhesion sites.  UACA is more widely expressed in 
skeletal muscles.  The mouse orthologue of UACA localises to the cell cytoplasm 
and reportedly mediates apoptosis (Hahn, Bera et al. 2006).  Based on these 
findings and invoking homology between POTE proteins, it is conceivable that 
ANKRD18A may too be involved in cytoskeletal regulation.  
 
Tissue and cellular expression information for ANKRD18A mRNA is based on 
data obtained from the Genotype-Tissue Expression (GTEx) Project and the 
BLUEPRINT Epigenome Project.  GTEx is a resource database and associated 
tissue bank launched by the NIH to facilitate the study of the relationship 
between genetic variation and gene expression in tissues (Consortium 2013) 
(www.genome.gov).  Based on the database from GTEx, which RNA sequenced 
53 human tissue samples, ANKRD18A mRNA expression was noted to be 
highest in testis (5 FPKM) followed by spinal cord (2 FPKM), thyroid (1 FPKM), 
pituitary gland (0.8 FPKM), pancreas (0.7 FPKM), prostate gland (0.5 FPKM) and 
various regions of the brain with expression levels ranging from 0.5 to 1.0 FPKM.  
The cut-off level for detection was 0.5 FPKM. (FPKM is the fragments per 
kilobase of transcript per million mapped reads.  It is the relative expression of 
transcript in proportion to the number of cDNA fragments that originate from it.)  
Cellular expression of ANKRD18A mRNA is from the Blueprint haematopoietic 
database.  
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Figure 1.17 - Dendogram of the ANKRD gene family.  ANKRD18A is only 
expressed in primates whereas ANKRD26 expression is not limited to primates. 
 
The BLUEPRINT epigenome project is a collaborative endeavour funded by the 
EU to study how genes are activated or repressed in healthy and diseased 
haematopoietic cells (www.blueprint-epigenome.eu).   Based on the database 
from the Blueprint project, ANKRD18A mRNA expression in CD34-CD41+CD42+ 
MK cells was below the 0.5 FPKM cut-off. There was however, higher 
ANKRD18A mRNA expression in other hematopoietic cells: neutrophilic 
metamyelocyte (7 FPKM), mature eosinophil (5 FPKM), segmented neutrophil of 
bone marrow (2 FPKM), erythroblast (1 FPKM), conventional dendritic cell (0.8 
FPKM), and various αβ T and B cells (0.5-1 FPKM).   Contrary to the Blueprint 
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data, the PlateletWeb (plateletweb.bioapps.biozentrum.uni-wuerzburg.de) 
indicates that there is protein expression of ANKRD18A in platelets (unquantified 
and source of information unclear).  However, PlateletWeb does not indicate that 
ANKRD18B is expressed in platelets. 
   
The speculative domain structure of ANKRD18A gives few clues as to the 
physiological role of this protein. In order to characterise the function of 
ANKRD18A, a molecular probe specific for this protein is a key requirement.  
Previously, this project used polyclonal antibodies directed against peptides 
derived from amino acid residues 53-66 and 260-289 of the ANKRD18A 
sequence.  However, variable results in Western blotting experiments raised 
doubts as to the reliability and specificity of these antibodies. 
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1.7. Aims of this project 
The overall aim of this project is to characterise ANKRD18A.  Only then will it be 
possible to determine whether or not the genetic aetiology of Patient II:5 and 
II:3’s severe thrombocytopenia is due to the mutation in ANKRD18A.  An 
essential reagent for studying proteins is a specific antibody.  Because of 
variable results obtained when using ANKRD18A peptide antibodies that were 
already present in the laboratory, as well as the fact that there exists another 
protein, ANKRD18B, which has a 93% amino acid sequence identity with 
ANKRD18A, the first objective of this project was to generate an antibody which 
would be specific to ANKRD18A.  This specificity entailed an antibody which 
recognises the tertiary structure of ANKRD18A (or functional domains thereof).  
This antibody will permit subsequent in vitro experiments such as imaging 
studies for cellular localization and protein expression; flow cytometry assays to 
check for protein expression; and Westerns and immunoprecipitation 
experiments to confirm protein expression.   
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2. Materials and methods 
2.1. Cell Culture 
Human endothelial kidney (HEK) 293T cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin (P/S), 1% glutamine.  Dami (human 
megakaryoblastic) cells were grown in Roswell Park Memorial Institute (RPMI) 
medium supplemented with 10% FBS, 1% P/S and 1% glutamine (From Watson 
Lab protocol manual). 
 
2.2. Transient Transfections   
2.2.1. HEK 293T cells  
HEK293T cells were transfected with plasmid DNA using transfectant reagents 
transfectamine, lipofectamine or PEI.  Protocols for commercial reagents 
transfectamine and lipofectamine were according to kit protocols. HEK293 cells 
transfected using PEI followed the protocol in Table 2.1.  Cells were plated at the 
aforementioned densities 24 hours prior to transfection in media consisting of 
DMEM + 10% FCS + 1% glutamine but no P/S.  A day later, media was changed 
to DMEM + 2% FCS + 1% glutamine and no P/S.  A transfection cocktail cDNA + 
PEI + Opti-MEM was made, vortexed and incubated at room temperature for 10 
minutes before adding dropwise onto cells.  72 hours later, cells were harvested 
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by discarding media and placed in -80 ºC for more than 1 hour to assist in cell 
lysis (Protocol from Ben Willcox’s group). 
Plate size       Cells plated       Media volume      Opti-mem    DNA       PEI 
24-well             1x105                  500 µl                    25 µl            400 ng    2.5 µl 
6-well               5x105                  2 ml                      125 µl            2 µg       12.5 µl 
15 cm               5x106                 20 ml                     2.25 ml         36 µg      225 µl 
Table 2.1 - Protocol for HEK293T transient transfections using PEI. 
 
2.2.2. Dami cells  
Dami cells were transiently transfected using only PEI.  PEI was used because it 
is cheaper than the other proprietary transfection kits.  Transfections were 
performed using the same method as HEK293T cells except that the media used 
for plating the Dami cells consisted of RPMI + 10% FCS + 1% glutamine and no 
P/S.  Also, added to the media to differentiate Dami cells when plating the cells 
were 28.5 ng/ml hTPO + 6.2 ng/ml PMA per 10 ml of media (Protocol from S. 
Fletcher).  TPO and PMA are added on the day of plating Dami cells (24 hours 
before transfection). 
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Plate size       Cells plated     Media volume     Opti-mem     DNA          PEI 
24-well             8x104               500 µl                   30 µl            500 ng      1.5 µl   
12-well             2 x105                    1 ml                      60 µl            1 µg           3 µl 
 6-well              4 x105              2 ml                     150 µl           2.5 µg       7.5 µl 
Table 2.2 - Protocol for Dami cells transient transfections using PEI.   
 
2.3. Preparation of cellular lysates 
2.3.1. Washed Platelets 
Platelets were first obtained from whole blood by venipucture from healthy, drug 
free volunteers with a syringe containing 10% sodium citrate.  The blood was 
further anticoagulated by adding 10% acid citrate dextrose (ACD: 120 mM 
sodium citrate, 110 mM glucose, 80 mM citric acid).  The blood was spun at 200g 
for 20 minutes to separate the blood into its cellular fractions.  Platelets (platelet 
rich plasma, PRP), located in the top fraction, were retained, prostacyclin (10 
µg/ml) was added to inhibit platelet activation, and the PRP was again spun at 
1000g for 10 minutes.  The plasma supernatant was discarded and the platelet 
pellet washed with 25 ml modified Tyrodes-HEPES buffer (134 mM NaCl, 0.34 
mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 
mM MgCl2, pH 7.3) and 3 ml ACD. Prostacyclin was added again for the final 
spin at 1000g x 10minutes. The platelet pellet was resuspended in Tyrodes-
HEPES buffer at a concentration of 5-10X108/ml for Westerns and IPs and 
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2x107/ml for spreading experiments.  Platelets rested for 30 minutes before being 
used for further experiments (From Watson lab protocol manual).    
 
2.3.2. Platelet lysates  
Platelet lysates were prepared by adding the same volume of 2X Lysis buffer 
(300 mM NaCl, 20 mM Tris Base, 2 mM EGTA, 2 mM EDTA, 2% NP-40) and 
protein inhibitors (0.5 mM Leupeptin, 0.5 mM AEBSF, 0.05 mM Apotinin, and 
0.02 mM pepstatin), as the volume of washed platelets and placed on ice for 10 
minutes. Once lysis was completed, the tube of lysed platelets was centrifuged at 
10,000g for 10 minutes at 4 ºC (From Watson Lab protocol manual). 
 
2.3.3. Lysates of HEK293T (adherent cells) and Dami (suspended) 
cells  
Lysates of HEK293T and Dami cells were prepared by using RIPA buffer (50 mM 
Tris-HCl, pH 8, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM 
EDTA, 1% EDTA).  Adherent cells at ~80% confluency were lysed with 700 µl 
RIPA buffer plus inhibitors (as mentioned above) for a 10 cm dish, on ice.  
Suspension cultures at a density of 1 – 2 × 106 cells/ml were lysed with 100 µl of 
RIPA buffer plus inhibitors, on ice (From Cold Spring Harbor Protocols). 
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2.4. Construct design utilizing high-throughput cloning and 
expression at the Oxford Protein Production Facility (OPPF) 
2.4.1.   ANKRD18A Functional Domains Used 
Constructs listed in Table 2.3 were made using various forms (because of 
different fusion tags) of the expression vector pOPINF.  Inserts were the different 
functional domains of ANKRD18A:  
1. ankyrin repeat domain (amino acids1-260, as determined by HHpred) 
2. ankyrin repeat domain (amino acids 35-235, as determined by Phyre2) 
3. tropomyosin homology domain (amino acids 450-790) 
4. colicin IA homology domain (amino acids 790-992) 
Cloning was done with a ligase-free technology called InFusion (Clontech).  
Inserts were generated by PCR so cloning was independent of restriction sites.   
2.4.2. Vectors used 
1. pOPINE- POI-C-HIS6 (POI=protein of interest, C-HIS6=C terminal His tag) 
2. pOPINF- N-HIS6-3C-POI (N-HIS6=N terminal His tag, 3C= 3C protease site) 
3. pOPINFS- N-HIS6-3C-POI-C-STREPII (STREPII=streptavidin binding 
peptideII) 
4. pOPINJ- N-HIS6-GST-3C-POI 
5. pOPINM- N-HIS6-MBP-3C-POI (MBP=maltose binding protein) 
6. pOPINS3C- N-HIS6-SUMO-3C-POI (SUMO=small ubiquitin-like modifier) 
7.   pOPIN-3C-HALO7- POI-3C-HALO-C-HIS6 (HALO= Halotag) 
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2.4.3. Cloning 
Inserts were generated by PCR with primers designed for In-Fusion cloning by 
OPPF.  Primers had melting temperatures Tm > 68 ºC on target gene.  Template 
was purified plasmid DNA encoding GFP-tagged wild-type ANKRD18A.  Once 
the PCR reaction cycle was completed, PCR products were purified using the 
AMPureXP Magnetic Bead Purification kit (AgenCourt/Beckman).  Prior to 
purification, PCR reaction was treated with DpnI restriction enzyme (specific for 
methylated DNA) to digest the template but not the PCR product.  This step was 
required for cases where the template had the same antibiotic resistance as the 
target pOPIN vector.  Once purification was completed, the PCR product was 
eluted from magnetic beads with elution buffer (10 mM Tris-HCl, pH 8.0). 
Ligation reaction was performed using 1 µl of linearized pOPIN vector with 10 - 
250 ng of DNA encoding the purified insert, with added appropriate volume of 
sterile water for total volume of 10 µl.  This was added to a dry-down In-Fusion 
plate (Clontech).  The ligation reaction was allowed to proceed at 42 ºC for 30 
minutes. Following that, the reaction mixture was immediately placed on ice and 
diluted with 40 µl of TE buffer.  For transformation, 5 µl of diluted mixture was 
immediately added to OmniMaxII competent cells, and incubated on ice for 30 
minutes, followed by heat shock at 42 ºC for 30 seconds, then back on ice for 2 
minutes, then 300 µl of Power broth/SOC was added and the mixture was 
incubated at 37 ºC for 1 hour.  LB agar plates were prepared by mixing 
appropriate antibiotic (carbenicillin 50mg/ml, 1:1000)+ 20% X-gal (in DMF) + 
IPTG (500mM, 1:500).  After an hour, competent cells were plated onto agar 
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plates and then incubated overnight at 37 ºC.  Next day, white colonies were 
picked.   Blue colonies are secondary to inefficiently linearized parental plasmid.  
Picked colonies were placed in power broth supplemented with appropriate 
antibiotics.  Cultures were grown overnight in shaker.  Plasmids are then mini-
prepped using a Bio-Robot 8000 to obtain cDNA. 
2.4.4. HEK293T transient transfections  
Transfection utilised the transfectant reagent GeneJuice (EMDMillipore), which 
was composed of a nontoxic cellular protein and a small amount of a proprietary 
polyamine. The transfection procedures followed manufacturers’ 
recommendations.  
2.4.5. E. coli transformations and protein expression 
A volume of 3 µl of purified plasmid was added to competent cell E. coli strains 
B834 or Rosetta (DES) LysS aliquots in 96 well plates and the transformation 
was done as described above.  Agar plates were prepared as mentioned above 
and supplemented with antibiotics at a dilution of 1:1000 of the standardised 
stocks.  In order to avoid loss of the pRARELysS plasmid in Rosetta, 
chloramphenicol was added as well.  Typically, five transformation reactions 
were added onto agar plates and incubated overnight at 37 ºC.  On the following 
day, single colonies were picked and used to inoculate growth cultures (power 
broth) supplemented with appropriate antibiotics and incubated overnight at      
37 ºC while shaking (200 rpm).  The overnight cultures were diluted by 
inoculating 3 ml of power broth with either 150 µl of B834 or 250 µl of Rosetta 
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cultures, incubated in 37 ºC under shaking for 3 - 5 hours.  Subsequently, 
cultures were cooled (under shaking) in 20 ºC shaker for 20 min, and then 
induced by adding IPTG to a final concentration of 1 mM per well, following by 
incubation overnight at 20 ºC (under shaking).   
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Clone OPTIC Gene name aa_N aa_C 
OPPF 
No. 
Vector Tag 
MW of 
Tag 
(kDa) 
Domains 
Domain 
MW 
A1 13915 ANKRD-FL 2 992 14229 pOPINE (His)6 0.9 Full length 116 kD 
B1 13915 ANKRD-FL 2 992 14230 pOPINF 3CProt+His6 2.2   C1 13915 ANKRD-FL 2 992 14231 S3C Sumo-3C 13.2   D1 13915 ANKRD-FL 2 992 14232 M MBP 43   E1 13915 ANKRD-FL 2 992 14233 E-3C-HALO E3CHalo 35.3   F1 13915 ANKRD-35 35 235 14234 pOPINE (His)6 0.9 ANK repeat 
(Phyre2) 
23 kD 
G1 13915 ANKRD-35 35 235 14235 pOPINF 3CProt+His6 2.2   H1 13915 ANKRD-35 35 235 14236 S3C Sumo-3C 13.2   A2 13915 ANKRD-35 35 235 14237 M MBP 43   B2 13915 ANKRD-35 35 235 14238 E-3C-HALO E3CHalo 35.3   C2 13915 ANKRD-1 2 260 14239 pOPINE (His)6 0.9 ANK repeat 
(HHpred) 
30 kD 
D2 13915 ANKRD-1 2 260 14240 pOPINF 3CProt+His6 2.2   E2 13915 ANKRD-1 2 260 14241 S3C Sumo-3C 13.2   F2 13915 ANKRD-1 2 260 14242 M MBP 43   G2 13915 ANKRD-1 2 260 14243 E-3C-HALO E3CHalo 35.3   H2 13915 ANKRD-450 450 790 14249 pOPINJ GST 30 Tropomyosin 40 kD 
A3 13915 ANKRD-450 450 790 14250 pOPINFS Strep II 1.1   B3 13915 ANKRD-450 450 790 14246 S3C Sumo-3C 13.2   C3 13915 ANKRD-450 450 790 14247 M MBP 43   D3 13915 ANKRD-450 450 790 14248 E-3C-HALO E3CHalo 35.3   E3 13915 ANKRD-450 450 790 14244 E (His)6 0.9   F3 13915 ANKRD-790 790 992 14251 pOPINJ GST 30 Colicin 1A 24 kD 
G3 13915 ANKRD-790 790 992 14252 pOPINFS Strep II 1.1   H3 13915 ANKRD-790 790 992 14253 pOPINS3C Sumo-3C 13.2   A4 13915 ANKRD-790 790 992 14254 pOPINM MBP 43   B4 13915 ANKRD-790 790 992 14255 E (His)6 0.9   C4 13915 ANKRD-790 790 992 14256 E-3C-HALO E3CHalo 35.3   D4 13915 ANKRD-
450a 
450 992 14257 pOPINJ GST 30 Tropomyosin + 
Colicin 1A 
64 kD 
E4 13915 ANKRD-
450a 
450 992 14258 pOPINFS Strep II 1.1   F4 13915 ANKRD-
450a 
450 992 14259 pOPINM MBP 43   G4 13915 ANKRD-
450a 
450 992 14260 pOPINS3C Sumo-3C 13.2   H4 13915 ANKRD-
450a 
450 992 14261 E-3C-HALO E3CHalo 35.3   
! ! !
! ! !
! ! ! ! !Table 2.3 - DNA plasmid constructs generated at OPPF. Abbreviations used: 
3C = cleavage site for picornavirus endopeptidase 3C; SUMO = small ubiquitin-
like modifier; MBP = maltose binding protein; GST = glutathione-S-transferase; 
HALO = Promega HaloTag; Phyre2 = protein fold prediction server Phyre2 
(www.sbg.bio.ic.ac.uk/phyre2); HHpred = homology detection and structure 
prediction by HMM-HMM comparison (toolkit.tuebingen.mpg.de/hhpred). 
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Next day, 1 ml of induced culture was centrifuged at 6000 × g for 10 min.  The 
supernatant was discarded and cell pellets were placed in a -80 ºC freezer for at 
least 20 min to aid cell lysis.  Frozen cells were resuspended in lysis buffer (NPI-
Tween), supplemented with 1 mg/ml lysozyme and 400 units/ml DNAase type I, 
then stored on ice for 30 min., centrifuged at 5000 × g for 30 min. at 4 ºC.  The 
lysate was kept and transferred to a 96 well plate for purification of proteins using 
Qiagen Magnetic Ni-NTA beads with the Qiagen Bio-Robot 8000. 
 
2.5.  Plasmid DNA Preparation 
Validation of DNA construct correction was done by Sanger sequencing of all 
constructs that expressed protein when transfected into HEK293T cells: clones 
A4, B3, C3, E2, E3, F2, G2, H1, H3.  Sequencing reaction included 200 ng of 
plasmid DNA, 3.2 pmol of primer plus molecular grade water for a total volume of 
10 µl.  Primers (Sigma) used for sequencing were the T7 primer (5’ end): TAA 
TAC GAC TCA CTA TAG GG and the TriEX Down Primer (3’ end): CAC AAA 
TAC CAC TGA GAT CGA and ANKRD18A_JFR (starting at bp 493):  CTT ATT 
ATA CAC GGC ATA ATG (Table 2.6).  Reaction mix was then sent to the 
Birmingham Genomics Facility for sequencing (sequencing mixture protocol per 
Birminham Genomics Facility).  Plasmid DNA used for sequencing was prepared 
following the protocol from DNA Plasmid miniprep kit (Sigma PLN350).   
Following confirmation of the validity of construct sequence, the highest 
expressing clones were chosen for protein purification: clones F2 and G2.  Large 
amounts of plasmid DNA were required for large scale transfection of HEK293T 
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cells in 15 cm plates.  Plasmid DNA was prepped following the protocol from a 
MaxiPrep kit (Sigma NA0310). 
 
2.6. SDS-PAGE (sodium dodecyl sulphate polyacrylamide gels) 
and Western Blotting 
 
Denatured proteins were separated by electrophoresis using 8%, 9%, or 10% 
SDS-PAGE gels. Running buffer consisted of 25mM Tris Base, 190mM glycine 
0.1% SDS, pH 8.3.  Prestained molecular weight markers (New England Biolabs 
P7712) were run alongside samples.  Using the wet transfer method, separated 
proteins in the gels were electro-transferred onto PVDF (polyvinylidene 
difluoride) membranes (Biorad 162-0177) at 20V overnight or 100V for 1 hour.  
Transfer buffer consisted of 25 mM Tris Base, 190 mM glycine, and 20% 
methanol.  Following completion of transfer, membranes were blocked for 1 hour 
at room temperature in blocking buffer: 5% whole milk in TBS-T (Tris buffered 
saline with Tween-20): 200 mM Tris, pH 7.6, 1.37 M NaCl, 0.1% Tween 20. 
Following block, primary antibody was placed in block buffer and incubated at 4 
ºC overnight.  The following day membranes were washed 5X, 10 minutes each 
in TBS-T with increased salt concentration (200 mM Tris, 5 M NaCl, 0.1% Tween 
20) (TBS-T protocol per M. Tomlinson).  Then membranes were placed in HRP 
(horseradish peroxidase) conjugated secondary antibodies (GE Healthcare 
NA931V) in TBS-T for 1 hour at room temperature.  After incubation, membranes 
were again washed 5X with high salt TBS-T.  Once washes were completed, the 
membranes were incubated with enhanced chemiluminescence (ECL, 
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Amersham Biosciences, RPN 2232) reagent, 1 ml from each bottle, for 1 minute 
at room temperature, then developed by exposure to autoradiographs.  Primary 
antibodies used for Western blotting: rabbit polyclonal α-ANKRD18A (Abgent, 
AP18045a), rabbit polyclonal ANKRD18A: α-21233 and α-21234 (Biogenes), and 
rabbit polyclonal ANKRD18A: α-25277 (Biogenes) and rabbit polyclonal α-
GAPDH (Abcam, ab9485) (Protocols for Westerns from Watson lab protocol 
manual, transfer protocol from N. Morgan). 
2.6.1. Immunoprecipitation (IP) 
Cellular lysates, prepared as described above, were pre-cleared with 25 µl 
protein A sepharose (PAS) beads, rocking for 1 hour at 4 ºC.  Insoluble debris 
and beads then were pelleted by centrifugation at 10,000g at 4 ºC. The cleared 
lysate was transferred to a new tube, 1 µg of antibody was added and the 
eppendorf tube was rocked again for 15-60 minutes at 4 ºC.  Another 25 µl of 
PAS was added and the mixture again rocked at 4 ºC, overnight.  Next day, PAS 
beads were pelleted at 9,000 rpm, 20 seconds, 4 ºC.  The beads were then 
washed with four changes of 1X lysis buffer without inhibitors.  Proteins were 
eluted from the beads by adding 35-50ul 2X Laemmli sample buffer, boiled for 5 
minutes at 100 ºC.  Antibody used for IP was the rabbit polyclonal α-ANKRD18A, 
α-25277 (Protocol from Y. Senis). 
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2.7. Protein Purification 
2.7.1. Preparation of cleared lysate for Ni+2-NTA column 
chromatography 
Cells from the -80 ºC freezer were thawed on ice for 15 minutes or more then 
lysed on ice with 10 ml of lysis buffer containing 20 mM sodium phosphate, 500 
mM NaCl, 10 mM imidazole, 1% NP-40, DNAse I, protease inhibitors, pH 7.4.  
Protease inhibitors (Sigma S8830), used at 1:10, were made by dissolving a 
tablet containing various inhibitors (EDTA free) into 10 ml of H2O.  DNAse I 
(Sigma DN-25), used at 1:500, was prepared by dissolving 100 mg in 1 ml of 
H2O.  Following lysis, cells were scraped off the plate and the lysate was placed 
into ultracentrifuge tubes (Beckman 50 ml polyallomer tubes with caps) that fit 
the JA25.50 rotor.  The lysate was spun for 45 min. at 70,000g using the 
Beckman Coulter J2 ultracentrifuge. The supernatant was then cleared through a 
0.45 µm filter before it was loaded onto the Ni+2-NTA column. 
2.7.2.  Preparation of Ni+2-NTA Column 
Gibson pump tubing was filled with distilled H2O.  The 1 ml Ni+2-NTA column (GE 
Healthcare 17-5247-01) was clamped onto a stand and the top stopper removed.  
The tubing was connected to the column by allowing the distilled H2O to fill the 
column 'drop-to-drop' to avoid introducing air into the system and then the 
connecter with the tubing was screwed onto the column and the snap-off end of 
the column removed. The column was then washed with 5 column volumes of 
distilled H2O, then equilibrated with 10 column volumes of Binding Buffer (20 mM 
sodium phosphate, 500 mM NaCl, 10 mM imidazole, pH 7.4).  Elution Buffer 
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consisted of 20 mM sodium phosphate, 500 mM NaCl, 500 mM imidazole, pH 
7.4.  Columns were run at a rate of around 1 ml/min using the Gibson pump.  
Lysate were loaded onto the column twice to maximize binding to the column.  
Once loading was completed, the column was washed with 10 column volumes 
of the Binding Buffer.  Both clones F2 (MBP-Ank repeat domain) and G2 (E3C 
Halo-Ank repeat domain) were eluted using a buffer with increasing 
concentrations of imidazole.  Elutions of 10 column volumes were used per step.  
Concentrations of imidazole used per step were 60 mM, 80 mM, 100 mM, 150 
mM, 200 mM, 300 mM and 500 mM (Table 2).  To make the buffers with these 
concentrations of imidazole, one mixed the Binding Buffer with the Elution Buffer 
at various ratios using the formula:  (10 mM)x + (500 mM)y = 60 mM(x + y),   x = 
Binding buffer volume, y = Elution buffer volume 
Final imidazole concentration Binding Buffer 
volume (ml) 
Elution Buffer 
volume (ml) 
60 mM 4.5 0.5 
80 mM 4.4 0.6 
100 mM 4.1 0.9 
150 mM 3.35 1.65 
200 mM 3.05 1.95 
300 mM 2 3 
500 mM 0 5 
Table 2.4 - Volumes of Binding and Elution Buffers that are mixed to arrive 
at the different concentrations of imidazole needed to elute protein from 
the Ni+2-NTA column. 
 
Each different concentration of imidazole elution was collected in a different 15 
ml conical tube.  Once collection was completed, 40 µl was taken from each tube 
to be run on a Coomassie gel to determine at which fraction is the elution 
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cleanest.  40 µl of elution was mixed with 10 µl of 5x sample buffer, boiled for 5 
min and run on a 10% acrylamide gel.  Clone F2 eluted with the highest purity 
after the imidazole concentration of 100 mM.  Elutions from using imidazole 
concentrations of 100 mM and greater (100 mM, 150 mM, 200 mM, 300 mM, and 
500 mM imidazole) were combined and dialyzed thrice-overnight and then next 
day twice for 2 hours or greater, each in dialysis buffer consisting of 20 mM Tris, 
150 mM NaCl, pH 7.8.  Clone G2 eluted with imidazole concentrations of 300 
mM and greater so the following fractions were pooled for dialysis: 300 mM and 
500 mM imidazole. Dialysis also consisted of 3 exchanges lasting two hours or 
greater, each time.  Dialysis buffer consisted of 20 mM Tris, 200 mM NaCl, pH 
7.8.  Dialysis tubing was boiled for 5 min in 10 mM EDTA and stored in 20% 
ethanol prior to use (Protocol for preparation and use of Ni+2-NTA column and 
buffers from GE Healthcare manual, and as described in Wang et. Al. (Wang, 
Sambandan et al. 2013). 
2.7.3. Preparation of Anion Exchange Column 
Following completion of dialysis, dialysate was loaded onto a 1 ml anion 
exchange column (HiTrap Q HP, GE Healthcare 17-1151-01), at a rate of 1 
ml/min using the Gibson pump.  The anion exchange column was prepared by 
first removing the top stopper and loading the column with the Start Buffer by first 
adding it dropwise so not to introduce air into the column.  Once loaded, the 
bottom stopper was removed and the column was washed with 10 column 
volumes of Start Buffer: 20 mM Tris, 50 mM NaCl, pH 7.8 to remove the 
preservatives in the column.  The column was then washed with 10 column 
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volumes of Regeneration Buffer (20 mM Tris, 1 M NaCl, pH 7.8) and then 
equilibrated with 10 column volumes of Start Buffer.  Once the above column 
preparation was completed, the dialysate was loaded onto the column once 
followed by washing of the column once with Start Buffer and then elution 
commenced with stepwise ionic strength gradients (increasing concentrations of 
NaCl). Start Buffer: 20 mM Tris, 50 mM NaCl, pH 7.8, Elution Buffer: 20 mM Tris, 
500 mM NaCl, pH 7.8.  Formula used to determine the increasing NaCl 
concentrations:  x + y = 10, 50x + 500y = 175(x+y). x = Start Buffer volume, y = 
Elution Buffer volume (Protocol for column preparation and buffers from GE 
Healthcare). 
Final NaCl 
concentration 
Start Buffer volume (ml) Elution Buffer volume 
(ml) 
175mM 7.222 2.778 
200mM 6.667 3.333 
250mM 5.556 4.444 
300mM 4.444 5.556 
350mM 3.333 6.667 
400mM 2.222 7.778 
500mM 0 10 
Table 2.5 - Volumes of Start and Elution Buffers mixed to arrive at the 
concentrations of NaCl needed to elute protein from the anion exchange 
column. 
 
 
Each elution fraction was collected in 15 ml conical tubes.  From each fraction, 
40 µl was taken and mixed with 5x sample buffer, boiled, run on a SDS-PAGE, 
then stained with Coomassie stain to determine at which NaCl concentration is 
the protein eluted.  For Clone F2, fractions eluted with 250-500 mM NaCl, 
inclusive, were pooled, then dialyzed in 20 mM Tris, 200 mM NaCl, pH 7.8 thrice, 
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2 hours or greater, each. Following dialysis, protein was concentrated with 
Amicon Ultra-15 centrifugal filters (Millipore UFC903024).  For Clone G2, 
fractions eluted with 350-500 mM NaCl, inclusive, were pooled, then dialyzed 
thrice in 20 mM sodium phosphate, 500 mM NaCl, pH 7.5.  Each dialysis lasted 2 
hours or more, each time.  Afterwards the dialysate is concentrated with the 
Amicon Ultra-15 filters (Protocol for Amicon use from Millipore instructions, 
protocols for dialysis buffer recipes from Biogene recommendation). 
2.7.4. Concentration of eluted protein 
Following completion of dialysis, the dialysate concentration was measured using 
a NanoDrop spectrophotometer.  Determining protein concentration using the 
NanoDrop required the molecular weight (MW) of the protein and its coefficient of 
extinction. For Clone F2, its MW is 72.126 kilodaltons (g/mol) and extinction 
coefficient is 81165 M-1cm-1. For clone G2, its MW is 64.842 kD and the 
extinction coefficient is 73,380 M-1cm-1.  The protein was concentrated using 
Amicon Ultra-15 filters. The filters were first pre-wetted with ddH2O, spinning at 
2300 rpm for 15 min.  Dialysate was then placed into the column and spun 
cautiously so as not to dry out the filter.  First spin was at 2500g for 10 min and 
repeated until volume decreased to about 2 ml.  Speed was then decreased to 
1000g for 10 min.  When the volume reached 1 ml, the concentration was 
checked on the NanoDrop.  This was done 3 times and the values averaged to 
arrive at the concentration value.   
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2.7.5. Passivation of Amicon ultra-filtration membranes  
Membranes were overnight in 2 ml of 5% PEG 6000 (Stock, 20%).  Next day, p 
PEG 6000 was poured out and column rinsed with sterilised double distilled 
water.   2 ml of sterilised double distilled water was placed into column again and 
spun at 2300 rpm for ~20 minutes so that only 500 µl of water remained. 
Previous step was repeated.  Remaining 500 µl of water was removed and 
replaced with 2 ml of sterilised distilled water inside filter (column) and 5 ml 
outside filter (Protocol from K. Fütterer). 
 
2.8. Coomassie stain 
8-10% SDS-PAGE was stained with Coomassie stain to determine at which 
imidazole or NaCl fractions the protein was eluted. The gel waas stained for at 
least 1 hour, then destained until bands are discernable and background blue 
stain is light blue. Following destain, the gel needs to be placed in a gel drying 
solution for at least 1 hour to delay cracking of the gel.  Coomassie stain: 0.1% 
Coomassie R250, 10% glacial acetic acid, 40% methanol.   Coomassie destain: 
20% methanol, 10% glacial acetic acid.  Gel drying solution:  10% methanol, 5% 
glycerol (Protocol from K. Fütterer). 
 
2.9. Lentiviral production 
On day prior to transfection, 3x106 HEK293T cells were plated onto 10 cm dishes 
in 10 ml of DMEM with 10% FCS plus glutamine. Next day, media was removed 
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and replaced with 3 ml of DMEM with 2% FCS + glutamine. 1 ml of Opti-mem 
plus 9 µg of DNA (4.39 µg of target gene + 3.29 µg of packaging vector, PAX2, 
+1.32 ug of envelope vector, PMD2G) plus 36ug of PEI were pipetted into an 
eppendorf tube. Tube was vortexed then mixture sat at room temperature for 10 
minutes then added dish drop-wise to dish followed by north-south and east-west 
movements of plate to mix its contents.  Plates were put in 37ºC incubator for 48 
hours then the supernatant was harvested for lentivirus (Protocol from R. Bicknell 
Lab). 
2.9.1. Concentrating Lentivirus 
All the supernatant from the above lentiviral transfection was placed into 50 ml 
conical tubes.  Cellular debris was removed from the supernatant by centrifuging 
at 300g for 5 minutes.  The supernatant was placed into concentrators (Corning 
Spin X UF, 20 ml, Sigma 431487) once concentrators had been rinsed with 10 ml 
of sterile distilled water by centrifuging at 4000g for 10 minutes.  The supernatant 
was centrifuged for 2 hours at 4000g.  Once completed, what remained at the top 
of the concentrator (~2 ml) was kept and 8 µg/ml of polybrene (Sigma 107689) 
was added.  The mixture was filtered through a 0.45 µm filter (Protocol from R. 
Bicknell Lab). 
 
2.10. Isolating cDNA for RT-PCR and quantitative real time PCR 
Total RNA was isolated and purified using the Machery-Nagel kit (cat. no. 
740955.10).  10 µl was taken from RNA prep and mixed with 10 µl of premix from 
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the ABI RT kit (cat.no. 4368814) which converted total RNA to single-strand 
cDNA by using the following program on the PCR thermocycler: 25 ºC for 10 min, 
37 ºC for 2 hours, 85 ºC for 5 min, 4 ºC forever.  The RT-PCR program which 
used to determine mRNA expression was: Denaturation 94 ºC for 3 min, 
Denaturation 94 ºC for 1 min, Annealing 60 ºC for 1 min, Extension 72 ºC for 1 
min, repeat 39 times, Extension 72 ºC for 5 min, 4 ºC forever.  RT-PCR reaction 
mixture consisted of 12.5 µl Sigma Red Taq polymerase, 0.5 µl forward primer 
(10 µM), 0.5 µl forward primer (10 µM), 10.5 µl H2O, and 1 µl cDNA (Protocol 
from N. Morgan). 
Primer name Primer sequence (5'-3') 
ANKRD18A_CF (Forward) GCCCGGTATTCGCAACAGCTT 
ANKRD18A_BR (Reverse) CGATGCTGTGCTTGCTTAGG 
ANKRD18B_CF (Forward) CTCAGTTTTGGGAGACGCCTG 
ANKRD18B_CR (Reverse) GCGCCACGTTTCAGGAGAATA 
β-actin (Forward) GCGGGAAATCGTGCGTGACATT 
β-actin (Reverse) GATGGAGTTGAAGGTAGTTTCGT 
GAPDH (Forward) GAAGGTGAAGGTCGGAGT 
GAPDH (Reverse) AAGATGGTGATGGGATTT 
T7 (Forward) TAATACGACTCACTATAGGG 
TriEX Down (Reverse) CACAAATACCACTGAGATCGA 
ANKRD18A_JFR (Reverse) CTTATTATACACGGCATAATG 
Table 2.6 - Primer sequences used in RT-PCR and Sanger sequencing 
 
2.10.1. Preparing quantitative real-time reaction plates 
Reaction mixture consisted of SYBR green 12.4 µl, Forward Primer 0.1 µl (10 
µM), Reverse Primer 0.1 µl (10 µM), H2O 9.8 µl, cDNA 2.5 µl.  Every reaction 
was done in triplicate. NTC is PCR H20 (negative control).  Control neat was the 
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positive control.  In this case, Damis and the retinoblastoma cell lines were used. 
These dilutions of neat were used: the first set is 1:5, 2nd set is 1:25, 3rd set is 
1:50. Sequences of ANKRD18A and 18B primers are as written in Table 2.6.  
Quantitation of ANKRD18A and 18B mRNA expression were compared against 
two internal standards, β-actin and GAPDH.  Sequence of primers for β-actin and 
GAPDH are in Table 2.6.  The instrument used was Applied Biosystems real-time 
PCR 7500 Fast and the thermal cycling conditions were UP activation 95 ºC 20 
sec HOLD, Denature 95 ºC 3 sec 40 cycles, Anneal/Extend 60 ºC 30 sec 40 
cycles. The Sequence Detection System software calculated the baseline and 
threshold for the amplification curves (Protocol from N.Morgan). 
 
2.11. Immunofluorescence confocal microscopy 
HEK293 and Dami cells were transfected as above in 24 well plates with 
coverslips placed in them.  Coverslips were initially sterilized in 70% EtOH and 
dried prior to placing into wells of plate.  48 hours after transfection, media in the 
wells were removed and cells were washed with PBS 3 times.  After final wash, 
cells were fixed in 200 µl of 10% formalin for 5 min.  Once fixation was 
completed, cells were washed again 3 times with PBS.  After final wash, if cell 
permeabilization was required, 200 µl of 0.1% TritonX-100 was added to each 
well and incubated for 5 minutes.  After 5 minutes, cells were again washed with 
PBS 3 times before 200 µl of the blocking solution (45 ml of 5% BSA + 5 ml of 
10% goat serum) was added to each well and incubated for a minimum of 1 hour.  
Once blocking was completed, primary antibody was added directly into blocking 
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solution and cells were incubated in primary antibody for 1 hour.  The amount of 
antibody used varied, depending on antibody concentration: monoclonal anti-myc 
antibody 1:200 (Cell Signalling Technology, 9B11), monoclonal anti-His antibody 
1:750 (R&D Systems, MAB050), polyclonal anti-ANKRD18A 1:100.  After 
incubation with primary antibody, cells were again washed 3 times with PBS.  
After washing, cells were incubated with 200 µl of fluorochrome labelled 
secondary antibody for 1 hour in the dark.  [Alexa Fluor 488 goat anti-mouse IgG 
H+L 2 mg/ml (A10680, Life Technology), Alexa Fluor 647 goat anti-rabbit IgG 
H+L 2 mg/ml (A21244, Life Technology)].  After incubating in secondary 
antibody, cells were again washed 3 times with PBS.  If visualization of the 
nucleus was required, cells were then stained with TO-PRO-3 Iodide (Invitrogen 
T3605), 1:2000 for 20 min in the dark.  Following TO-PRO, cells were again 
washed 3 times with PBS and then coverslips were taken out of the wells and 
mounted onto slides with Hydromount (National Diagnostics, HS-106).  Slides 
were then examined on the Leica DMIRE2 confocal microscope.  All cells were 
imaged with a 60X oil objective.  GFP tagged proteins and Alexa Fluor 488 
secondary antibody were imaged following excitation with the 488 nm line on an 
Argon-ion laser.  TO-PRO-3 and Alexa Fluor 647 were imaged after excitation 
with a 633 nm line on an Argon-ion laser.  Analyses of images were performed 
using ImageJ software (Fletcher, Iqbal et al. 2014). 
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2.11.1. Plasmids transfected into HEK293T cells and HeLa cells 
for confocal microscopy 
1.  pCMV-GFPWT ANKRD18A  
2.  pCMV-GFP MUT ANKRD18A  
3.  pCMV-GFP vector 
4.  pCMV-MycWT ANKRD18A  
5.  pCMV-MycMUT ANKR18A  
6.  pCMV-Myc vector 
 
 
2.12. Platelet spreading 
Glass coverslips were coated overnight at 4 ºC using 100 µg/ml fibrinogen 
followed by washing with three changes of PBS.  The coverslips were then 
blocked with 5 mg/ml of heat denatured BSA for 1 hour at room temperature 
followed by washing with another three changes of PBS. Washed platelets were 
then added to the coverslips to allow for adherence and spreading for 45 minutes 
at 37 ºC.  Afterwards, non-adherent platelets were removed with three changes 
of PBS washes.  Adherent platelets on the coverslips were fixed with 10% 
formalin at room temperature for 10 minutes.  Coverslips were then mounted 
onto glass slides using Hydromount and imaged by confocal microscopy as 
above (Protocol from Watson lab). 
 
2.13. Flow Cytometry 
Cells transiently transfected in 6 well plates were trypsinised if adherent 
(HEK293T cells) or cell plate is tapped forcefully to dislodge the small amount of 
adherent cells (Dami cells).  Media was collected and cells were spun down at 
1000 rpm for 5 min to remove supernatant.  Cells were then washed with PBS 
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and incubated with PBS/10% FBS for 20 min.  Cells were washed with PBS 
again, then fixed with 500 µl of 10% formalin for 5 min.  Following fixation, cells 
were permeabilised with 500 µl of 1% TritoninX-100/PBS for 5 min.  Again, 
afterwards, cells were washed with PBS.  Following wash, cells were incubated 
with primary antibody (anti-25277) at 1:100 for 20 min in PBS + 2% FBS.  Control 
antibody used was a monoclonal anti-IgG (CalTag, MAB8406).  After incubation, 
cells were washed with PBS/1% FBS.  After wash, cells were then incubated with 
secondary antibody, Alexa Fluor 488 goat anti-rabbit IgG (Life Technology 
A11008) or Alexa Fluor 488 goat anti-mouse IgG at 1:500 in PBS/2% FBS for 20 
min.  Cells were again washed with PBS/1% FBS.  Following wash, cell were 
resuspended in PBS and analysed on the AccuriC6 (BD Biosciences) flow 
cytometer (Protocol from J. Reyes).  
 
2.14. Isolation of CD34+ cells from human umbilical cord blood 
by density gradient centrifugation  
 
2.14.1. Isolation of Mononuclear Cells 
All reagents were at room temperature.  Cord blood was diluted with 15 ml of 
blood with 35 ml of Buffer 1 (Sterile Buffer 1= 5 ml of ACD in 45 ml of PBS, pH 
7.2).  Acid Citrate Dextrose (ACD): Sodium Citrate - 25 g/L, Glucose - 20 g/L, 
Citric Acid- 15 g/L).  35 ml of diluted sample was carefully laid over 15 ml of 
Ficoll-Paque (d=1077 g/ml, GE Healthcare Life Sciences, #17-1440-02) in 50 ml 
Falcon tube – the two layers must not be mixed.  Low density mononuclear cells 
were obtained after centrifugation for 30 minutes at 400g at 20 ºC with no brake. 
Chapter Two Materials and methods 
 
 
117 
 
The upper layer was aspirated and discarded.  The mononuclear cell layer 
(lymphocytes, monocytes, thrombocytes) is at the interphase.  The interphase 
was transferred to a new 50 ml Falcon tube.  The volume of transferred 
interphase layer was estimated and added to at least 3 volumes of Buffer 1, 
mixed and centrifuged at 300g for 10 minutes at 20 ºC.  After spin, supernatant 
was removed completely.  To isolate CD34+ cells, pellet (by flicking the tube) was 
resuspended in 50 ml of Buffer 1 and centrifuged at 200g for 10 minutes at 20 ºC.  
Supernatant was removed completely.  Pellet was resuspended in 500 µl of 
Buffer 2 (Sterile Buffer 2:  ACD, PBS pH 7.2, 0.5% BSA) (Protocol from D. Bem).   
2.14.2. Isolation of CD34+ cells from mononuclear cells 
Subsequent steps required all reagents to be at 4ºC.  30 µm pre-separation filter 
was moistened  (Miltenyi Biotec, #130-041-407) with Buffer 2 and then cells 
passed from above through nylon mesh.  Cells were washed once with 500 µl of 
Buffer 2 and then pellet resuspended in 500 µl Buffer 2 and cell suspension 
placed into MACS column (Miltenyi Biotec, #130-042-201) and centrifuged at 
300g for 10 minutes at 4 ºC.  Cell pellet resuspeded in 300 µl Buffer 2 for up to 
108 total cells.  100 µl FcR Blocking Reagent (MACS MicroBead Kit, Miltenyi 
Biotec, #130-046-702) was added for up to 108 total cells.  100 µl CD34 
MicroBeads was added for up to 108 total cells.  Mixture was mixed and 
incubated for 30 minutes at 4 ºC.    Afterwards, cell number was determined by 
counting [10 µl of trypan blue (Sigma) plus 90 µl of cell solution].  Cells were 
washed by adding 5-10 ml of Buffer 2 for up to 108 total cells and centrifuged at 
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300g for 10 minutes at 4 ºC.   Supernatant was aspirated completely.  Cells up to 
108 cells were resuspended in 500 µl Buffer 2 (Protocol from D. Bem). 
2.14.3. Magnetic Separation 
An appropriate MACS column and MACS separator (Miltenyi Biotec) were 
chosen according to the number of total cells and the number of CD34+ cells.  P 
The column was placed in the magnetic field of a suitable MACS Separator.  The 
column was prepared by rinsing with Buffer 2.  For MS column, 500 µl of Buffer 2 
and for LS column, 3 ml of Buffer 2.  Cell suspension was placed onto column 
drop-wise.  Flow-through, which contained unlabelled cells, (can be used as 
negative control) was collected.  Column was washed three times with the 
appropriate amount of Buffer 2:  MS-3x500 µl and LS-3x3 ml.  Unlabelled cells 
were collected from wash and combined with previous flow-through.  Column 
removed from the separator and placed onto a suitable collection tube.  An 
appropriate amount of Buffer 2 was pipetted onto the column and the 
magnetically labelled cells were immediately flushed out by firmly pushing the 
plug into the column (MS-1 ml and LS- 5 ml) (Protocol from D. Bem). 
 
Column Max # of 
labelled cells 
Max # of 
total cells 
Separator 
MS 107 2 × 108 MiniMACS (Octo Vario Super) 
LS 108 2 × 109 MidiMACS(Quadro Vario Super) 
Table 2.7 - Choosing the appropriate MACS column and separator based on 
total and CD34+ cell numbers 
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2.14.4. Evaluation of hematopoietic progenitor cell purity 
Purity of the isolated hematopoietic progenitor cells were evaluated by flow 
cytometry or fluorescence microscopy.  Analysis of CD34+ cells were 
accomplished by direct immunofluorescent staining using an antibody 
recognising an epitope different from that recognised by the CD34 monoclonal 
antibody QBEND/10. 
 
2.14.5. Expansion and differentiation of CD34+ cells 
CD34 cells were expanded for 5 days using the cocktail of growth factors 
suspended in the media, Stem Pro 34 (Invitrogen) plus 0.1% 
Penicillin/Streptamycin (Sigma), 0.1% glutamine (Sigma) and 1.3 ml nutrients. 
Growth factors (Miltenyi Biotec) are:  Flt3-L 50 µg/ml, IL3 10 µg/ml, h-SCF 50 
µg/ml, TPO 20 µg/ml, and IL6 10 µg/ml.  After 5 days the cocktail changed to h-
SCF (1 ng/ml), IL6 (7.5 ng/ml), IL9 (13.5 ng/ml) and TPO (30 ng/ml) so that 
CD34+ cells can differentiate to megakaryocytes.  Following 12 days of 
differentiation, cells were checked for ploidy and expression of CD41 using flow 
cytometry and mRNA expression using RT-PCR as described in (Pinault 2013).  
2.14.6. Evaluation of ploidy in megakaryocytes  
Used for checking maturation stage of megakaryocytes.  Cells were incubated for 
45 minutes at 37 ºC with 0.1% Triton X-100 (Sigma), RNAse (Sigma) and 
propidium Iodide (Sigma) to stain for DNA.  Ploidy was determined using the BD 
FACS Calibur flow cytometer (Protocol from A. Mazharian).  
Chapter Two Materials and methods 
 
 
120 
 
2.15. Transmission electron microscopy 
PRP was prepared by centrifugation at 200g for 10 minutes and fixed with equal 
volume of 0.1% glutaaldehyde (GA) in 0.1 M sodium cacodylate buffer (pH 7.4) 
at room temperature for 15 minutes.  Platelets were post-fixed with 3% GA in 0.1 
M sodium cacodylate buffer at 4 ºC for 30 minutes.  The cells were further fixed 
with 1% osmium tetroxide in 0.1M sodium cacodylate buffer for 1 hour at 4 ºC.  
Cells were then rinsed with distilled water, dehydrated in a graded series of 
alcohol and embedded in Epon resin.  Ultrathin sections (70-90 nm) were stained 
with uranyl acetate and lead acetate.  All imaging was done in a Tecnai G2 Spirit 
microscope (FEI, Eindhoven, Netherlands) using a Morada EM CCD digital 
camera (Olympus SIS, Münster, Germany) (Bem, Smith et al. 2015). 
 
2.16. Statistical analysis of α-granules in electron micrographs 
Results were shown as mean ± SEM.  Statistical analysis was performed with 
Excel software (Microsoft) using a two-way ANOVA test. P < 0.05 was 
considered statistically significant.  
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3. Initial characterisation of the ANKRD18A variant 
3.1. Introduction 
Prior to the commencement of this PhD, a whole exome-sequencing approach 
was used to identify the genetic aetiology for the severe thrombocytopenia seen 
in two cousins from a consanguineous family (Figure 1.14).  Whole exome 
sequencing (WES) identified a homozygous in-frame deletion mutation 
(c.2401_2404delGAA) in the gene, ankyrin repeat domain 18A gene 
(ANKRD18A), of both children.  To confirm that this mutation in ANKRD18A is 
causing the thrombocytopenia seen in the two patients, experiments needed to 
be conducted using patient platelets. 
 
3.2. Quantitation of ANKRD18A mRNA expression in patient 
platelets 
 
Unfortunately, because both study patients are children who received frequent 
platelet transfusions, it was difficult to obtain regular blood samples to study the 
patients’ platelet defects.   Prior to my joining the laboratory, some blood was 
obtained from both patients and the following studies were performed to 
characterize their platelets.  Both patients had severe thrombocytopenia: their 
platelet counts in the platelet rich plasma (PRP) was significantly below the 
reference range seen in healthy volunteers (patient II:5 1.5x107/ml and patient 
II:3 2.5x107/ml, reference range 2.1-7.1x108/ml [mean ± 2 s.d.]). Mean platelet 
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volume (MPV) in patient II:5 was 15.0 fl and in patient II:3, it was 10.4 fl 
(reference range 7.68 – 10.0 fl [mean ± 2 s.d.]).  Of note, full blood counts from 
both patients’ parents were normal.  
 
Prior to functional studies on the patients’ platelets, one first needed to measure  
the abundance of ANKRD18A mRNA using real time quantitative PCR (qRT-
PCR).  This experiment compared the ANKRD18A mRNA levels of the patients’ 
leukocytes with those of healthy controls.  Quantitation was not performed on 
patient platelet mRNA because of the assumption that being anuclear, platelets 
would have minimal mRNA, which would further compound the results from the 
very low platelet counts.  Instead, quantitation of ANKRD18A mRNA was 
performed using patient leukocytes from the buffy coat.   
 
Using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, 
Foster City, CA, USA), relative gene expression quantification was performed 
according to the comparative CT method using β2 microglobulin (B2M) as an 
endogenous control.  qRT-PCR product accumulation was measured by SYBR 
green, a DNA intercalating dye.   When measuring RNA expression of target 
genes, to control for errors between samples, there needs to be coincident 
measurement of RNA expression of a reference gene (in this case, B2M) so that 
there is normalization of the target gene expression data.  In this experiment, the 
CT (threshold cycle) of target genes was compared to the CT of reference genes 
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(relative qRT-PCR method).  The threshold cycle is the intersection of the 
reaction curve to the threshold line, which is a level above the background 
fluorescence.  The CT indicates the number of cycles it takes to detect a signal 
above background fluorescence in the samples 
(www.thermofisher.com/uk/en/home/life-science/pcr/real-time-pcr/qpcr-
education/pcr-understanding-ct-application-note.html).  To analyse the qRT-PCR 
data, the double ΔCT analysis method was used (Livak and Schmittgen 2001).  
This method involved averaging CT values for the target gene and reference 
gene and the controls.  The average CT value for the reference gene was 
subtracted from that of the target gene’s CT value.  The same was done for the 
CT values of the controls of the target gene and reference gene.    Afterwards, 
the difference of the above two CT values provided a ΔΔCT value, which then 
converted to linear form by the calculation of 2-CT.          
 
Compared with control leukocytes, ANKRD18A mRNA levels were significantly 
reduced by more than 80% in patient leukocytes (p<0.02) (Figure 3.1). The 
reduction in the patients’ ANKRD18A mRNA was presumably due to impaired 
stability of the mutated transcript (N.Morgan, unpublished data).  
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Figure 3.1 - A homozygous ANKRD18A mutation results in decreased 
expression of ANKRD18A mRNA in 2 patients with a severe 
thrombocytopenia.  ANKRD18A mRNA production, as assessed by real-time 
quantitative PCR (qRT-PCR) on total RNA isolated from PBMCs from the 2 
patients (II:5 and II:3) and 2 healthy controls (C1 and C2).  ANKRD18A mRNA 
levels were expressed as relative expression compared to β2 Microglobin mRNA 
levels.  Values are mean ± SEM for 3 experiments for all samples.   * P < 0.05 
(N. Morgan, unpublished data). 
 
3.3. Functional Studies using patient platelets 
Prior to functional studies, the patients’ resting levels of platelet surface 
glycoproteins: CD42b (GPIbα, a component of the GPIb-IX-V complex which 
binds von Willebrand factor), CD41 (integrin αIIb, which binds fibrinogen), and 
GPVI (binds collagen) were measured by flow cytometry (Figure 3.2).   
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A. 
 
B. 
 
Figure 3.2 – Patients’ platelets [(A) II:5 and (B) II:3] have similar surface 
receptor expression levels compared to control when surface area of 
patient platelets were normalised to control.  However, CD42b levels for 
patient II:5 is reduced and GPVI levels are slightly reduced for patient II:3, both 
due to unclear reasons  (N. Morgan, unpublished data). 
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For Patient II:5, levels of CD42b were reduced when compared to healthy 
control.  Levels of CD41 and GPVI were similar in the control and patient  (The 
patient’s MPV was larger and the surface area of the patient’s platelets were 
approximately 30% larger than the control).   The significance of the CD42b 
result is uncertain as previous investigations were not compatible with a 
diagnosis of Bernard-Soulier disease.  For Patient II:3, levels of GPVI were 
slightly reduced  and levels of CD42b and CD41 were comparable in the control 
and patient  (The patient’s MPV is larger and the surface area of the patient’s 
platelets is approximately 15% larger than the control).   The significance of the 
GPVI result is uncertain (N. Morgan, unpublished data). 
 
Platelet function was then assessed by flow cytometry using an assay that was 
validated using dilutions of PRP from healthy volunteers. The control PRP was 
diluted 1 in 10 with phosphate-buffered saline (PBS) to enable assessment of 
fibrinogen binding. PRP was stimulated with ADP, collagen-related peptide 
(CRP) and PAR-1 peptide (PAR-1 specific thrombin receptor activating peptide 
with the amino acid sequence SFLLRN). Both the expression of P-selectin (FITC 
conjugated mouse anti-human CD62 antibody, BD Pharmingen), which is a 
marker of dense and a-granules release upon platelet activation and binding of 
fluorescent fibrinogen (DAKOCytomation Polyclonal Rabbit Anti-Human 
Fibrinogen/FITC) to the activated form of the platelet surface αIIbβ3 (GPIIb/IIIa) 
complex were assessed by flow cytometry on an Accuri C6 flow cytometer.  Both 
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patients’ PRP showed markedly reduced response to ADP, CRP and PAR-1 
peptide when assessing for expression of FITC-conjugated anti-CD62P.  
Strikingly, patient II:5 showed an abolition of the response to ADP, CRP and 
PAR-1 peptide (Figure 3.3A).  The response of patient II:3 to the same agonists 
was markedly reduced (Figure 3.3A).   In both patients, the response assessed 
using binding of fluorescent fibrinogen was reduced when compared with normal 
ranges derived from healthy volunteers PRP (Figure 3.3B).  It cannot be 
ascertained however, whether these abnormal results were a reflection of 
decreased platelet numbers or because ANKRD18A plays a role in platelet 
activation (N. Morgan, unpublished data). 
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Figure 3.3 – Patients’ platelets have decreased responses to α-CD62P (A) 
and decreased fibrinogen binding to αIIbβ3 (B) after stimulation with low 
and high dose agonists: ADP, CRP and PAR-1 peptide.  Healthy volunteers 1 
in 10 = PRP from control individuals diluted 1 in 10 with PBS.   Data for healthy 
volunteers shown as mean + 1 s.d. (n=9). Isotype control = IgGk1.  (N. Morgan, 
unpublished data). 
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3.4. Electron microscopy of ANKRD18A patient platelets  
To study the patients’ platelet ultrastructure, transmission electron microscopy 
(TEM) images were obtained from patient II:3 (Figure 3.4).  TEM images of the 
platelets from patient II:3 revealed that they were larger but fewer in number than 
normal subjects (macrothrombocytopenic).  Also, it appeared that these large 
platelets may have more α-granules.  However, upon further analysis whereby 
the surface area of the larger platelets are taken into account  (number of α 
granules in platelet/surface area of platelet), one sees that the number of α 
granules is no greater than that of platelets from a healthy subject using the two-
way ANOVA statistical test (Control: 1.01 ± 0.42 vs. Patient:  0.98 ± 0.32).  A 
total of 24 platelets were counted from the patient slide and 51 platelets from the 
control slide.  Surface area of platelets was determined by using the ImageJ 
analysis tool. 
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Figure 3.4 – Transmission electron microscopy image demonstrating 
patient platelets to be enlarged but number of α granules in patient 
platelets not significantly different from number of α granules in healthy 
control platelets.  Patient with macrothrobocytopenia but the number of α 
granules (arrow) remain comparable to control α granule numbers when surface 
area of platelets were taken into account (N=1). TEM images courtesy of Denai 
Bem. 
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3.5. Utilising full-length wild-type and mutant ANKRD18A 
plasmids for transfections and protein expression  
Because of limited patient blood that could be obtained for experimental use, it 
was necessary to construct cDNA plasmids with full length ANKRD18A wild-type 
and mutant (Δ801) sequences which could then be transiently transfected into 
cells for further characterisation of the protein, ANKRD18A.  Human full-length 
wild-type and mutated ANKRD18A plasmids were constructed by cloning the 
respective cDNAs into pEGFP and pCMV-Myc vectors (cloning performed by I. 
Sanchez-Guiu).  The ANKRD18A mutated construct (p.Glu801del) was created 
using the Quikchange Site directed mutagenesis kit.  
3.5.1. Determining transfection efficiencies of full-length GFP-tagged 
ANKRD18A constructs 
Following the construction of the tagged full-length ANKRD18A plasmids, 
attempts were made to transfect them into HEK293T to determine the protein 
expression of WT and mutant ANKRD18A by blotting with α-GFP or α-myc in 
Westerns.  Unfortunately, no bands appeared at the correct molecular weight for 
any tagged recombinant proteins (~145 kD for GFP-tagged constructs).  The only 
protein which was recognised by the α-GFP antibody was GFP protein itself 
(Figure 3.5B).  It was thus decided to first check, using flow cytometry, what were 
the transfection efficiencies of the full-length plasmids.  HEK293T cells, 
transiently transfected with DNA plasmids encoding full-length wild-type and 
mutant (Δ799) ANKRD18A fused to a GFP-tag, were analysed for GFP 
fluorescence with an excitation light source at 488 nm.  Recombinant full-length 
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wild-type and Δ801 ANKRD18A (GFP-ANKRD18A) expressed only poorly 
(around 15-20% compared to vector control) (Figure 3.5A).  Although it appeared 
that there was some transfection of these plasmids into HEK293T cells, it still 
proved difficult to demonstrate protein expression of GFP-tagged wild-type and 
Δ801 ANKRD18A when corresponding plasmids were transfected into HEK293T 
cells and immunoblotted with a GFP antibody (Figure 3.5B).  Attempts were 
made to see if the protein of these full-length constructs were in the insoluble 
fraction rather than the whole lysates.  This was done by immunoblotting 
Westerns loaded with the insoluble fraction.  Done by myself and repeated at 
OPPF, both attempts proved fruitless.  No expression of the proteins was seen. 
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Figure 3.5 - Lower transfection efficiencies using GFP-full length wild-type 
and mutant ANKRD18A plasmids compared to GFP-empty vector.  (A) Flow 
cytometry analysis of HEK293T cells untransfected and transfected with 
plasmids encoding GFP-ANKRD18A (WT), GFP-ANKRD18A (Δ801), GFP vector 
control.  (B) Immunoblot of HEK293T WCLs treated as in panel A and 
immunoblotted with α-GFP.  Untransfected (lane 1), GFP vector (lane 2) GFP-
ANKRD18A (WT) (lane 3), GFP-ANKRD18A (Δ801) (lane 4).  Arrow in left panel 
identifies the GFP (MW 27 kDa) protein and the arrowhead in the right panel 
demonstrates where the GFP-tagged full length ANKRD18A protein should be 
located, 143 kDa.  (N=20) 
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Given the findings from the above flow cytometry experiment, which 
demonstrated that the full-length constructs of wild-type and mutant ANKRD18A 
could be transfected into cells, albeit at a very small amount, it was decided to 
proceed with immunofluorescence confocal microscopy.  The rationale for this 
was because, with immunofluorescence confocal microscopy, fewer number of 
cells need to be transfected with the desired plasmid for one to visualise protein 
expression whereas with Westerns, many more cells need to be transfected in 
order for protein expression to be visualised by immunoblotting.  The preliminary 
confocal experiment using the full-length GFP tagged plasmids suggested that 
both wild-type and mutated ANKRD18A were localised to the cytoplasm (Figures 
3.6). 
 
The question we wished to answer by using confocal microscopy was whether 
ANKRD18A played a role in the development of platelets from megakaryocytes.  
The transition from megakaryocyte to platelets is characterised by the presence 
of subcellular structures such as the invaginated membrane system (IMS), 
proplatelets, and preplatelets.  These structures have been found to co-localise 
with components of the cell cytoskeleton, including filamentous F-actin, β1-
tubulin, microtubules, and spectrin (Machlus and Italiano 2013).  Possibly, co-
localisation of ANKRD18A with these and related sub-cellular membrane 
structures could provide a strong hint as to a mechanistic role for ANKRD18A in 
the development of platelets from megakaryocytes.   To begin investigating the 
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possible association of ANKRD18A with cytoskeletal elements, it was necessary 
to first determine the cellular localisation of ANKRD18A.  This was first 
accomplished by transfecting full length wild-type and mutant forms of GFP-
tagged ANKRD18A cDNA into HEK293T cells followed by imaging of the cells by 
confocal microscopy (Figure 3.6).  
 
The decision to first attempt the confocal experiment with HEK293T cells 
stemmed from the fact that all previous experiments had been performed on 
HEK293T cells.  This is because they are easily transfectable and easier to 
manage.  We wanted to perform preliminary over-expression experiments using 
HEK293T cells but were aware that the question which we wished to answer 
regarding ANKRD18A’s possible role in megakaryocyte development, would 
require us to best answer those questions in the future using cells which are 
megakaryocyte-like, such as the megakaryoblastic cell lines Dami cells or MEG-
01 cells, and ultimately with megakaryocytes.    
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Figure 3.6 – Confocal microscopy images of HEK293T cells demonstrating 
cytoplasmic localisation of WT and MUT ANKRD18A following transient 
transfection with plasmids encoding full length (B) wild-type GFP-tagged 
ANKRD18A and (C) mutant GFP-tagged ANKRD18A (Δ801).   Row A 
demonstrate images of untransfected HEK293T cells.  Presence of cells is 
verified using the nuclear stain TO-PRO3.   Scale bar = 10 µm (N=2). 
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To further strengthen the observation of a potential cytoplasmic localisation of 
ANKRD18A, the experiments were repeated, transfecting HeLa cells with the 
myc-tagged full-length plasmids.  After 48 hours of incubation, the HeLa cells 
were imaged using immunofluorescence confocal microscopy.  The primary 
antibody used was a monoclonal anti-myc antibody, nuclear staining was with 
TO-PRO-3, and secondary antibody was with α-mouse Alexa Fluor 488 (Figure 
3.7).  Again, results of this experiment suggested that WT and mutant 
ANKRD18A localised to the cytoplasm. 
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Figure 3.7 – Immunofluorescence confocal microscopy images of HeLA 
cells transiently transfected with plasmids encoding (A) myc-tag empty 
vector (B) myc-tagged WT ANKRD18A and (C) myc-tagged mutant 
ANKRD18A (Δ801) demonstrating cytoplasmic localisation of WT and MUT 
ANKRD18A.  Primary antibody used was a monoclonal anti-myc antibody and 
secondary antibody was α-mouse Alexa Fluor 488.  Nuclear staining was with 
TO-PRO-3 iodide.  Scale bar = 8 µm   (N=2) 
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3.6. Summary 
In summary, using WES, our group has identified a mutation in a gene, which 
may be the genetic basis for the severe thrombocytopenia seen in a family.  
Preliminary TEM experiments using patient platelets indicated that the mutation 
results in low platelet counts and the platelets are enlarged 
(macrothrombocytopenia).  Further analysis using patient leukocytes indicated 
that ANRD18A mRNA levels were lower in the patients when compared to levels 
seen in healthy donors.  Once platelet size was taken into account, platelet levels 
of resting surface receptor CD41 was normal for both patients whereas CD42b 
levels were decreased in patient II:5 and GPVI levels were slightly decreased in 
patient II:3.  Reasons for the lower levels remain unclear. Work-up for Bernard-
Soulier Syndrome was negative in patient II:5.  
 
Assessment of patient platelet function using flow cytometry to measure 
expression of FITC-conjugated a-CD62P and binding of fluorescent fibrinogen 
demonstrated decreased responses to agonists ADP, CRP and PAR-1 peptide.  
One cannot be certain however, if this result was because of low platelet counts 
or of functionally defective platelets.  Low platelet counts could have resulted in 
lower platelet activation because agonists cause platelet degranulation resulting 
in endogenous secretion of ADP and serotonin, which would lead to further 
platelet stimulation.  If there were lower numbers of platelets, less endogenous 
agonist would have been produced leading to less platelet stimulation.   
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However, what argues against this theory were the two studies with patients 
suffering from ITP and WAS/XLT, where the patients were treated with 
elthrombopag (thrombopoietin-receptor agonist) to see if increasing patients’ 
platelet numbers would increase platelet activity.  Elthrombopag did increase 
platelet numbers, but did not improve platelet activity in both sets of patients 
(Psaila, Bussel et al. 2012, Gerrits, Leven et al. 2015).     
 
Due to scarcity of patient platelets to work with, as well as a lack of a reliable 
antibody to ANKRD18A, cDNA plasmids of the full-length human sequences of 
wild-type and mutant ANKRD18A tagged with GFP and myc were constructed.  
Using cells transfected with the GFP tagged ANKRD18A plasmids, flow 
cytometry experiments demonstrated only 15-20% expression of the ANKRD18A 
wild-type and mutant proteins as compared to the GFP protein alone.  
Immunoblotting experiments using cells transfected with the same constructs 
demonstrated no expression of the ANKRD18A proteins whereas the control, 
GFP protein, was expressed.  These plasmids were also used to transiently 
transfect HEK293T cells and HeLa cells to determine the cellular localisation of 
ANKRD18A utilising confocal immunofluorescence.  Results from the transfection 
of both cell lines suggested that ANKRD18A localised to the cytoplasm.    
 
Further imaging studies could have been performed using the peptide antibodies 
which recognise ANKRD18A.  However, there was a concern that these peptide 
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antibodies for ANKRD18A might also recognise ANKRD18B as well, given the 
93% amino acid identity.  However, since it appears that ANKRD18B mRNA is 
not expressed in lymphocyte cell lines (Figure 4.6), post-transcriptional gene 
silencing (RNAi) could have been performed on these cells to delete ANKRD18A.   
Confocal immunofluorescence could then have been utilised using the peptide 
antibodies to recognise and localise ANKRD18A in cells manibulated and 
unmanibulated with RNAi.  These images could then further substantiate the 
cellular localisation of ANKRD18A as well as identify whether the peptide 
antibody is specific to ANKRD18A. 
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4. Characterisation of ANKRD18A peptide-derived 
antibodies  
4.1. Introduction 
The overall objective of this study was to characterise ANKRD18A.  To achieve 
this objective it was essential to have reagents, which could be used to probe for 
the presence of ANKRD18A in the proteome.  At the initiation of this project, 
ANKRD18A polyclonal antibodies had been purchased, but when used in 
immunoblotting experiments, gave conflicting results.  It was difficult to discern if 
the polyclonal peptide antibodies made in-house (α-21233 and α-21234) and a 
commercial (Abgent) polyclonal antibody were specific to ANKRD18A.  When 
used to probe HEK293T and Dami whole cell lysates, the peptide antibodies 
identified a predominant band at an incorrect molecular weight; and, the 
commercial polyclonal antibody purchased from Abgent, when used to probe 
platelet lysates produced no bands at all.   Additionally, there was confusion 
because of the existence of another protein, ANKRD18B, which has an amino 
acid sequence, which is 93% identical to ANKRD18A.  Because of the need for 
an antibody, which is specific to ANKRD18A, it was decided to generate an 
antibody that recognises an epitope on the tertiary structure of ANKRD18A.   
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4.2. Comparison of ANKRD18B and ANKRD18A 
ANKRD18B belongs to the same POTE family of genes as ANKRD18A.  
ANKRD18B has a 93% amino acid sequence identity to ANKRD18A (Figure S3) 
and is found in close proximity to ANKRD18A on human chromosome 9.  The 
two genes most likely arose from ancestral duplication (N. Morgan).  Because 
ANKRD18B’s amino acid sequence is so similar to ANKRD18A, it was essential 
that antibodies to ANKRD18A could discriminate between these two closely 
related proteins.  The uniprot database indicates that ANKRD18B has two 
isoforms:  the long isoform has 1401 amino acids with a calculated molecular 
weight of ~160 kDa  (http://web.expasy.org/protparam/) and a shorter isoform, 
which has 1011 amino acids with a calculated molecular weight of ~116 kDa. 
 
The peptide sequence of ANKRD18A that was used to raise α-21233 and α-
21234 differed from the corresponding sequence in ANKRD18B by only one 
amino acid.  Thus, it is conceivable that α-21233 and α-21234 recognise 
ANKRD18A and both isoforms of ANKRD18B.  Because of this uncertainty, it 
was necessary to characterise ANKRD18B to ascertain how it differs from 
ANKRD18A.  
 
Within the Ensembl genome browser is the Expression Atlas, which provides 
from various projects and consortiums, microarray and RNA-sequencing data on 
gene expression patterns in a particular anatomical part of an organism or a 
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particular cell.  Of these projects, one, which is sponsored by the National 
Institutes of Health in Bethesda, Maryland, is the Genotype-Tissue Expression 
Project (GTEx), (www.genome.gov).  Based on data from GTEx, ANKRD18B 
mRNA is expressed in fewer human tissues than ANKRD18A (at levels above 
0.5 FPKM and Section 1.6.1).  ANKRD18B mRNA is only expressed in testis (2 
FPKM), cerebellum (3 FPKM), cerebellar hemisphere (2 FPKM), and cerebral 
cortex (0.5 FPKM).  Also within the Expression Atlas is data from the 
BLUEPRINT Epigenome Project (www.blueprint-epigenome.eu), which examined 
cells from differentiated haematopoietic lineages.  ANKRD18B mRNA expression 
in healthy haematopoietic cells, unlike ANKRD18A mRNA expression, did not 
appear to be expressed in leukocytes (if it is expressed, it is expressed below the 
0.5 FPKM cut-off); rather, it is expressed only in CD34-CD41+CD42+ MK cells (1 
FPKM) as determined by strand-specific RNA sequencing of rRNA-depleted total 
RNA from common types of cultured or uncultured primary cells of differentiated 
haematopoietic lineages from healthy individuals in the BLUEPRINT Epigenome 
Project.  In addition, sequencing of poly A mRNA from cultured or uncultured 
primary cells of different haematopoietic lineages from healthy individuals in the 
BLUEPRINT Epigenome Project also demonstrated expression of ANKRD18B 
mRNA in CD34-CD41+CD42+ MK cells (0.6 FPKM).   However, according to the 
PlateletWeb, a systems biology analysis of signalling networks in human 
platelets,  (http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de), no 
ANKRD18B is expressed in platelets.   
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Because of the conflicting information derived from the genome and proteome 
databases, it was necessary to ascertain myself whether ANKRD18B mRNA is 
present in platelets of healthy donors and in cultured cells.   A set of primers 
were designed, ANKRD18B_CF and ANKRD18B_CR (sequences in Table 2.6), 
which were used in RT-PCR experiments to establish whether ANKRD18B 
mRNA was expressed in healthy platelets and cultured cells.  Based on my RT-
PCR experiment, ANKRD18B mRNA did not appear to be present in healthy 
donor platelets (Figure 4.1).  The expected size of ANKRD18B is 371 bp.  The 
PCR appeared to have worked because using β-actin primers (the positive 
control) resulted in a band at the correct size of 223 bp.  
 
Figure 4.1 - ANKRD18B mRNA is not expressed in platelets or leukocytes 
as determined by RT-PCR.  Expected size of ANKRD18B is 371 base pairs (bp).  
Expected size of β-actin is 223 bp.  Bands seen in left gel are primer dimers.  
Lower bands seen in both gels are primer dimers.  (N=1) 
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Figure 4.2 – ANKRD18A mRNA is expressed in platelets and leukocytes as 
determined by RT-PCR. Lanes 1, 5, 9, 13, 16 use ANKRD18A primers. Lanes 2, 
6,10,14,17 use β-actin primers and Lanes 3, 7,11,15,18 use GAPDH primers. P 
= platelets. B = buffy coat.  Expected size of ANKRD18A is 394 bp.  Expected 
size of β-actin is 223 bp.  Expected size of GAPDH is 225 bp.   (N = 3) 
 
 
The above results contrasts with my RT-PCR experiment for ANKRD18A, which 
suggested that there is ANKRD18A mRNA expression in platelets; however, one 
cannot ascertain whether this result is due to leukocyte contamination or actually 
there is ANKRD18A mRNA in platelets.  This is especially relevant since 
according to the BLUEPRINT Epigenome Project, ANKRD18A mRNA is 
predominantly expressed in myeloid and lymphoid cells, with negligible 
expression in megakaryocytes (www.blueprint-epigenome.eu).  To determine 
whether there is leukocyte contamination in this experiment, one would need to 
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check by flow cytometry for the presence of a cell population which is positive for 
CD45 (leukocyte common antigen) following the isolation of platelets (platelet 
rich plasma, PRP) from whole blood.  To remove leukocyte contamination one 
would need to perform CD45+ bead selection after the preparation of PRP 
(Denis, Tolley et al. 2005).  
 
When probing for the presence of ANKRD18A (394 bp) and ANKRD18B (371 bp) 
mRNA expression in a variety of cell lines, it appeared that ANKRD18A mRNA 
was present in all the cell lines tested. These cell lines included lymphocyte cell 
lines (1654, Lgn, RY, and HK), HEK293T cell line derivatives (D+ and YTW) and 
HeLA, Dami and HEK293T cells.  On the other hand, ANKRD18B mRNA 
expression was only present in HeLA, Dami cells and HEK293T cells plus its 
derivatives (Figure 4.3).    
 
The above RT-PCR results which demonstrated that ANKRD18B mRNA is not 
expressed in any of the lymphoid cell lines is consistent with the BLUEPRINT 
databases which suggested that ANKRD18B mRNA is not expressed in myeloid 
and lymphoid cells. 
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Figure 4.3 – ANKRD18A mRNA is expressed in lymphoid cells lines, Damis, 
HeLAs and HEK293T cells and its derivatives. ANKRD18B mRNA is 
expressed in Damis, HeLAs and HEK293T cells and its derivatives.  Lanes 
1=H2O, lane 2= 1654, a B-cell line, lane 3= Lgn, a lymphocyte cell line, lane 
4=D+, a HEK293 cell line derivative, lane 5=YTW, a HEK293 derivative, 6= RY, a 
lymphocyte cell line, 7= HeLa, 8= HK, a lymphocyte cell line, 9=Dami.  Upper 
band is ANKRD18B or ANKRD18A mRNA.  Expected size of ANKRD18B is 371 
bp.  Expected size of ANKRD18A is 394 bp.  Expected size of GAPDH is 225 bp.  
Lower bands are primer dimers.   (N=1) 
 
 
4.3. Initial characterisation of existing ANKRD18A antibodies 
Prior to the initiation of my PhD studies, two ANKRD18A polyclonal antibodies, 
which were directed against two non-overlapping peptides, were available in the 
laboratory.  One was a commercial antibody purchased from Abgent, a rabbit 
polyclonal antibody which recognised the peptide sequence 260-289; the other 
were two bespoke antibodies which were two separate bleeds from a rabbit 
(antibodies α-21233 and α-21234) that had been immunised with the 
ANKRD18A-derived peptide encompassing residues 53-65 (Figure 4.4).  The 
peptide antibodies had been purified on an affinity column, which had the 
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ANKRD18A peptide bound to its matrix so that monospecific IgG to ANKRD18A 
was obtained.  These antibodies were used to immunoblot for the presence of 
ANKRD18A in whole cell lysates (WCLs) of HEK293T and Dami (a 
megakaryocytic cell line) cells and from platelets of different healthy donors.  In 
these Western experiments, Dami WCLs were divided into adherent Damis and 
Damis in suspension because when cultured, Damis are initially adherent but go 
into suspension when more mature (Greenberg, Rosenthal et al. 1988).  The 
question arose whether expression of ANKRD18A would differ between adherent 
Damis vs. Damis in suspension.  However, the primary question, which we 
needed to answer, was whether α-21233 and α-21234 would recognise 
ANKRD18A as well as both isoforms of ANKRD18B since the peptide sequence 
of ANKRD18A that was used to raise α-21233 and α-21234 differed from the 
corresponding sequence in ANKRD18B by only one amino acid.  Another 
concern was that the immunoblotting results obtained when using the 
commercial Abgent antibodies were not consistent with the results obtained from 
using α-21233 and α-21234.  (Results from immunoblots using α-21233 and α-
21234 did not differ so only the immunoblots using α-21234 will be included in 
this thesis.)  When the Abgent antibody was used to probe for ANKRD18A in the 
WCLs from HEK293Ts and Damis, a band appeared at the correct molecular 
weight, ~ 116 kDa (Figure 4.5A).  As expected, the Abgent antibody did not 
detect clone G2, the purified recombinant protein E3C Halo-ankyrin repeat 
domain (amino acids 1-260) because this peptide antibody recognises the 
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antigen sequence from residues 260 to 289 (lane 4, Figure 4.5A).  When using 
the bespoke peptide antibodies α-21233 and α-21234 to probe for ANKRD18A in 
WCLs of HEK293T and Dami cells, a clear band was apparent in the region 
between the molecular weight markers of 135 and 190 kDa (Figure 4.5B), which 
is higher than the expected molecular weight for ANKRD18A.  Because the 
amino acid sequences of the peptides used to raise α-21233 and α-21234 are 
virtually identical to the amino acid sequence of the two isoforms of ANKRD18B 
at the amino terminus, it is quite possible that α-21233 and α-21234 were 
recognising the long isoform of ANKRD18B (ANKRD18B_1401) in Figure 4.5B 
since the calculated molecular weight of this protein is ~160 kDa 
(http://web.expasy.org/protparam/).  It did not appear that α-21233 and α-21234 
were recognising the short isoform of ANKRD18B (ANKRD18B_1101, MW 118 
kDa) as well.  
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Figure 4.4 – Sequence alignment of ANKRD18A and ANKRD18B for 
residues 1-329 (of ANKRD18A amino acid sequence).  ANKRD18B exists in 
two isoforms (1011 and 1401 amino acids, respectively).  The peptide sequence 
used as antigens to raise polyclonal antibodies are highlighted by horizontal bars. 
1       10        20        30        40        50        60
ANKRD18A     MRKL SFGRRLGQALLSSMDQEYAG GY IRDWELRKIHRAAIKGDAAEVE CLTRRFRD                                                R        F P D
ANKRD18B_1011 MRKL SFGRRLGQALLSSMDQEYAG GY IRDWELRKIHRAAIKGDAAEVE CLTRRFRD                                                H        L R H
ANKRD18B_1401 MRKL SFGRRLGQALLSSMDQEYAG GY IRDWELRKIHRAAIKGDAAEVE CLTRRFRD                                                H        L R H
        70        80        90       100       110       120
ANKRD18A     LD RDRKDRTVLHLACAHGRVQVVTLLL R CQI ICDRLNRTPLMKAVH QEEACAI L  A                          R                         V H D S
ANKRD18B_1011 LD RDRKDRTVLHLACAHGRVQVVTLLL R CQI ICDRLNRTPLMKAVH QEEACAI L  V                          K                         I D N C
ANKRD18B_1401 LD RDRKDRTVLHLACAHGRVQVVTLLL R CQI ICDRLNRTPLMKAVH QEEACAI L  V                          K                         I D N C
       130       140       150       160       170       180
ANKRD18A     L  GANPNIKDIYGNTALHYAVYN GTSLAERLLSHHANIEALNKEGNTPLLFAINSRRQ EC                     K                                   
ANKRD18B_1011 L  GANPNIKDIYGNTALHYAVYN GTSLAERLLSHHANIEALNKEGNTPLLFAINSRRQ KR                     E                                   
ANKRD18B_1401 L  GANPNIKDIYGNTALHYAVYN GTSLAERLLSHHANIEALNKEGNTPLLFAINSRRQ KR                     E                                   
       190       200       210       220       230       240
ANKRD18A     HMVEFLLKNQANIHAVDNFKRTALILAV HNLSSIVTLLLQQNI ISSQDMFGQTAEDYA                                           R               Q
ANKRD18B_1011 HMVEFLLKNQANIHAVDNFKRTALILAV HNLSSIVTLLLQQNI ISSQDMFGQTAEDYA                                           H               Q
ANKRD18B_1401 HMVEFLLKNQANIHAVDNFKRTALILAV HNLSSIVTLLLQQNI ISSQDMFGQTAEDYA                                           H               R
       250       260       270                              
ANKRD18A      C DLRSI QQILEHKNKMLKNHLRNDNQE AAMK                         L S     R                     T    .........................
ANKRD18B_1011  C DLRSI QQILEHKNKMLKNHLRNDNQE AAMK                         F C     Q                     T    .........................
ANKRD18B_1401  C DLRSI QQILEHKNKMLKNHLRNDNQE AAMK                         F C     Q                     A    NESFKTQGASSKVSLYHQSGVQWHD
                                        280                 
ANKRD18A                                           P NLKKRK             E...................................... A      E........RAKA 
ANKRD18B_1011                                       P NLKKRK             E...................................... E      KRKKLKKRKEGAK 
ANKRD18B_1401                                       P NLKKRK             ELRLLQPSPPRFKQFSCLSLPRSWDNRHMRPCPETAAMK E      KRKKLKKRKEGAK 
290       300       310       320       330       340         
ANKRD18A     HNLKVASEEKQERL RSENKQPQDSQSYGKKKD M GNFMLK DIAMLKEELYAIKNDSL                                 Y      K                 Q A
ANKRD18B_1011 HNLKVASEEKQERL RSENKQPQDSQSYGKKKD M GNFMLK DIAMLKEELYAIKNDSL                                 F      R                 E E
ANKRD18B_1401 HNLKVASEEKQERL RSENKQPQDSQSYGKKKD M GNFMLK DIAMLKEELYAIKNDSL                                 F      R                 E E
α-ANKRD18A (21234)
ANKRD18A aa 53 - 65  
α-ANKRD18A (Abgent)
ANKRD18A aa 260 - 289  
α-ANKRD18B (Abgent)
ANKRD18B(1011) aa 274 - 302  
Chapter Four                          Characterisation of ANKRD18A peptide-derived antibodies 
 
 
 
 
 
 
 
152 
 
 
Figure 4.5 – Western blots demonstrating Abgent antibody detecting (A) 
ANKRD18A expression in HEK293T and Dami cells at correct molecular 
weight of 116 kDa whereas (B) α-21234 detects a dominant band at the 
incorrect molecular weight. WCLs were analysed by SDS-PAGE and 
immunoblotted with two different α-ANKRD18A, (A) Abgent antibody and (B) α-
21234.  Lane 1- HEK293T cells, lane 2-adherent Dami cells, lane 3- Dami cells in 
suspension, lane 4- purified recombinant protein, clone G2 (Mr = 65kDa).  
Bottom panel:  loading control, blotted with α-GAPDH (Mr = 37kDa).  The 
expected MW of ANKRD18A is 116kDa.  Arrows indicate the expected positions 
of antigens (N=5). 
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When the Abgent ANKRD18A antibody was used to probe the WCLs from 
platelets of healthy donors, no ANKRD18A protein was detected (Figure 4.6A).  
However, when α-21233 and α-21234 were used to probe the WCLs of healthy 
donor platelets, a band appeared at the correct molecular weight of ~116 kDa 
(Figure 4.6B).  The protein that α-21233 and α-21234 recognised is probably 
ANKRD18A since ANKRD18B mRNA is not present in platelets (Figure 4.1), 
according to my experimental data.   And, as expected, α-21234 recognised 
clone G2 (lane 4, Figures 4.6B).    
 
Figure 4.6 – Western blots demonstrating Abgent antibody detecting (A) no 
ANKRD18A expression in platelets whereas (B) α-21234 detects ANKRD18A 
at correct molecular weight.  Platelet WCLs analysed by SDS-PAGE 
immunoblotted with (A) Abgent antibody and (B) α-21234.  Lanes 1-5 different 
donor platelets, lane 6-purified recombinant protein, clone G2. Bottom panels,   
loading controls.  Left bottom panel, Coomassie stained blot of above blot.  Right 
bottom panel, immunoblot for GAPDH.  Arrow in top right panel indicates 
ANKRD18A.  Arrowhead in top right panel indicates clone G2.   (N=5). 
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To confirm that in the above Western blots the protein that α-21234 recognised is 
ANKRD18A, one could silence ANKRD18A expression by RNAi whereby siRNA 
is transfected into HEK293T cells or Dami cells and WCLs from these cells are 
loaded onto SDS-PAGE and immunoblotted with α-21234 to see if the dominant 
band disappeared.  The only concern is that in HEK293T and Dami cells, α-
21234 recognised a protein whose molecular weight is between the molecular 
weight markers of 135-190 kDa.  The long isoform of ANKRD18A is only ~117 
kDa, so it remains unclear what protein is being recognised by α-21234 in these 
cells lysates.  However, should this 160 kDa disappear after RNAi, one could 
assume that it is ANKRD18A.  The next question would then be why and how, is 
ANKRD18A 160 kDa in these cells. 
 
Although α-21234 recognised a protein with the correct molecular weight in 
platelets, because it is unlikey that platelets can be transfected, it would be 
difficult to perform RNAi experiments on platelets.  Since platelets cannot be 
transfected, one would need to use megaloblastic cell lines such as MEG-01 or 
SET-02 cells to see if α-21234, when used to immunoblot for their WCLs, will 
identify a protein at the correct molecular weight of 116 kDa.  If yes, one could 
then also perform RNAi to silence ANKRD18A expression and then immunoblot 
the WCLs of these cells using α-21234 again, thus proving α-21234’s specificity 
for ANKRD18A. 
Chapter Four                          Characterisation of ANKRD18A peptide-derived antibodies 
 
 
 
 
 
 
 
155 
4.4. ANKRD18A and ANKRD18B in megakaryocyte development 
Since ANKRD18A mRNA could be detected in platelets from healthy donors, the 
question then arose regarding when ANKRD18A mRNA would be present during   
megakaryocyte development. Utilising quantitative real-time PCR (qRT-PCR) 
with ANKRD18A primers BR and CF (Table 2.6), it was demonstrated that 
ANKRD18A mRNA expression was present at day 0 of development and 
increased with progressive development of megakaryocytes (Figure 4.7).  In 
contrast, no ANKRD18B mRNA was detected in megakaryocytes during 
megakaryocytic development, as probed by qRT-PCR (Figure 4.8). 
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Figure 4.7 – ANKRD18A mRNA expression increases with megakaryocytic 
development as determined by qRT-PCR. (A) Determining the fold difference 
in ANKRD18A mRNA expression compared to the GAPDH reference during 3 
stages of megakaryocyte differentiation. Samples are run in triplicate from 2 
different cord blood (CB) preparations and retinoblastoma (RB) cell line as a 
control. (B) Agarose gel confirming expression of ANKRD18A mRNA from the 
samples that were run on the qRT-PCR plate. 1/5=1:5 dilution   (N=3). 
Chapter Four                          Characterisation of ANKRD18A peptide-derived antibodies 
 
 
 
 
 
 
 
157 
 
Figure 4.8 – No ANKRD18B mRNA expression in developing 
megakaryocytes.  Dami cDNA was used as positive control.  Dami 1/5 is cDNA 
at a dilution of 1:5, CB1 = cord blood sample 1 (N = 1). 
 
4.5. Probing for ANKRD18A and ANKRD18B protein expression 
Using a polyclonal peptide antibody, which was raised against a peptide of the 
short isoform of ANKRD18B (ANKRD18B_1101) (purchased from Abgent), 
expression of ANKRD18B in HEK293T, Dami cells and in platelets was 
determined by Western blotting. The sequence-derived molecular weight of 
ANKRD18B_1101 is about 118 kDa.  Similar to what was seen using the Abgent 
α-ANKRD18A (Figures 4.5A), one saw expression of ANKRD18B in the WCLs of 
HEK293T and Dami cells (Figure 4.9A) at the molecular weight of 118 kDa.  It is 
unclear why the Abgent α-ANKRD18B recognised only the short isoform of 
ANKRD18B and not the long isoform as well since the amino acid sequences of 
both isoforms are not very different.   
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Similar to the immunoblot probing for ANKRD18A expression in platelets using 
the Abgent a-ANKRD18A (Figure 4.6A), when using the Abgent a-ANKRD18B, 
there is no expression of ANKRD18B in platelets (Figures 4.9B).  Therefore, the 
Western blots indicate clear expression of ANKRD18B in HEK293T and Dami 
cells, but no expression in platelets (Figures 4.9A and 4.9B).  This correlates with 
the RT-PCR and qRT-PCR data above, which indicated no ANKRD18B mRNA 
expression in platelets (Figure 4.1) and megakaryocytes (Figure 4.8); but there is 
ANKRD18B mRNA expression in HEK293T and Dami cells (Figure 4.3).  
A 
 
B 
 
 
Figure 4.9 – Western blots demonstrating (A) ANKRD18B expression in 
HEK293T and Dami cells but (B) no ANKRD18B expression in platelets.  
HEK293T, Dami and platelet WCLs are immunoblotted with α-ANKRD18B (top 
panel) and for loading control, α-GAPDH (left bottom panel).  Right bottem panel 
is Coomassie stain for actin, which is the loading control.  (N=5) 
Chapter Four                          Characterisation of ANKRD18A peptide-derived antibodies 
 
 
 
 
 
 
 
159 
4.6. Summary  
In summary, the following observations have been made: 
1. ANKRD18A and ANKRD18B are 93% identical at the amino acid sequence 
level. 
2. Inconsistent results were obtained when immunblotting with the Abgent α-
ANKRD18A and α-21234 antibodies.  When HEK293T and Dami WCLs were 
immunoblotted with the Abgent α-ANKRD18A (Figure 4.5A), the most 
prominent band that appeared was between the molecular weight markers of 
100 to 135 kDa (~116 kDa).  When using α-21234 (Figure 4.5B), the most 
prominent band was between the molecular weight markers of 135 and 190 
kDa (~160 kDa).  When immunoblotting platelet WCLs with the Abgent α-
ANKRD18A (Figure 4.6A), no bands appeared.  When α-21234 was used to 
immunoblot platelet lysates (Figure 4.6B), bands appeared at the correct 
molecular weight of 116 kDa.   
3. ANKRD18A mRNA expression was present in platelets and all cell lines 
tested (Figure 4.2, Figure 4.3) whereas for ANKRD18B (Figure 4.1, Figure 
4.3), no mRNA expression was detected in platelets and only in selected cell 
lines (HeLA, Dami, and select HEK293T derivatives). 
4. The amount of ANKRD18A mRNA expression increased as megakaryocytes 
matured (Figure 4.7).  No ANKRD18B mRNA expression was detected in 
megakaryocytes (Figure 4.8). 
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5. When immunoblotting HEK293T and Dami WCLs using the Abgent α-
ANKRD18B (Figure 4.9A), the most prominent band was located between 
the molecular weight markers of 100 to 135 kDa (116 kDa).  When 
immunoblotting platelet WCLs (Figure 4.9B), no bands appeared.  This is 
consistent with the RT-PCR data, which suggested that there is no 
ANKRD18B mRNA in platelets.   
 
Thus, because the amino acid sequences of ANKRD18A and ANKRD18B are so 
similar at the amino terminus (Figures 4.4 and S3), this has resulted in difficulty 
creating peptide-generated antibodies that are specific to each protein.  The 
amino acid sequences of the peptides used to raise α-21233 and α- 21234 are 
nearly identical to the amino acid sequence of the two isoforms of ANKRD18B at 
the N terminus - the ANKRD18A peptide sequence differs from ANKRD18B 
amino acid sequence by one amino acid, alanine to valine (Figure 4.4).  It is quite 
possible that α-21233 and α-21234 were cross-reacting with ANKRD18B 
(ANKRD18B_1401).  This would then explain the enhanced band in the Western 
blot of the Dami / HEK293T WCLs where there was a dominant band between 
the 135 and 190 kDa markers (Figure 4.5B).  The long isoform of ANKRD18B 
has a sequence-derived Mr of ~160 kDa.  It did not appear that α-21233 and α-
21234 recognised the short isoform of ANKRD18B (ANKRD18B_1101, MW 118 
kDa) as well.  
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Another example of the difficulty in choosing peptide sequences to generate 
antibodies that would discriminate between ANKRD18A and ANKRD18B 
concerned the Abgent purchased ANKRD18A and ANKRD18B_1101 polyclonal 
antibodies.  Both of the Abgent ANKRD18A and ANKRD18B_1101 peptide 
sequences which were used to generate the respective polyclonal antibody are 
30 amino acids long and they overlap, having a common stretch of 8 identical 
amino acids over 9 consecutive residues.  It is difficult to know whether each 
antibody recognised the epitope that is unique to each protein or to an epitope 
that has an amino acid sequence shared by both proteins.  Therefore, cross-
reactivity could not be completely ruled out for these antibodies as well.  This 
explanation is plausible given that the immunoblots of HEK293T and Dami WCLs 
(Figures 4.5A vs. 4.9A) and platelet WCLs  (Figures 4.6A vs. 4.9B) using Abgent 
α-ANKRD18A and α-ANKRD18B looked almost identical.   
 
However, it is still possible that α-21234, the bespoke peptide antibody, is 
specific for ANKRD18A.   To prove this, RNAi experiments would need to be 
performed to silence ANKRD18A expression and then the antibody can be used 
to immunoblot WCLs of cells transfected with siRNA to determine if the expected 
band at the correct molecular weight has disappeared.  When HEK293T and 
Dami cells are to be used, it would be interesting to see if the prominent band at 
~160 kDa would disappear after RNAi.  If it does disappear, the question would 
be why ANKRD18A has a molecular weight of ~160 kDa in HEK293T cells and 
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Damis.  Since platelets cannot be transfected, RNAi experiments would need to 
be performed using cells most closely resembling platelets such as MEG-01 or 
SET-2 cells.  Of course, the best cells to use would be megakaryocytes.   
 
Hence, because of the necessity to ensure specificity and reduce the chances of 
cross-reactivity between ANKRD18A and ANKRD18B, what was required was an 
antibody, which would recognise the tertiary structure of ANKRD18A rather than 
a peptide antibody derived from ANKRD18A.  However, should this polyclonal 
antibody which recognises the tertiary structure of ANKRD18A fail to be specific 
as well, the only way to produce a specific antibody is to generate a monoclonal 
antibody.
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5. Generation of ANKRD18A recombinant protein and 
antibody production 
5.1. Introduction 
The mammalian adaptive immune system is able to respond to almost any type 
of molecular antigen.  When raising antibodies against a protein target, one has 
the choice of using either a peptide or a folded protein as an immunogenic 
stimulant.  Peptide antigens are typically generated through chemical synthesis, 
making them readily available.  However, the corresponding peptide sequence 
may not be solvent-accessible within the context of the folded protein, limiting 
application of a corresponding antibody to immune recognition of the target if not 
in the denatured state.  In contrast, using a folded protein as antigen will raise 
antibodies directed against solvent-accessible epitopes.  For a folded protein to 
be used as an antigen, it needs to be made through overexpression of the 
corresponding gene in a suitable expression host, and purified from cell extracts 
without denaturation.  When a full-length protein antigen is not amenable to 
recombinant expression, one can consider expressing one or several of its 
structural domains.  Thus, a 3D epitope (rather than a linear peptide sequence) 
reduces the risk of cross-reactivity. 
 
Given the inconsistent results obtained when immunoblotting with the peptide-
derived antibodies described in Chapter 4, the need for an antibody with better 
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selectivity was evident.  Raising such an antibody against a folded protein 
antigen rather than a short peptide would be expected to aid selectivity for 
ANKRD18A.  However, such an antibody is not completely fail-proof.  To 
definitely attain an antibody which would be specific to ANKRD18A would require 
generating a monoclonal antibody.    
5.2. Generation of ANKRD18A recombinant protein 
The amount of antigen required for antibody generation is in the order of 1 mg 
pure protein at a concentration of 1 mg/ml or greater.  Initially, it was intended to 
generate an antibody raised to the tertiary structure of full-length ANKRD18A 
protein.  However, because of the difficulty in transfecting cells with enough 
plasmids encoding full-length ANKRD18A so that expression could be visualised 
on a Western blot, it was finally decided to generate recombinant protein of 
ANKRD18A fragments, whereby the fragment encompassed the functional 
domains of ANKRD18A.  
5.2.1. Establishment and selection of ANKRD18A constructs to 
provide suitable expression levels 
Against the backdrop of poor expression of full-length ANKRD18A in mammalian 
cells, it seemed more promising to attempt expression of the structural domains 
of ANKRD18A (Table 5.1 and Figure 1.16).  These structural domains could then 
be used for immunisation and, by adding suitable affinity tags in expression 
plasmids, efficient purification of the recombinant protein fragments from cell 
extracts would be facilitated.  In order to rationalise the choice of domain 
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boundaries, the sequence of ANKRD18A was submitted to fold prediction 
servers (Table 5.1).   
       
Table 5.1 – Functional domains of ANKRD18A.  Phyre2 = protein fold 
prediction server Phyre2 (www.sbg.bio.ic.ac.uk/phyre2); HHpred = homology 
detection and structure prediction by HMM-HMM comparison 
(toolkit.tuebingen.mpg.de/hhpred) 
 
There are two isoforms of ANKRD18A.  The short isoform has been annotated to 
comprise nine ankyrin repeat motifs whereas the long isoform is comprised of 11 
ankyrin repeat domains at the amino terminus and both have a sequence of 
coiled–coil regions in the carboxy terminal region after the ankyrin repeat domain 
(Figure 1.16).  Given that the primary amino acid sequence of a protein 
determines its three dimensional structure, “threading” the sequence of 
ANKRD18A onto known protein structures is a powerful method to predict how a 
given sequence will fold (provided the database contains a structural 
homologue).  When there is a minimum of steric clashes this indicates which 
particular structural template is compatible with the sequence of the target, 
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ANKRD18A.  The fold prediction (using the Phyre2 and HHpred servers) 
confirmed with high confidence the amino terminal ankyrin repeat domain and 
detected two further domains downstream (Table 5.1): domains with homology to 
tropomycin and colicin IA.  This information was used to design expression 
plasmids encompassing the predicted structural domains of ANKRD18A.  
Because it was difficult to predict which functional domain will express at 
sufficient levels, it was necessary to make multiple DNA plasmid constructs, 
pairing various affinity tags with various domains.  Pairing the various domains 
with a variety of fusion partners were needed to determine which tag when fused 
with a particular protein, would assist the protein to fold properly as well as be 
soluble in certain buffers.  To expedite the cloning of these multiple constructs, 
the facilities of OPPF (Oxford Protein Production Facility at Harwell) which has 
established high-throughput procedures to allow parallel cloning of a given gene 
sequence into a collection of plasmid DNA vectors, were used.  A total of 32 
constructs with various tags fused to the four different functional domains of 
ANKRD18A are detailed in Table 5.2.  All constructs also contained the 
hexahistidine affinity tag. 
5.2.2. Testing expression of ANKRD18A constructs  
These 32 plasmids were first tested for expression in E. coli under auto-inducing 
conditions or induced by IPTG (Figures 5.1, 5.2, 5.3).  E. coli competent cell 
strains B834 (a methionine auxotroph that allows high specific activity labelling of 
target proteins with 35S-methionine or selenomethionine for crystallographic 
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studies, https://us.vwr.com) and Rosetta (designed to enhance the expression of 
eukaryotic proteins that contain codons rarely used in E. coli, 
www.emdmillipore.com) were transformed with the various plasmids and then 
protein was purified from the cell lysates over a Ni+2-NTA matrix.  Eluates from 
the Ni+2-NTA chromatography were analysed on a Coomassie stained SDS-
PAGE gel.  None of the plasmids expressed the correct protein, as determined 
by molecular weight: no bands appeared at the expected molecular weight 
except for GFP.  GFP served as the positive control.  When the different 
plasmids were transfected into the B834 strain of E. coli, the plasmids which 
expressed protein were clones F2, G2, D3 and H3.  However, as shown in the 
Coomassie gels (Figures 5.1 and 5.2), except for clone F2, only the tag was 
expressed, as evidenced by the molecular weights (G2, 35.3 kDa; D3, 35.3 kDa; 
and H3, 13.2 kDa).  For clone F2, it appears that both the full construct as well as 
the tag alone, were expressed (Full construct, 73 kDa; tag, 43 kDa).  When the 
different plasmids were expressed in the Rosetta strain of E. coli, again, of the 
clones which expressed, clones B2, F2, G2 and D3, what appears to be 
expressed were just the tags without the functional domains (Figures 5.2 and 
5.3).   The most likely reason why this occurred is that the DNA mixture, which 
was used for the transfection, contained both vector alone (unligated DNA) and 
ligated DNA.  Since transfection into E. coli is easier with smaller constructs, 
what was seen here were transfection and expression of just the plasmids of 
vector alone, which has the DNA sequences of the tags.      
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Clone OPTIC Gene name aa_N aa_C 
OPPF 
No. Vector Tag 
MW of 
Tag 
(kDa) Domains 
Domain 
MW 
A1 13915 ANKRD-FL 2 992 14229 pOPINE  (His)6 Nil Full length 116 kD 
B1 13915 ANKRD-FL 2 992 14230 pOPINF 3CProt+His6 2.2     
C1 13915 ANKRD-FL 2 992 14231 S3C Sumo-3C 13.2     
D1 13915 ANKRD-FL 2 992 14232 pOPINM MBP 43     
E1 13915 ANKRD-FL 2 992 14233 E-3C-HALO E3CHalo 35.3     
F1 13915 ANKRD-35 35 235 14234 pOPINE  (His)6 Nil 
ANK repeat 
(Phyre2) 23 kD 
G1 13915 ANKRD-35 35 235 14235 pOPINF 3CProt+His6 2.2     
H1 13915 ANKRD-35 35 235 14236 S3C Sumo-3C 13.2     
A2 13915 ANKRD-35 35 235 14237 pOPINM MBP 43     
B2 13915 ANKRD-35 35 235 14238 E-3C-HALO E3CHalo 35.3     
C2 13915 ANKRD-1 2 260 14239 pOPINE  (His)6 Nil 
ANK repeat 
(HHpred) 30 kD 
D2 13915 ANKRD-1 2 260 14240 pOPINF 3CProt+His6 2.2     
E2 13915 ANKRD-1 2 260 14241 S3C Sumo-3C 13.2     
F2 13915 ANKRD-1 2 260 14242 pOPINM MBP 43     
G2 13915 ANKRD-1 2 260 14243 E-3C-HALO E3CHalo 35.3     
H2 13915 ANKRD-450 450 790 14249 pOPINJ GST 30 Tropomyosin 40 kD 
A3 13915 ANKRD-450 450 790 14250 pOPINFS Strep II 1.1     
B3 13915 ANKRD-450 450 790 14246 S3C Sumo-3C 13.2     
C3 13915 ANKRD-450 450 790 14247 pOPINM MBP 43     
D3 13915 ANKRD-450 450 790 14248 E-3C-HALO E3CHalo 35.3     
E3 13915 ANKRD-450 450 790 14244 pOPINE  (His)6 Nil     
F3 13915 ANKRD-790 790 992 14251 pOPINJ GST 30 Colicin 1A 24 kD  
G3 13915 ANKRD-790 790 992 14252 pOPINFS Strep II 1.1     
H3 13915 ANKRD-790 790 992 14253 pOPINS3C Sumo-3C 13.2     
A4 13915 ANKRD-790 790 992 14254 pOPINM MBP 43     
B4 13915 ANKRD-790 790 992 14255 pOPINE  (His)6 Nil     
C4 13915 ANKRD-790 790 992 14256 E-3C-HALO E3CHalo 35.3     
D4 13915 ANKRD-450a 450 992 14257 pOPINJ GST 30 
Tropomyosin + 
Colicin 1A 64 kD 
E4 13915 ANKRD-450a 450 992 14258 pOPINFS Strep II 1.1     
F4 13915 ANKRD-450a 450 992 14259 pOPINM MBP 43     
G4 13915 ANKRD-450a 450 992 14260 pOPINS3C Sumo-3C 13.2     
H4 13915 ANKRD-450a 450 992 14261 E-3C-HALO E3CHalo 35.3     
Table 5.2 - DNA plasmid constructs generated at OPPF. Abbreviations used: 
3C = cleavage site for human rhinovirus 3C protease; SUMO = small ubiquitin-
like modifier; MBP = maltose binding protein; GST = glutathione-S-transferase; 
HALO = Promega HaloTag. 
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Figure 5.1  - Coomassie-stained SDS-PAGE gel of lysed E. coli  (B834) cell 
cultures expressing plasmids encoding ANKRD18A or fragments thereof. 
Molecular weight markers are in units of kDa. For clone designations, refer to 
Table 5.2.  (N=1) 
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Figure 5.2 - Coomassie-stained SDS-PAGE gel of lysed E. coli  (B834 and 
Rosetta) cell cultures expressing plasmids encoding ANKRD18A or 
fragments thereof. Molecular weight markers are in units of kDa. For clone 
designations, refer to Table 5.2.  (N=1) 
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Figure 5.3 - Coomassie-stained SDS-PAGE gel of lysed E. coli  (Rosetta) 
cell cultures expressing plasmids encoding ANKRD18A (or fragments 
thereof). Molecular weight markers are in units of 103 Dalton. For clone 
designations, refer to Table 5.2.   (N=1) 
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Because the 32 plasmids overall did not express in bacteria, the same plasmids 
were transiently transfected into HEK293T cells using a proprietary transfectant, 
GeneJuice.   WCLs from each transfection were analysed by immunoblotting 
SDS-PAGE gels with a monoclonal anti-His6 antibody (Figures 5.4 and 5.5).  
Clones that expressed were H1 (Ankyrin repeat , 23 kDa + Sumo3C, 13.2 kDa; 
total, 36.2 kDa), B2 (Ankyrin repeat, 23 kDa + E3C Halo, 35.3 kDa; total, 58.3 
kDa), E2 (Ankyrin repeat, 30 kDa + Sumo3C, 13.2 kDa; total, 43.2 kDa), F2 
(Ankyrin repeat, 30 kDa + MBP, 43 kDa; total, 73 kDa), and G2 (Ankyrin repeat, 
30 kDa + E3CHalo, 35.3 kDa; total, 65.3 kDa).  Clone E2 appeared to be the 
highest expressing clone but may have suffered from proteolytic degradation:  in 
addition to the expected band at ~ 43 kDa, there were two lower molecular 
weight bands of which the Mr corresponds approximately to the Sumo tag and 
the ankyrin repeat domain, respectively.  Clone F2 (MBP tag + ankyrin repeat 
domain) also revealed two bands, the heavier one corresponding to the Mr of the 
fusion protein, and the lighter matching the Mr of MBP (Figure 5.4).  After Sanger 
sequencing clone E2, it was determined that it was missing a large portion of its 
5’ end so the fact that its expression in HEK293T cells leads to multiple bands is 
irrelevant.  In regards to clone F2, the lower molecular weight band corresponds 
to MBP, which is what one would expect if the empty vector plasmid were 
transfected into the HEK293T cells.  The DNA mixture used to transfect 
HEK293T probably contained a mixture of ligated and unligated DNA.  The 
empty vector does contain the His tag sequence and that is why the Western blot 
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when blotted with anti-His6 displays bands corresponding to molecular weights of 
the fusion protein (73 kDa) and MBP alone (43 kDa).   
 
In Figure 5.5, the clones that expressed encompassed B3 (Tropomyosin, 40 kDa  
+ Sumo3C, 13.2 kDa; total, 43.2 kDa), C3 (Tropomyosin, 40 kDa + MBP, 43 kDa; 
total, 83 kDa), E3 (Tropomyosin, 40 kDa + His tag, 2.2 kDa; total, 42.2 kDa), and 
A4 (Colicin1A, 24 kDa + MBP, 43 kDa; total, 67 kDa).  The positive control was 
His-tagged GFP.    
 
 
Figure 5.4 – Western blot analysis of whole cell lysates from HEK239T cells 
transiently transfected with expression plasmids encoding ANKRD18A 
(and fragments thereof) and immunoblotted with anti-His6. Refer to Table 5.2 
for clone designations. Molecular weight markers are given in units of kDa.  
(N=1) 
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Figure 5.5 - Anti-His6 blot of whole cell lysates from HEK239T cells 
transiently transfected with expression plasmids encoding ANKRD18A 
(and fragments thereof). Refer to Table 5.2 for clone designations. Molecular 
weight markers are given in units of kDa.   (N=1) 
 
These nine plasmids, which exhibited promising expression levels, were 
sequenced by Sanger sequencing.  Results from sequencing revealed that clone 
E2 was missing a large portion of its DNA sequence at the 5’ end and therefore 
this clone was discarded.  
5.2.3. Testing of transfection agents 
The preliminary expression experiments at OPPF used GeneJuice, a proprietary 
transfection agent while subsequent experiments performed in Birmingham used 
PEI.  Given that mg amounts of purified protein were needed for immunisation 
relatively inexpensive PEI was preferred as the transfecting agent.  To confirm 
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that plasmid constructs tested at OPPF (Figures 5.4 and 5.5) also expressed 
when using PEI as a transfectant, HEK293T cells were transiently transfected 
with 2 µg of each of the eight plasmids which had expressed protein at OPPF 
(Clones as designated in Figure 5.6 and Table 5.3).  HEK293T cell lysates were 
analysed on a SDS-PAGE gel and immunoblotted with a monoclonal His6 
antibody.  All eight clones exhibited protein expression, with clones G2 and F2 
having the highest amount of expression (Figure 5.6).  It should be noted that 
clone G2 contains a second band, which has a molecular weight of its tag, E3C 
Halo (~35.3 kDa). 
 
 
Figure 5.6 – Anti-His6 immunoblot of HEK293T cells transiently transfected   
with plasmids encoding ANKRD18A fragments and its respective tags 
using PEI.  Refer to Table 5.2 for clone designations and sizes.  The highest 
expression clones (F2 and G2) are encircled in red.  (N=2) 
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Clone Functional 
Domain 
Molecular 
Weight 
(kDa) 
Residue 
range 
Purification 
tag 
Total mole-
cular 
weight (kDa) 
H1 Ankyrin 
Repeat(Phyre2) 
23 35-235 His6-Sumo3C 36.2 
F2 Ankyrin Repeat 
(HHPred) 
30 1-260 His6-MBP 73 
G2 Ankyrin Repeat 30 1-260 His6-Halo3C 65.3 
B3 Tropomyosin 40 450-790 His6-Sumo3C 53.2 
C3 Tropomyosin 40 450-790 His6-MBP 83 
E3 Tropomyosin 40 450-790 His6 40 
H3 Colicin 1A 24 790-992 His6-Sumo3C 37.2 
A4 Colicin 1A 24 790-992 His6-MBP 67 
Table 5.3 – Summary of ANKRD18A recombinant proteins with detectable 
expression when transiently transfected into HEK293T cells.    The clones 
highlighted in green were chosen for purification.  MBP = maltose binding protein, 
Sumo = small ubiquitin-like modifier, Halo = modified haloalkane dehalogenase; 
all constructs, except for E3, include a cleavage site for human rhinovirus 3C 
protease. 
 
5.2.4. Purification of selected ANKRD18A recombinant proteins  
While the constructs generated at OPPF included different fusion partners (i.e. 
MBP or HALO), they all coded for a hexa-histidine tag.  Making use of this His-
tag, recombinant proteins were extracted from cleared cell lysates by Nickel -
Nitrilotriacetic (Ni+2-NTA) column chromatography, often an effective method to 
obtain purified protein.   
 
Because of the need to maximise protein production, clone G2 was initially 
chosen for purification since it was one of the highest expressing clones.  
However, while purification over a Ni+2-NTA column was effective, the eluted 
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protein was subsequently not stable, and frequently precipitated during dialysis.  
In contrast, clone F2 proved more stable in purified form.  
 
 
Figure 5.7  – Coomassie stained SDS-PAGE gel demonstrating purification 
of clone F2 using Ni+2-NTA chromatography.  Elution fractions using 100-
500mM imidazole were collected for dialysis.  Arrow points to recombinant 
protein, MBP-ankyrin repeat protein, clone F2.  Molecular markers on the left are 
in units of kDa.  (N=10) 
 
Harvesting cell monolayers from ten 15 cm tissue culture plates, cells which were 
transiently transfected with the DNA of clone F2, were lysed by applying 
detergent-containing buffer and the cleared lysate was passed twice over a Ni+2-
NTA resin, followed by elution with an imidazole step gradient (details in section 
2.7.1 of Chapter 2). Fractions eluted from using imidazole concentrations of 100-
500 mM imidazole (Figure 5.7) were then pooled and dialyzed thrice against a 
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buffer containing 20mM Tris, 150mM NaCl, pH 7.8.  Following dialysis, the 
dialysate was loaded onto an anion exchange column to obtain single band pure 
proteins. 
 
Ion exchange chromatography is based on the principle of proteins binding 
through ionic interaction to the column resin. The protein can be eluted in a 
differential fashion either through gradually increasing the ionic strength of the 
buffer (thereby reducing the affinity between protein and resin) or by altering the 
pH (thereby changing the overall charge of the protein, and thus affecting its 
affinity to the resin). The choice of resin (positively vs negatively charged) is 
determined by the isoelectric point, pI (the pH at which the overall charge of a 
protein is zero) of the protein to be purified, and the availability of a buffer with a 
pKa value sufficiently far away from the pI (at least 1 pH unit above the pI of 
substance to be bound to anion exchange column) so as to maximise solubility of 
the protein (Duong-Ly and Gabelli 2014).  Therefore, because the pI of clone F2 
is 6.64 and that of clone G2 is 6.34, the dialysis buffer which was chosen after 
elution from the nickel column was 20 mM Tris, 150 mM NaCl, pH 7.8 and 20 
mM Tris, 200 mM NaCl, pH 7.8, respectively, because the pKa (25ºC) of Tris is 
8.07.  The NaCl concentration needed to be more concentrated than usual 
(normally ~50mM NaCl) to prevent precipitation of the recombinant proteins in 
the dialysis buffers.  Fortunately, this elevated concentration did not prevent the 
proteins from binding the resin of the anion exchange column.     
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Ultimately, clone F2 was further purified using anion exchange chromatography, 
whereby increasing concentrations of sodium chloride were used to elute the 
recombinant protein (Figure 5.8).  Through this two step purification, single band 
pure fusion protein was obtained, with a total amount of ~2.2 mg at a 
concentration of 2.16 mg/ml (Figure 5.13).  
 
 
Figure 5.8 – Coomassie stained SDS-PAGE gel demonstrating purification 
of clone F2 using anion exchange chromatography.  Fractions eluted using 
increasing concentrations of NaCl (250-500mM) are pooled for concentration.  
The arrow points to purified clone F2.   (N=10) 
 
 
Chapter Five                          ANKRD18A recombinant protein and antibody production 
 
 
 
 
 
 
 
180 
5.2.5. Proteolytic cleavage of the MBP tag from the ANKRD18A 
recombinant protein (clone F2). 
When immunising an animal to raise antibodies, using a fusion protein can 
generate antibodies specific to either fusion partner (purification tag as well as 
the target protein).  The expression constructs had been designed such that they 
included a proteolytic cleavage site to cleave the fusion protein using 
recombinant human rhinovirus 3C (HRV3C) protease.  Therefore, following 
concentration of the pooled purified fractions of clone F2, the fusion protein was 
incubated with HRV3C protease and protease activity was assessed by 
analysing the reaction mixtures on SDS-PAGE gels.  Starting with manufacturer 
recommended ratios of protease to enzyme, next to no proteolytic digest was 
detected.  Increasing the enzyme concentrations to 4 units for every 10 µg led to 
discernible cleavage of the fusion protein (Figure 5.9).  Also, overnight incubation 
at 4 ºC proved superior to room temperature for 1 – 6 hours.  
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Figure 5.9 – Removing MBP tag from recombinant protein MBP-ANKRD18A 
(clone F2) with HRV3C protease.  Lane 1- Uncut F2, lane 2-10 µg F2, 2 µl 
HRV3C, 8 hours incubation at 4ºC, lane 3- 50 µg F2, 6 µl HRV3C, 8 hours at 
4ºC, lane 4- Control protein, 2 µl HRV3C, 8 hours at 4ºC, lane 5- 10 µg F2, 3 µl 
HRV3C, overnight incubation at 4ºC, lane 6- 50 µg F2, 11 µl HRV3C, overnight 
incubation at 4ºC, lane 7- Control, 3 µl HRV3C, overnight incubation at 4ºC.   
Each lane contains 10 µl of sample plus 30 µl of Laemmli sample buffer.  (N=5) 
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Figure 5.10 – Cleaving MBP tag from clone F2 (recombinant protein, MBP-
ankyrin repeat domain).  Each reaction mixture contains 200 µg of F2 with 40 µl 
(80 units) of HRV3C protease.  Lane 1- unconcentrated F2, lane 2- filtrate from 
concentration of F2, lanes 3-7 cleaved F2.   Each lane contains 10 µl of sample 
and 30 µl of Laemmli sample buffer.   (N=1) 
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Figure 5.11 – Binding MBP tag to Ni+2-NTA beads by IMAC.  Clone F2, 50 µg 
digested with 11 µl of HRV3C protease added to 200 µl Ni+2-NTA beads in 
suspension, rotated overnight at 4ºC.  Lane 1 - 1 µl  (2 units) of protease alone, 
lane 2- supernatant after overnight incubation with beads, lane 3- 1st wash of 
beads with 20mM Tris/150mM NaCl, pH7.8, lane 4- 2nd wash of beads, lane 5- 
beads alone.  Each lane contains 10 µl of sample with 30 µl of 5X Laemmli 
sample buffer.   POI=protein of interest (ankyrin repeat domain).   (N=2) 
 
 
It was also noted that large concentrations of the fusion protein could not be 
cleaved by just increasing the amount of HRV3C protease.  Rather, it appeared 
that the concentration of the fusion protein needed to be ~200 µg and 
suspending in a volume greater than 1 ml in a microfuge tube for the HRV3C 
protease enzymatic reaction to occur (Figure 5.10).  The most likely reason for 
this is because when too concentrated the cleavage site is obstructed.  
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Therefore, for large amounts of clone F2 to have its tag cleaved with HRV3C, the 
reaction mixture needs to be separated into many separate microfuge tubes.   
In order to separate the MBP tag from the ankyrin repeat domain following 
incubation with HRV3C protease, Ni+2-NTA beads were used, with the reasoning 
that the MBP domain, which includes the hexa-histidine tag, would be retained 
on the resin, while the ankyrin repeat domain would be released into the 
supernatant.  This experiment was initially attempted using immobilised metal ion 
affinity chromatography (IMAC), whereby the POI + MBP mixture was incubated 
with Ni+2-NTA sepharose beads overnight at 4 ºC, then the beads are pelleted 
and the supernatant evaluated by SDS-PAGE, staining with Coomassie dye 
(Figure 5.11).  As mentioned above, the tag was expected to remain bound to the 
Ni+2 resin, as it carried the His6-peptide, while the purified protein of interest 
would be suspended in the supernatant.  Contrary to expectation, the pelleted 
nickel beads, when eluted with SDS sample buffer, contained both the tag and 
the cleaved protein, while no cleaved protein was found in the supernatant.  So, 
while the proteolysis had cleaved the MBP tag from the ankyrin repeat domain, 
the failure to partition the two proteins into pellet and supernatant respectively, 
indicated that they were still bound to each other.  The failure to separate the two 
fusion partners after proteolytic cleavage of the peptide linker suggested that 
non-covalent interactions existed between these domains.  By varying the buffer 
composition, it was tested whether this non-covalent interaction could be 
disrupted. This interaction was attempted to be interrupted by varying the buffer 
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composition, including altering pH, increasing the salt concentration to 1 M NaCl, 
adding 300 mM urea, adding the reducing agent dithiothreitol (DTT), or eluting 
the cleaved protein with increasing concentrations of glycerol.  None of these 
strategies succeeded in separating the affinity tag from the protein of interest.  
 
Finally, separation of the MBP tag from the ankyrin repeat domain was achieved 
by loading the cleaved mixture of proteins onto a Ni+2-NTA column.  The MBP 
tag did bind to the Ni+2 on the column matrix, and the ankyrin repeat domain  
 
       
Figure 5.12 - Separation of MBP tag from ankyrin repeat domain using Ni+2-
NTA column.  Lane 1- mixture of F2 cleaved with HRV3C protease, lane 2- FT, 
lane 3- wash, lane 4-8- increasing imidazole concentration from 60mM to 
500mM.  Arrow points to band representing ankyrin repeat domain.  Each lane 
contains 40 µl of sample and 10 µl of Laemmli sample buffer.   (N=1) 
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was able to be eluted with the flow-through (Figure 5.12).  The ankyrin repeat 
domain was able to be separated from the MBP tag.  However, the only caveat 
was that only a small amount of protein was eluted.  Through these experiments, 
it became clear that generating a sufficient quantity of the purified and cleaved 
ankyrin repeat domain was probably unrealistic: attempts to proteolytically cleave 
the F2 fusion protein was possible although difficult and isolating the ankyrin 
repeat domain from the reaction mix yielded only a small amount of the target 
protein.  Because the two step purification of the intact fusion protein was 
relatively successful, immunization with the fusion protein was given 
consideration. 
 
Adopting this strategy, clone F2 was purified as a fusion protein.  Omitting 
proteolytic cleavage of the MBP tag, a single band pure protein was forwarded to 
Biogenes for the immunisation of two rabbits to obtain ANKRD18A-specific 
polyclonal antibody (Figure 5.13).  In order to facilitate affinity purification of the 
resulting antibodies, 5 mg of clone G2 was purified (at a concentration greater 
than 0.5 mg/ml).  Clone G2 consists of the ankyrin repeat domain fused to a Halo 
tag (a modified haloalkane dehalogenase designed to covalently bind to synthetic 
ligands from Promega).  The purified protein of clone G2 was used for 
immobilization on an immuno-affinity column. The antibody that had been raised 
by immunizing the rabbits with the purified protein of clone F2 was purified using 
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the clone G2-coated affinity column, which selected for antibody that recognized 
the ankyrin repeat domain of ANKRD18A. 
 
 
Figure 5.11 – Coomassie stained SDS-PAGE demonstrating purified protein 
of clone F2 sent to Biogenes for generation of antibody.  Lane 1- 
preconcentrated protein, lane 2-concentrated protein, lane 3- flow through from 
concentration.  Each lane contains 5 µl of sample and 30 µl of Laemmli sample 
buffer.  Total concentration of protein after concentration is 2.16 mg/ml in total 
volume of 1 ml.  (N=1) 
 
 
5.2.6. Production and purification of the ANKRD18A recombinant 
protein (clone G2) 
The purification steps used to isolate the protein of clone G2 was similar to those 
of clone F2 in that the first purification step involved Ni+2-NTA chromatography 
followed by anion exchange chromatography then concentration of protein using 
Amicon centrifugal filters.   For Ni+2-NTA chromatography, the protein of clone G2 
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eluted at a higher concentration of imidazole, 300 mM (Figure 5.14).  Fractions 
obtained from imidazole elutions of 300 to 500 mM were pooled and dialysed in 
20 mM Tris, 200 mM NaCl, pH 7.5.  A series of trials at lower NaCl 
concentrations (i.e. less than 200mM) led to significant and rapid precipitations of 
protein during dialysis.  Raising NaCl to 200 mM proved critical in preventing 
precipitation during dialysis, but the question arose whether this concentration of 
NaCl would limit clone G2’s affinity to the Q-sepharose matrix for ion exchange 
chromatography.  Fortunately, 200 mM NaCl was still compatible with G2 binding 
to the anion exchange column resin and elution occurred over a NaCl gradient 
from 350 to 500 mM NaCl (Figure 5.15).  The pooled eluants were then dialysed 
against 20 mM sodium phosphate, 500 mM NaCl, pH 7.5.   
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Figure 5.12 – Coomassie stained SDS-PAGE demonstrating purification of 
precleared lysates from thirty 15cm plates of HEK293T cells transiently 
transfected with cDNA from clone G2 (E3C Halo-ankyrin repeat domain).  
Elutions using 300-500mM imidazole are collected for dialysis and further 
purification using the anion exchange column.  Each lane contains 40 µl of 
sample and 10 µl of Laemmli sample buffer (N=20). 
 
 
Following dialysis, the pooled eluants were concentrated using Amicon Ultra-15 
centrifugal filters.  However, the solubility of fusion protein G2 was low and the 
protein was prone to precipitation if concentrated beyond 0.5 mg/ml.  Adding 
glycerol (8% v/v) to the dialysis solution did not markedly improve solubility.  In 
addition, the Amicon membrane was passivated (through incubation with 5% v/v 
solution of polyethyleneglycol 6000) to minimize stickiness of the protein to the 
ultrafiltration membrane, but this also proved to very little effect.  Nevertheless, 
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after 20 preparations of clone G2, 5.05 mg of purified clone G2 (concentration 
1.02 mg/ml) was finally attained and sent to Biogenes for immobilization on an 
immuno-affinity column. 
 
Figure 5.13 – Coomassie stained SDS-PAGE demonstrating purification of 
pooled Ni++-NTA eluants of clone G2 on an anion exchange column.  
Elutions from lanes 5-7 using 350 to 500mM NaCl are pooled for dialysis and 
then concentration.  Each lane contains 40 µl of sample and 10 µl of Laemmli 
sample buffer. Arrow points to purified elutions (N=20).  
 
5.3. Characterisation of ANKRD18A polyclonal antibody 25277  
Antibody 25277 is an affinity purified polyclonal antibody raised in rabbits to 
recognise the folded structure of the ankyrin repeat domain of ANKRD18A.  Two 
polyclonal antibodies were received from Biogenes, 25277 and 25278, each 
raised in different rabbits.  However, α-25277, which had a concentration of 0.24 
Chapter Five                          ANKRD18A recombinant protein and antibody production 
 
 
 
 
 
 
 
191 
mg/ml, was chosen as the one to use after data from flow cytometry and  
immunofluorescence experiments and immunoblotting for Westerns, suggested 
that α-25277 is more specific. 
5.3.1. Assessing specificity of α-25277 
In a flow cytometry (Accuri B6 cell sorter) experiment, following incubation with 
either α-25277 (1:100) or a non-specific IgG, unpermeabilised and permeabilised 
HEK293T cells were analysed.  The cells sorting histogram (Figure 5.16) 
demonstrated that permeabilised HEK293T cells (Figure 5.16B), when treated 
with α-25277, caused an increase in fluorescence intensities (Table 5.4).  This 
increase is reversed in a dose dependent fashion when the purified ANKRD18A 
fragment, clone G2, was added (Table 5.4).  In contrast, unpermeabilised cells 
demonstrated only a modest increase in fluorescence intensities (Figure 5.16A 
and Table 5.4).  These data suggested that ANKRD18A is located intracellularly 
because α-25277 only caused a large increase in fluorescence signal in the 
permeabilised cell.  Also, the fact that the purified recombinant ankyrin repeat 
domain protein was able to reverse the response, supports specificity of α-25277 
for ANKRD18A.  Another control which should have been conducted to further 
support the claim that α-25277 is specific is to use a mock protein in place of 
clone G2 to see if there is any decrease in fluorescent intensities following the 
co-application of a-25277 and mock protein to the HEK293T cells.   
In order to further ascertain specificity of α-25277 for its target antigen, 
immunofluorescence confocal microscopy was performed.  These experiments 
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entailed a two-step process.  In both experiments, Dami cells were transiently 
transfected with plasmid DNA encoding clone G2.  In the first experiment, 
transfected Dami cells were stained with the primary antibody, α-His (1:750)  
(which recognises the hexa-histidine tag of the recombinant protein), the 
secondary antibody, α-mouse Alexa Fluor 488 (1:300) and a nuclear stain, TO-
PRO-3.  As a control, transfected Dami cells were stained with just secondary 
antibody.   Results of this experiment (Figure 5.17) suggested that the 
recombinant protein, clone G2, is localised to the nucleus since the α-His stain 
co-localises with the TO-PRO-3 stain.  
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Figure 5.14 - Flow cytometry experiment probing specificity of the 
polyclonal α-ANKRD18A, α-25277, using HEK293T cells.  A) and B) 
Concentrations of antibody stocks were as follows: Non-specific IgG (1 mg/ml), 
α-rabbit IgG conjugated to FITC (2 mg/ml), α-25277 (0.24 mg/ml). Clone G2 = 
purified ANKRD18A (1-260) (N=2).   
 
 Unpermeabilised Permeabilised 
 Mean FL1-A Mean FL1-A 
Control 5015.5 3743.2 
Non-specific IgG 9830.0 15218.4 
α-rabbit IgG conjugated to FITC 9696.3 28937.1 
α-ANKRD18A (1:100) + G2 (10 µg/ml) 10305.2 46729.1 
α-ANKRD18A (1:100) + G2 (20 µg/ml) 9825.4 33112.0 
α-ANKRD18A (1:100) + G2 (40 µg/ml) 15830.5 23332.3 
α-ANKRD18A (1:100) 24508.3 134113.3 
Table 5.4 - Flow cytometry experiment probing specificity of the polyclonal 
α-ANKRD18A, α-25277. Values indicated are the mean FL1-A fluorescence 
intensities for the conditions shown in the panels in Figure 5.18 above (N=2). 
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Figure 5.15 – Immunofluorescence confocal microscopy images of Dami 
cells stained with α-His and TO-PRO-3 demonstrating intranuclear 
localization of fusion protein (clone G2).  Dami cells are transiently 
transfected with cDNA from clone G2 (E3C-Halo ankyrin repeat domain).  A) 
primary antibody: α-His monoclonal (1:750), secondary antibody:  α-mouse Alexa 
Fluor 488 (1:300)  B) TO-PRO-3 (1:2000)  C) Overlay of panels A and B. 
 
 
For the subsequent experiment, a different set of transfected Dami cells were 
stained with both α-His (1:750) and α-25277 (1:100) as primary antibodies and 
the corresponding secondary antibodies, α-mouse Alexa Fluor 488 and α-rabbit 
Alexa Fluor 647 (both at 1:300), respectively.   In this experiment, Dami cells 
were not stained with TO-PRO-3 as well because TO-PRO-3’s far-red 
fluorescence has peak absorbance at 642 nm and emission at 661 nm, which 
overlaps with absorbance and emission peaks of Alexa Fluor 647.  Again, the 
controls for this experiment were Dami cells stained only with the secondary 
antibodies: α-mouse Alex Fluor 488 and α-rabbit Alexa Fluor 647.  In this 
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experiment, the transfected recombinant protein, clone G2, localised to the 
nucleus, as evidenced by the α-His stain (Figure 5.18A) and the results of the 
previous experiment.  α-25277 also stained for protein that localised to the same 
area as that which was stained with α-His, i.e. the nucleus (Figure 5.18B). Since 
α-His is specific for the recombinant protein, co-localisation of the signals 
associated with α-25277 and α-His, indicated that they bind to the same protein.  
Results from the second experiment suggested that both the recombinant protein 
and ANKRD18A co-localised to the nucleus, suggesting that ANKRD18A is a 
nuclear protein. These experiments also further underscored the specificity of α-
25277 for ANKRD18A because its staining results concurred with those of α-His, 
which binded to the transfected recombinant protein (Figure 5.18 and Figure S2).  
                                                                
 
Figure 5.16 – Immunofluorescence confocal microscopy images of Dami 
cells stained with α-His and α-25277 demonstrating intranuclear 
localisation of ANKRD18A.  Dami cells are transiently transfected with cDNA of 
plasmid for Clone G2. A) primary: α-His6, secondary: α-mouse Alexa Fluor 488,  
B) primary: α-25277, secondary: α-rabbit Alexa Fluor 647, C) overlay of A and B    
(N=2). 
A B C 
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5.3.2.  Immunoblotting to assess ANKRD18A antibody 25277  
Finally, specificity of α-25277 was probed in immunoblot experiments, including 
dot blots, Westerns, and immunoprecipitation (IP) experiments.  Dot blots 
assisted in determining the appropriate dilution of antibody stock to be used in 
immunoblotting and IP experiments.  HEK293T cells lysed with RIPA buffer were 
used in the dot blot experiments.  From the dot blots, it was ascertained that α-
25277 could be used at a dilution down to 1:1500 (Figure 5.19).  When α-25277 
was used to immunoblot WCLs of Dami, HEK293T cells and platelets in SDS-
PAGE gels, no dominant band appeared at the expected molecular weight of 116 
kDa (Figure 5.20 and 5.21).  Dami and HEK293T cells were lysed with RIPA 
buffer, which can lyse the nuclear membrane to release intranuclear proteins.  
The platelets were lysed with a buffer containing the detergent NP-40, which 
cannot lyse nuclear membranes.  However, this is a mute point since platelets do 
not have nuclei.   As is typical for a polyclonal antibody, which is used to 
immunoblot Westerns, multiple bands were observed, but in this case, when 
immunoblotting the WCLs of HEK293T and Dami cells, there were multiple 
bands but no predominant band to suggest that the antibody was recognizing a 
particular protein.  Since these cells were lysed with RIPA buffer, it is quite 
possible that genomic material had been released upon lysis of the nucleus and 
when run in a Western, resulted in the “smeary” appearance seen in each lane of 
the gel.  Nevertheless, in order to confirm that α-25277 recognised its antigen, a 
strong, if not dominant band was expected between the 100 and 135 kDA 
Chapter Five                          ANKRD18A recombinant protein and antibody production 
 
 
 
 
 
 
 
197 
markers, for the Dami/HEK293T blot (Figure 5.20).  For the platelet blot (Figure 
5.21), one saw a dominant band at the correct molecular weight of ~116 kD in 
the Donor 2 lane.  This however was not seen in the other WCLs of the other 
donors.   It appeared that the WCLs of donors 1 and 3 were very concentrated 
resulting in difficulty identifying individual bands in the two lanes.  Also, for 
donors 4 and 5, the WCLs appear not concentrated enough, thus there may not 
be enough ANKRD18A protein in the lane to be identified with α-25277.  
Thus, both of these Westerns were technically flawed and would require further 
modification of experimental conditions for one to obtain better blots for analysis 
and determination of whether α-25277 could be used for immunoblotting 
experiments.  
 
 
Figure 5.17 – Dot blot demonstrating the antibody dilution of α-25277 to be 
used for experiments.  1 = WCLs from HEK293T cells, 2 = WCLs from Dami 
cells differentiated for 24 hours, 3 = WCLs of Dami cells differentiated at 48 
hours, 4 = WCLs of Dami cells differentiated at 72 hours.  N=2 
1 2 3 
4 4 4 
α-25277  
1:500 1:1000 1:2000 Dilution 
1 2 3 1 2 3 
Chapter Five                          ANKRD18A recombinant protein and antibody production 
 
 
 
 
 
 
 
198 
 
Figure 5.18 – Immunoblot of Dami and HEK293T WCLs using α-25277.  
Blotting antibody dilution is 1:1500 (N=3). 
 
 
 
Figure 5.19 – Immunoblot of healthy donor platelet WCLs using α-25277. 
Blotting antibody dilution is 1:1500 (N= 3). 
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Because no ANKRD18A protein was detected in the Westerns immunoblotted 
with α-25277, the question arose whether enough protein had been present in 
the WCLs of HEK293T and Dami cells and platelets that had been tested 
(Figures 5.20 and 5.21).  Immunoprecipitation experiments were thus performed 
with WCLs from HEK293T and Dami cells and platelets using α-25277 and non-
specific IgG as a control.  The IPs were loaded onto SDS-PAGE gels and 
immunoblotted using the same antibodies, α-25277 (Figure 5.22B) and non-
specific IgG as control (Figure 5.22A), respectively.  Again, Dami and HEK293T 
cells were lysed with RIPA buffer and platelets were lysed with buffer containing 
NP-40.  The immunoblot blotted with α-25277 failed to show a clear-cut band at 
the expected molecular weight of ~116 kDa.  Of note, the positive control, 
purified protein of clone G2, did not appear when immunoblotting with α-25277, 
so this experiment is mute and would need to be repeated (Figure 5.22B).  In the 
analogous experiment for platelet WCLs, immunoprecipitation again used non-
specific IgG and α-25277 followed by immunoblotting with non-specific IgG 
(Figure 5.23A) and α-25277 (Figure 5.23B).   There was a questionable band at 
~116 kDa, but its intensity was comparatively weak.  Nevertheless, the lane 
containing the positive control (Figure 5.23B, lane 1), the purified protein of clone 
G2, had a band at the correct molecular weight of 65 kDa.  
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Figure 5.20 – Immunoblot of ANKRD18A immunoprecipitated from whole 
cell lysates of HEK293T and Dami cells.  IP antibodies are (A) IgG and (B) α-
ANKRD18A, α-25277.  Blotting antibodies used are monoclonal (A) IgG and (B) 
α-ANKRD18A, α-25277 at 1:1500 dilution.  Lane 1 - Clone G2, lane 2 - Dami 
cells, lane 3 - HEK293T cells, lane 4 - BSA (N=2). 
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Figure 5.21 – Immunoblot of ANKRD18A immunoprecipitated from whole 
cell lysates of healthy donor platelets (D1 and D2).  IP antibodies are (A) IgG 
and (B) α-ANKRD18A, α-25277.  Blotting antibodies used are (A) monoclonal 
IgG and (B) α-ANKRD18A, α-25277 at 1:1500 dilution.  Lane 1-Clone G2, lane 2- 
D1, lane 3- D2, lane 4-BSA (N=1). 
 
 
5.4. Summary 
Given these data, it is still indeterminate whether polyclonal antibody α-
ANKRD18A-25277, is suitable for the detection of the ANKRD18A antigen. 
Although in flow cytometry and immunofluorescence confocal microscopy 
experiments, the specificity of α-25277 for ANKRD18A was suggestive, the fact 
that α-25277 did not immunoblot for ANKRD18A when using HEK293T, Dami 
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and platelet whole cell lysates in Westerns and immunoprecipitation experiments 
makes it questionable whether α-25277 is specific for ANKRD18A.   
 
In the flow cytometry experiment, when the concentration of the immunising 
antigen was titrated upwards, it reversed the shift of the cell population in cell 
sorting experiment (Figure 5.16 and Table 5.4).  And, when used in confocal 
experiments to immunolocalise ANKRD18A in Dami cells (Figures 5.17 and 
5.18), α-25277 identified ANKRD18A by co-localising with ANKRD18A which had 
been transfected into Dami cells as determined by immunolocalisation using α-
His.  In such experiments, ANKRD18A was present in its native state and not its 
denatured state.  This suggests that α-25277 would work equally well in 
immunohistochemistry and electron microscopy experiments. 
 
In contrast, the results from the immunoblotting and immunoprecipitation 
experiments of whole cell lysates indicated that specific detection of ANKRD18A 
by α-25277 were not compelling.  In these experiments however, ANKRD18A is 
denatured (through treatment with SDS and boiling at 95 ºC), which may have 
disrupted the epitope that α-25277 recognised, and thus prevented the expected 
signal to appear in the corresponding blots.  Also, it should be noted that due to 
time constraints, the immunoblots and IP experiments using α-25277 adhered to 
standard protocols used in the laboratory.  More time was needed to fine-tune 
the experimental conditions:  cell concentrations in cell lysates might have 
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needed to increase or decrease; there may have been genomic DNA 
contamination in the WCLs for the Western blots; the choice of lysis buffer might 
have needed to be altered i.e. the detergent in the cell lysis buffer changed or 
decreased in concentration or the salt concentration of the lysis buffer may have 
needed to be increased. 
 
In order that specificity of α-25277 can be confirmed, ANKRD18A expression 
needs to be silenced by RNAi.  The above flow cytometry and confocal 
microscopy experiments need to be repeated using HEK293T cells and Dami 
cells transfected with siRNA to silence ANKRD18A expression.  If α-25277 is 
specific to ANKRD18A, the shift seen in the above flow cytometry experiment will 
be abrogated when these “knockdown” cells are used.  Likewise, when the 
confocal immunofluorescence microscopy experiments are repeated with the 
“knockdown” cells, no protein should be localized with α-25277.  This can be 
confirmed by transfecting in the cDNA of clone G2 into the “knockdown” Dami 
cells to see if after transfection of this plasmid, α-25277 can localize the 
recombinant protein.  Overall though, given all of these conflicting data, the most 
realistic chance of obtaining an antibody, which is specific to ANKRD18A, is to 
generate a monoclonal antibody. 
 
Although it may seem that the above efforts to purify the recombinant protein, 
comprised of a functional domain of ANKRD18A fused to a tag, were 
Chapter Five                          ANKRD18A recombinant protein and antibody production 
 
 
 
 
 
 
 
204 
superfluous, especially since α-25277 was shown to be less than effective, there 
are uses for the purified recombinant proteins.  Because these recombinant 
proteins contain an ankyrin repeat domain, they can be used to “fish-out” 
potential binding partners for ANKRD18A.  This can be accomplished by 
performing protein-protein interaction assays such as pull-downs or co-
immunoprecipitation experiments with platelet lysates and then followed up with 
identification of potential binding partners using mass spectrometry. Identifying 
potential ANKRD18A binding partners will be helpful in determining possible 
functions for ANKRD18A.          
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6. Discussion 
6.1. Conclusions from work of this thesis 
6.1.1. Evolutionary context of ANKRD18A and its link to platelet 
disorders  
The overall aim of this project was to characterise the novel protein, ANKRD18A.  
A mutant form of ANKRD18A is suspected to be linked to the severe 
thrombocytopenia identified in two children from a consanguineous family (Figure 
1.14); however, the molecular mechanism causing this inherited platelet disorder 
remains to be clarified.  By determining the function of ANKRD18A, this project 
sought to establish whether there is a causative link between the two patients’ 
thrombocytopenia and the deletion mutation identified in the ANKRD18A gene. 
    
A homologue of ANKRD18A, ANKRD26, has been implicated in an autosomal 
dominant form of thrombocytopenia, THC2 or ANKRD26-RT (Noris, Perrotta et 
al. 2011).  ANKRD26 has 1050 amino acid residues and its amino acid sequence 
is 44% identical to ANKRD18A.  Patients with THC2 have various single 
nucleotide substitutions in the 5’-UTR of ANKRD26 (Bluteau, Glembotsky et al. 
2012).  These mutations contrast with the genetic alteration found in ANKRD18A, 
which is an in-frame deletion of an entire codon in the centre of exon 13 of the 
gene.  In addition to ANKRD26, there exists another homologous protein, 
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ANKRD18B, which has a 93% amino acid identity with ANKRD18A.  Its function 
remains unknown.   
 
The domain structure of ANKRD18A gives few clues as to its physiological role in 
the eukaryotic cell.  ANKRD18A has three distinct regions of homology to 
proteins of known structure (Figure 1.16) as determined by fold prediction using 
threading (Phyre2, HHpred).  The amino terminus consists of ankyrin-like 
repeats, followed by a coiled coil region that appears to resemble the structures 
of tropomyosin and at the carboxy terminus, the colicin IA homology domain.  
Ankyrin repeat domains have a variety of functions, but are primarily known as 
mediators of protein-protein interactions, particularly in eukaryotes (Li, Mahajan 
et al. 2006).  Tropomyosin is an integral component of actin filaments and is 
involved in cellular pathways which regulate the cellular cytoskeleton (von der 
Ecken, Muller et al. 2015).  The fact that ANKRD18A has this tropomyosin 
homology domain further suggests that it may play a role in the cytoskeleton.  
Colicin IA is a transmembrane protein, which forms voltage-gated ion conducting 
channels across the plasma membrane of target bacteria.  The C-terminal region 
of ANKRD18A shows remote homology to the bacterial channel-forming protein 
colicin IA.  The homology was detected using the fold prediction server Phyre2 
(http://www.sbg.bio.ic.ac.uk/phyre2) by threading.  The sequence identity over 
the homologous region is very low (9% identity), but the prediction has a high 
confidence level (98%).  The homology extends over the coiled-coiled region of 
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colicin IA, including the receptor binding region of colicin IA, but excluding the 
channel-forming domain of this bacterial protein.  In the fold prediction, the 
ANKRD18A Δ801 deletion mutation maps to a small helix in the receptor-binding 
region of colicin IA.  However, given the very low level of sequence identity 
between the two proteins, a prediction of what effect the analogous deletion 
would have in colicin IA is not possible (Gouaux 1997, Wiener, Freymann et al. 
1997, Stroud, Reiling et al. 1998).        
6.1.2. Generation of ANKRD18A recombinant protein and subsequent 
antibodies 
In order to characterise the function of ANKRD18A, a molecular probe specific 
for this protein is a key requirement.  Prior to my joining the laboratory, the 
laboratory had acquired two polyclonal antibodies directed against peptides 
derived from amino residues 53-66 and 260-289 of the ANKRD18A sequence 
(Figure 4.4).  Testing these set of polyclonal antibodies raised doubts as to their 
specificity for ANKRD18A (Chapter 4).  Secondly, the closely related sequence of 
ANKRD18B, a protein of similarly unknown function, further confounded the 
results.  For example, when probing WCLs of HEK293T cells with the α-
ANKRD18A antibody 21234, the dominant band was between 135 and 190 kDa, 
suggesting that the long isoform of ANKRD18B (Mr 165 kDa), rather than 
ANKRD18A (Mr 116kDa) had been detected (Figure 4.5B).  Thus, to overcome 
ambiguity and potential cross-reactivity resulting from antibodies raised against 
peptides, a strategy was devised to generate an antibody raised against the 
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folded, full-length ANKRD18A.  A polyclonal antibody was decided upon with the 
intention that should results prove positive and interesting, a monoclonal 
antibody would be made later in the future. 
 
Prior to my joining the laboratory, GFP and myc-tagged constructs had been 
made which encode the wild-type and a mutant form of full-length ANKRD18A.  
These were intended for use in over-expression experiments to determine the 
biological functions of ANKRD18A.  However, subsequent flow cytometry 
experiments demonstrated poor transfection efficiencies with these plasmid 
cDNAs (Figure 3.5A).  Likewise, α-GFP immunoblotting of whole cell lysates from 
HEK293T cells transiently transfected with full-length GFP-ANKRD18A in 
Westerns revealed no expression (Figure 3.5B).  Attempts were also made to 
immunoblot the insoluble fractions of HEK293T cells transfected with full-length 
GFP-ANKRD18A and full-length constructs made at OPPF.  These attempts 
failed to demonstrate expression by blotting with α-GFP or α-His6.    
 
 As a first priority, my work focussed on generating one or more antibodies 
directed against the folded form of ANKRD18A.  Given the difficulty of expressing 
full-length ANKRD18A, an alternative strategy was devised whereby a suitable 
antigen was generated by expressing and purifying the ankyrin repeat domain of 
ANKRD18A (Table 5.1).  Approximate boundaries of the (putative) structural 
domains of ANKRD18A were determined through fold prediction.  To reduce the 
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risk of erroneous domain predictions, two alternative fold prediction servers were 
used, which consistently predicted the ankyrin repeat domain at the amino 
terminus of ANKRD18A.  This bioinformatics-led approach helped generate a 
rational basis for designing the plasmid expression constructs (Table 5.2). 
 
The parallel processing capability of OFFP (the Oxford Protein Production 
Facility) enables one to rapidly identify combinations of fragments and affinity 
tags that will lead to expression of soluble protein.  Since protein expression can 
be highly dependent on the expression host, a pool of 32 expression constructs 
was tested for expression in both E. coli cells (Figures 5.1, 5.2, 5.3) and the 
mammalian cell line, HEK293T (Figures 5.4, 5.5).  In these pilot tests at OPPF, 
expression in HEK293T cells was generally more successful than in E. coli.  The 
most likely reason why expression was more effective in HEK293T cells rather 
than in E. coli is because prokaryotic and eukaryotic gene sequences differ in 
their usage of the genetic code, and corresponding expression hosts differ in the 
prevalence of synonymous tRNAs.  Thus, it is often found that mammalian gene 
sequences express poorly in prokaryotic hosts and vice versa.  Several 
constructs encompassing the amino terminal ankyrin repeat domain, which is 
consistently identified as a conserved domain by bioinformatical analysis, 
demonstrated good protein expression, suggesting that this fragment indeed 
forms an integral structural domain.  Nonetheless, even the more speculative 
fragments, the central tropomyosin-like domain and the carboxy terminal colicin 
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1A-like domain resulted in soluble protein (Figure 5.6).  Consistent with my 
previous transfection experiments, none of the full-length constructs expressed.  
While it cannot be ruled out that the transfection protocol is to blame, it could also 
be that overexpression fails because folding of full-length ANKRD18A is not 
sufficiently supported by activity of cognate chaperones.  In the absence of 
chaperone-assisted folding, the ANKRD18A polypeptide may be subject to 
proteolytic degradation (Goldberg 2003). 
 
Milligram quantities of pure protein are required for generating antibodies.  In 
order to produce large amounts of protein in mammalian cells, relatively 
inexpensive PEI was preferred as a transfectant.  Of the clones which expressed 
(Table 5.3), the highest expressing clones were clone G2 (E3C Halo – ankyrin 
repeat domain) and clone F2 (MBP – ankyrin repeat domain).  While the plasmid 
constructs G2 and F2, demonstrated good expression, the recombinant protein 
proved challenging in terms of controlling solubility in aqueous buffer.  Over 
many expression and purification experiments, in which the protocol was varied 
in terms of buffer composition, it became clear that proteolytically cleaving the 
fusion protein to obtain the isolated ankyrin repeat domain was largely futile.    
Thus, it was necessary to immunise with the fusion protein clone F2 and to ‘filter’ 
the resulting polyclonal antibodies through affinity purification, whereby clone G2 
was immobilised onto the affinity column. 
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The protein of clone G2 was initially chosen to be the antigen for antibody 
generation; however, because of precipitation difficulties encountered during the 
purification process, clone F2 was ultimately chosen.  Purification of clone F2 
was relatively clear-cut once the purification conditions were determined.  One of 
the difficulties encountered for clone F2 was in proteolyticaly cleaving MBP, the 
affinity tag (Figure 5.9).   Not only does this fusion protein require large amounts 
of HRV3C protease to remove the MBP tag, but also, each cleavage reaction 
mixture cannot contain too concentrated a protein or else the protein cannot be 
completely cleaved (Figure 5.10).  This suggested that possibly the protein of 
clone F2 was folded in such a way which obstructed the cleavage site.  Another 
difficulty encountered after proteolysis was in separating the MBP tag from the 
ankyrin repeat domain in the reaction mixture using the Ni+2-NTA matrix.  
Repeated separation attempts using Ni+2-NTA bead slurry failed whereas using a 
Ni+2-NTA pre-packed column demonstrated some level of separation, albeit 
small (Figures 5.11 and 5.12).  The most likely explanation for why separation 
occurred using the pre-packed column but not the slurry is that binding kinetics of 
pre-packed Ni+2-NTA columns are different from that of Ni+2-NTA beads.  
  
The protein of clone G2 proved difficult to keep in solution following purification 
over the Ni+2-NTA resin.  During dialysis that preceded the ion exchange 
chromatography step or during subsequent concentration through ultrafiltration, 
the protein was prone to precipitate to a considerable degree.  To enable affinity 
Chapter Six                                                                                           Discussion                                                                                                                              
 
 
 
 
 
 
212 
 
purification of the antibody raised in rabbits, Biogenes required clone G2 to be at 
a concentration between 0.5 to 1.0 mg/ml.  Even at this moderate concentration, 
precipitation occurred in an unpredictable fashion.  In order to help increase 
stability of the protein, glycerol was added to the buffer.  Glycerol is frequently 
used as a co-solute to promote protein stability and to reduce protein aggregation 
as it can interact with both hydrophobic and hydrophilic surface patches of the 
protein (Bondos and Bicknell 2003).  
6.1.3. Characterisation of α-25277 
Ultimately, affinity purified polyclonal antibodies were produced by immunisation 
of two rabbits.  Of the corresponding antibodies, α-25277 and α-25278, the 
former proved more sensitive and specific, and was hence used in subsequent 
experiments. Binding of α-25277 to the ankyrin repeat domain was demonstrated 
through flow cytometry and immunofluorescence confocal microscopy.  For the 
flow cytometry experiment, application of α-25277 to permeabilised vs. 
unpermeabilised cells transfected with clone G2 cDNA were compared (Figure 
5.16 and Table 5.4).  Only the former showed a distinct increase in fluorescence. 
This increase could be reversed in a dose-dependent fashion with addition of 
increasing concentrations of purified recombinant protein, clone G2; thus, 
demonstrating that purified clone G2 competes with binding of α-25277 to 
ANKRD18A or the recombinant ankyrin repeat domain expressed in the 
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transfected cells.  The other explanation for this result could be that clone G2 
was competing with α-25277’s ability to bind non-specifically.  
 
Immunofluorescence confocal microscopy provided additional evidence for  
binding of α-25277 to ANKRD18A (Figures 5.17 and 5.18).  Binding could be 
demonstrated by simultaneous labelling of recombinant clone G2 expressed in 
Dami cells with α-His, which recognises the hexa-His affinity tag of transfected 
G2 and α-25277, which recognises the ankyrin repeat domain of both transfected 
G2 and endogenous ANKRD18A.  Co-localisation of these two signals in 
transfected cells strongly suggested that they adhered to the same entity. 
 
Prior to the acquisition of a-25277, initial determination of ANKRD18A sub-
cellular localisation was performed utilising fluorescence confocal microscopy 
whereby cDNA plasmids of GFP or myc-tagged wild-type and mutant full-length 
ANKRD18A were transiently transfected into HEK293T and HeLA cells 
respectively and stained with the corresponding primary antibodies, α-GFP or α-
myc (Figures 3.6, 3.7).  This experiment was attempted despite the low 
transfection efficiencies of the full-length plasmids because confocal microscopy 
is a relatively sensitive method of detecting proteins – at least more so than 
immunoblotting.  The results of these experiments suggested that full-length wild-
type and mutant ANKRD18A both localise to the cytoplasm.  Later, upon 
acquisition of α-25277, these immunofluorescence confocal microscopy 
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experiments were repeated, although this time, some conditions altered:  Dami 
cells, a megakaryocytic cell line, were used, α-His and α-25277 were the primary 
antibodies, and the cDNA of clone G2 was transfected into Dami cells.  The 
rationale for choosing Dami cells was that this cell line is more similar to 
megakaryocytes since it is derived from megakaryoblastic tumor cells, whereas 
HEK293T cells are derived from endothelial kidney cells.   Staining of transfected 
Dami cells in the latter experiments, firstly with α-His and TO-PRO-3, a 
fluorescent dye use for nuclear counterstaining, suggested that the recombinant 
protein, G2, which was transfected into Dami cells, is located in the nucleus 
(Figure 5.17); secondly, when similarly transfected cells were stained with α-His 
and α-25277 together as primary antibodies (secondary being α-mouse Alexa 
Fluor 488 and α-rabbit Alexa Fluor 647, respectively), the same area of the cell 
fluoresced, suggesting that both the recombinant protein and endogenous 
ANKRD18A were localised to the same area (Figure 5.18) and, since the 
recombinant protein was known to be in the nucleus from the first experiment, 
one could conclude that endogenous ANKRD18A also localised to the nucleus.   
In the second experiment, TO-PRO-3 is not used because its peak absorption 
and emission spectra overlap with Alexa Fluor 647.  These findings thus contrast 
with those from the initial experiments using full-length ANKRD18A plasmids. It is 
possible that the results of prior experiments are questionable since HEK293T 
cells were transfected with full-length ANKRD18A plasmids, which have a poor 
transfection efficiency (Figure 3.5A).  To further substantiate this conclusion that 
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ANKRD18A is localised to the nucleus, one can perform another 
immunofluorescence confocal microscopy experiment whereby transfected 
Damis are stained with α-25277 as the primary antibody and TO-PRO-3 for the 
nuclear stain.  Because TO-PRO-3 is used, a different secondary antibody would 
need to be used, α-rabbit Alexa-Fluor 488.  Should the staining of α-25277 and 
TO-PRO-3 overlap, one can be certain that ANKRD18A localises to the nucleus.  
6.1.4. Comparison of experimental findings with predictions by the 
Blueprint progenitors database  
Two of my experimental observations conflict with the predictions by the 
Blueprint progenitors database (blueprint.haem.cam.ac.uk).  Firstly, my 
experimental observations suggested that there is ANKRD18A mRNA expression 
in platelets (Figure 4.2).  However, the Blueprint database suggests that there is 
negligible ANKRD18A mRNA expression in megakaryocytes (Figure 6.1).  
Secondly, my experimental observations suggested that ANKRD18B mRNA is 
absent in megakaryocytes and platelets.  This again conflicts with predictions by 
the Blueprint progenitors database, which indicates that ANKRD18B mRNA is 
present in megakaryocytes.  However, the Blueprint database conflicts with data 
from the PlateletWeb (plateletweb.bioapps.biozentrum.uni-wuerzburg.de), which 
suggests that ANKRD18A is expressed in platelets while ANKRD18B is not.  
 
Using the Blueprint Progenitors web application one can create river plots, heat 
maps and bar plots from hematopoietic progenitor datasets to identify the relative 
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mRNA expression of genes in haematopoiesis.  The Blueprint project utilised 
RNA sequencing to illustrate the transcriptional diversity of lineage committed 
human blood progenitors (Chen, Kostadima et al. 2014).  When ANKRD18A and 
its homologues, ANKRD18B and ANKRD26, were entered as a query into the 
tools portal, the portal predicted transcript specific RNA expression of these three 
homologues in hematopoietic progenitors.  The river plot suggested that all three 
mRNAs are expressed in megakaryocytes - although in relatively very small 
amounts.  And, of the three, ANKRD18A mRNA is barely expressed in 
megakaryocytes (Figure 6.1).  To interpret a river plot, one needs to realise that 
the amount of relative mRNA expression correlates with the thickness of the 
branches of the river plot.  Thus, if one were to look at ANKRD26 mRNA 
expression, one sees that it is highly expressed in haematopoietic stem cells and 
its progenitors.  However, not much is expressed in the late stages of 
megakaryopoiesis because normally, its expression is silenced by RUNX1 and 
FLI1 transcription factor binding.  Only when the 5’-UTR of ANKRD26 is mutated, 
as seen in familial thrombocytopenia 2 (THC2), is there mRNA expression of 
ANKRD26 in megakaryocytes (Bluteau, Balduini et al. 2014).  
 
The river plot prediction contradicts my qRT-PCR data, which suggested that 
ANKRD18A mRNA expression increases with differentiation of megakaryocytes 
(Figure 4.7).  The increase in ANKRD18A mRNA in developing megakaryocytes 
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was quite distinct; however, because the qRT-PCR method is very sensitive this 
result may still represent only a weak level of expression in absolute terms. 
 
Antibody α-25277 was also used for immunoblotting and in immunoprecipitation 
experiments.  When used to probe for denatured ANKRD18A in HEK293T, Dami 
and platelet WCLs in Westerns, α-25277 was not able to identify a protein with 
the predicted molecular weight of 116 kDa (Figures 5.20 and 5.21).  The Western 
blot showed multiple bands but not one clear band at the correct molecular 
weight.  When α-25277 was used to immunoprecipitate WCLs of HEK283T, Dami 
and platelets followed by immunoblotting with α-25277, no clear bands appeared 
to suggest that the antibody recognises the protein, which is denatured at the 
blotting stage (Figure 5.22 and 5.23).  It is plausible though that α-25277 is 
unable to detect the unfolded protein, as it was raised against the folded ankyrin 
repeat domain and may require an epitope that is non-contiguous in terms of the 
primary sequence.   
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Figure 6.1 – River plot representing relative mRNA expression of ANKRD26, 
ANKRD18B and ANKRD18A across the various cell lineages of 
hematopoiesis.  Line thickness increases with more mRNA expression.  HSC = 
hematopoietic stem cell, MPP = multipotent progenitor, LMPP = lymphoid primed 
multipotent progenitor, CLP = common lymphoid progenitor, CMP = common 
myeloid progenitor, GMP = granulocyte-monocyte progenitor, MEP = 
megakaryocyte-erythrocyte progenitor, EB = erythroblast, MK = megakaryocyte 
(blueprint.haem.cam.ac.uk). 
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6.2. Future research 
There are many questions, which remain to be answered regarding this project.  
Firstly, it is still unclear whether ANKRD18A is the gene which, when mutated, 
results in the thrombocytopenia exhibited by the two patients described above.  
Secondly, my limited characterisation of ANKRD18A has only generated more 
questions.  For instance, it still unclear whether ANKRD18A is localised to the 
cytoplasm or the nucleus given my immunofluorescence confocal microscopy 
results.  However, given that ANKRD18A mRNA levels increase with 
differentiation of megakaryocytes, one can hypothesize that it is localised to the 
nucleus and may play a role in megakaryopoiesis; thus, explaining why the 
ANKRD18A-mutated patients develop thrombocytopenia.  To confirm that 
ANKRD18A plays a role in megakaryopoiesis, megakaryocytes generated from 
CD34+ cells could be infected with short hairpin RNA (shRNA) lentiviruses 
targeting ANKRD18A to see if RNAi-mediated gene silencing will impede 
megakaryocyte development and thus disrupt the production of platelets.  
Quantitation of knockdown could then be determined using qRT-PCR with 
comparisons to internal controls B-actin and GAPDH.  And, α-25277 or α-21234 
could be used to immunoblot WCLs of megakaryocytes to determine if the 
protein expression of ANKRD18A has been eradicated.  However, it will be 
necessary to clarify whether α-25277 or α-21234 are specific to ANKRD18A 
before either can be used for that purpose.  Otherwise, since the advent of gene 
Chapter Six                                                                                           Discussion                                                                                                                              
 
 
 
 
 
 
220 
 
editing and more specifically, the CRISPR technique, it will be possible to mimic 
the patient’s mutations for the candidate gene variants using induced Pluripotent 
stem cells (iPS).   Megakaryocytes can be produced by forward programming 
(Moreau, Evans et al. 2016) to provide a platform to study these patients’ 
phenotype in more detail.  Thirdly, it remains unclear whether the polyclonal 
antibody, which was generated for this project, α-25277, is specific to 
ANKRD18A.  To determine the specificity of α-25277, an experiment which could 
be fairly quickly performed, is to suppress ANKRD18A expression using siRNAs.  
These cells could then be analysed by flow cytometry using α-25277.  This 
experiment is essentially repeating what had been done before; however, this 
time, one would hope to see that the shift in the tracing seen before, using α-
25277 on ‘regular’ HEK293T cells, would be negated by using cells in which 
ANKRD18A expression has been silenced.  Suppression of ANKRD18A 
expression in Dami cells could also be performed and again, analysis on the 
effectiveness of gene silencing could be performed by repeating the confocal 
experiment.  Anti-25277 would be used to localise for any protein expression in 
these cells.  If possible, the ANKRD18A-silenced cells could also be transiently 
transfected with the cDNA plasmid of clone G2 to demonstrate that the 
‘knockdown’ is reversed.   In addition, α-25277 could be used for immunoblotting 
WCLs of cells with and without silencing by RNAi once the immunoblotting 
conditions for using α-25277 have been clarified.  Finally, to help further 
characterise the functions of the novel protein ANKRD18A, one could identify its 
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possible binding partners whose functions may thus reflect what functions 
ANKRD18A may have.  Using either of the purified recombinant proteins (clones 
F2 and G2), both of which contain the ankyrin repeat domain, which mediates 
protein-protein interactions, one could perform pull-down experiments or co-
immunoprecipitation experiments with platelet WCLs to identify proteins which 
may interact with ANKRD18A.  Mass spectrometry would then be utilised to 
identify the potential interacting partners. 
 
6.3. Final conclusion 
The purpose of this project was answer the hypothesis that the mutation 
identified in the novel gene, ANKRD18A, is the cause for the severe 
thrombocytopenia seen in two related children of a consanguineous family.  
Whole exome sequencing followed by Sanger sequencing had identified 3 
possible variants that may cause this phenotype of severe thrombocytopenia: 
p.801_801del of ANKRD18A; p.G447R of GNE and p.A509V of FRMPD1.  All 
three variants were present in the two affected children and were within a tightly 
linked region of homozygosity on chromosome 9p (Johnson, Fletcher et al. 
2016).  The variant in ANKRD18A was chosen as the likely variant to have 
caused the phenotype.   
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TEM micrographs of patient platelets showed that the patients’ platelets are 
enlarged, but fewer in number (macrothrombocytopenic), confirming the MPV of 
10.4 – 15 fL that was initially observed (Figure 3.3).  Utilising qRT-PCR, it was 
demonstrated that the amount of ANKRD18A mRNA increased as the 
megakaryocytes differentiate (Figure 4.7) and using immunofluorescence 
confocal microscopy, it was demonstrated that ANKRD18A may localise to the 
cytoplasm or the nucleus (Figures 3.6, 3.7, 5.17, and 5.18).  These data 
suggested that ANKRD18A may play a role in the cytoskeleton or be involved in 
megakaryopoiesis.  Definitive proof of ANKRD18A involvement in either cellular 
functions would require silencing the gene in immature megakaryocytes to see if 
megakaryocytic development is altered or curtailed.  Evidence to question or 
contradict the hypothesis that the variant of ANKRD18A is the cause of these 
patients’ severe thrombocytopenia and that ANKRD18A has a role in the 
megakaryocyte /platelet cytoskeleton or is involved with megakaryopoiesis, are 
three arguments.  Firstly, when comparing the amino acid sequences of 
ANKRD18A for Homo sapiens and its homologues such as Pan troglodytes 
(chimpanzee), Gorilla gorilla, and Nomascus leucogenys (gibbon), the triple 
glutamic residues within the amino acid sequence MLEEEVL, which is present in 
H. sapiens, is absent in gorilla; and, in N.leucogenys, the third glutamic acid 
residue, which is deleted in the two patients, is also absent.  This lack of 
conserved residues among ANKRD18A homologues suggests that ANKRD18A 
and the mutation at Δ801 are not significant.   Secondly, data from the RNA 
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sequencing of hematopoietic progenitors (blueprint.haem.cam.ac.uk), suggest 
that very little amount of ANKRD18A mRNA is present in hematopoietic 
progenitors. This is in contrast to the mRNA of GNE, which is expressed widely 
in hematopoietic progenitors (Figure 6.2).  Finally, to cast further doubt that the 
variant in ANKRD18A is the culprit gene are the publications in 2014 by two 
separate groups (Izumi, Niihori et al. 2014, Zhen, Guo et al. 2014), which 
identified 2 sets of siblings with congenital thrombocytopenia and GNE 
myopathy.  Our patients are currently of the ages ~8 and 11.  The patients 
mentioned in the two papers developed GNE myopathy in their mid-adolescence 
in one set of siblings and in their 20’s in the other set of siblings.  Should we not 
be able to confirm by experiments that the variant in ANKRD18A is the causative 
pathological variant, we will, with the passage of time, know which is the true 
causative variant, once our two patients develop neuromuscular abnormalities.  
 
Although the work for this thesis has not definitely determined that the variant in 
ANKRD18A results in severe thrombocytopenia, it has generated ANKRD18A 
purified recombinant protein directed to several functional motifs and 
subsequently, antibody generation.  Of use are the recombinant proteins 
containing the ankyrin repeat domains because they can be used for protein-
protein interaction experiments whereby platelet WCLs are incubated with clones 
F2 or G2 to “pulldown” potential binding partners.  More experiments will need to 
be performed to confirm that the polyclonal antibody, α-25277, is specific to 
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ANKRD18A.  Another other antibody to ANKRD18S, the peptide antibody, α-
21234, may also prove to be useful once specificity has been ascertained.  If, 
however, neither antibodies prove to be specific to ANKRD18A, the best way to 
obtain an antibody specific to ANKRD18A will be through generation of a 
monoclonal antibody.   
 
    
 
 
Figure 6.2 – Riverplot representing GNE mRNA expression across the 
various cell lineages of hematopoiesis (blueprint.haem.cam.ac.uk).
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7. Supplementary Data  
 
 
Figure S 1 – Utilising flow cytometry to probe specificity of α-ANKRD18A-
25277 in Dami cells.  Dami cells are undifferentiated and impermeabilised 
(panels A-D) or differentiated and permeabilised (panels E-H).  Dami cells are 
differentiated using TPO (3 ng/ml) and PMA (6.2 ng/ml).  Antibody stocks:  IgG (1 
mg/ml), α-25277 (0.24 mg/ml), and α-rabbit Alexa Fluor 488 (2 mg/ml).  IgG used 
at a dilution of 1:100, α-25277 used at dilution of 1:100 and α-rabbit Alexa Fluor 
488 used at dilution 1:500.  N=1 
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!
Image 
1  
Image 
2  
Image 
3  Mean SD  
Pearson's R 0.39 0.77 0.46 0.540 0.1011 
M1 0.653 0.813 0.745 0.737 0.0401 
M2 0.915 0.96 0.976 0.950 0.0158 
 
 
Figure S 2  – Bar graph demonstrating the mean co-localisation coefficients 
of confocal microscopy overlay images 1-3.  M1 and M2 = Manders split 
coefficient.  Images are differentiated Dami cells transiently transfected with 
cDNA of Clone G2.  Cells are stained with primary antibodies: α-His and α-25277 
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and secondary antibodies: α-mouse Alexa Fluor 488 and α-rabbit Alexa 647.  
N=3  
 
 
 
ACConoC T  
1
 
 
 
 
 
 
 
1
0
 
 
 
 
 
 
 
 
2
0
 
 
 
 
 
 
 
 
3
0
 
 
 
 
 
 
 
 
4
0
 
 
 
 
 
 
 
 
5
0
 
 
 
 
 
 
 
 
6
0
 
 
 
 
 
 
 
 
7
0
 
 
 
 
 
 
 
 
8
0
 
 
 
 
 
 
 
 
9
0
 
 
 
 
 
 
 
1
0
0
 
 
 
 
 
 
 
1
1
0
 
 
 
 
 
 
 
1
2
0
AN
KR
D1
8A
  
  
 
MR
KL
 S
FG
RR
LG
QA
LL
SS
MD
QE
YA
G 
GY
 I
RD
WE
LR
KI
HR
AA
IK
GD
AA
EV
E 
CL
TR
RF
RD
LD
 R
DR
KD
RT
VL
HL
AC
AH
GR
VQ
VV
TL
LL
 R
 C
QI
 I
CD
RL
NR
TP
LM
KA
VH
 Q
EE
AC
AI
 L
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 R
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
R 
  
D 
  
  
  
  
  
  
  
S 
  
  
  
V 
  
  
F 
  
  
  
  
  
  
  
  
  
 P
  
D 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
A 
  
  
  
  
  
  
  
  
  
  
  
  
H 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
01
1
MR
KL
 S
FG
RR
LG
QA
LL
SS
MD
QE
YA
G 
GY
 I
RD
WE
LR
KI
HR
AA
IK
GD
AA
EV
E 
CL
TR
RF
RD
LD
 R
DR
KD
RT
VL
HL
AC
AH
GR
VQ
VV
TL
LL
 R
 C
QI
 I
CD
RL
NR
TP
LM
KA
VH
 Q
EE
AC
AI
 L
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 H
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
N 
  
  
  
  
  
  
  
C 
  
  
  
I 
  
  
L 
  
  
  
  
  
  
  
  
  
 R
  
H 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
V 
  
  
  
  
  
  
  
  
  
  
  
  
D 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
40
1
MR
KL
 S
FG
RR
LG
QA
LL
SS
MD
QE
YA
G 
GY
 I
RD
WE
LR
KI
HR
AA
IK
GD
AA
EV
E 
CL
TR
RF
RD
LD
 R
DR
KD
RT
VL
HL
AC
AH
GR
VQ
VV
TL
LL
 R
 C
QI
 I
CD
RL
NR
TP
LM
KA
VH
 Q
EE
AC
AI
 L
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 H
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
N 
  
  
  
  
  
  
  
C 
  
  
  
I 
  
  
L 
  
  
  
  
  
  
  
  
  
 R
  
H 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
V 
  
  
  
  
  
  
  
  
  
  
  
  
D 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
1
3
0
 
 
 
 
 
 
 
1
4
0
 
 
 
 
 
 
 
1
5
0
 
 
 
 
 
 
 
1
6
0
 
 
 
 
 
 
 
1
7
0
 
 
 
 
 
 
 
1
8
0
 
 
 
 
 
 
 
1
9
0
 
 
 
 
 
 
 
2
0
0
 
 
 
 
 
 
 
2
1
0
 
 
 
 
 
 
 
2
2
0
 
 
 
 
 
 
 
2
3
0
 
 
 
 
 
 
 
2
4
0
AN
KR
D1
8A
  
  
 
L 
 G
AN
PN
IK
DI
YG
NT
AL
HY
AV
YN
 G
TS
LA
ER
LL
SH
HA
NI
EA
LN
KE
GN
TP
LL
FA
IN
SR
RQ
HM
VE
FL
LK
NQ
AN
IH
AV
DN
FK
RT
AL
IL
AV
 H
NL
SS
IV
TL
LL
QQ
NI
 I
SS
QD
MF
GQ
TA
ED
YA
 E
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Q 
  
  
  
  
  
  
  
R 
  
  
  
  
  
  
  
  
C 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
01
1
L 
 G
AN
PN
IK
DI
YG
NT
AL
HY
AV
YN
 G
TS
LA
ER
LL
SH
HA
NI
EA
LN
KE
GN
TP
LL
FA
IN
SR
RQ
HM
VE
FL
LK
NQ
AN
IH
AV
DN
FK
RT
AL
IL
AV
 H
NL
SS
IV
TL
LL
QQ
NI
 I
SS
QD
MF
GQ
TA
ED
YA
 K
  
  
  
  
  
  
  
  
  
  
  
E 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Q 
  
  
  
  
  
  
  
H 
  
  
  
  
  
  
  
  
R 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
40
1
L 
 G
AN
PN
IK
DI
YG
NT
AL
HY
AV
YN
 G
TS
LA
ER
LL
SH
HA
NI
EA
LN
KE
GN
TP
LL
FA
IN
SR
RQ
HM
VE
FL
LK
NQ
AN
IH
AV
DN
FK
RT
AL
IL
AV
 H
NL
SS
IV
TL
LL
QQ
NI
 I
SS
QD
MF
GQ
TA
ED
YA
 K
  
  
  
  
  
  
  
  
  
  
  
E 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
R 
  
  
  
  
  
  
  
H 
  
  
  
  
  
  
  
  
R 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
2
5
0
 
 
 
 
 
 
 
2
6
0
 
 
 
 
 
 
 
2
7
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
8
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AN
KR
D1
8A
  
  
 
 C
 D
LR
SI
 Q
QI
LE
HK
NK
ML
KN
HL
RN
DN
QE
 A
AM
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P 
NL
KK
RK
  
  
  
  
  
  
 E
  
S 
  
  
R 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
E 
  
  
  
  
  
  
L 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
T 
  
 .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
 A
  
  
  
 .
..
..
..
.R
AK
A 
AN
KR
D1
8B
_1
01
1
 C
 D
LR
SI
 Q
QI
LE
HK
NK
ML
KN
HL
RN
DN
QE
 A
AM
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P 
NL
KK
RK
  
  
  
  
  
  
 E
  
C 
  
  
Q 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
F 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
T 
  
 .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
 E
  
  
  
 R
KK
LK
KR
KE
GA
K 
AN
KR
D1
8B
_1
40
1
 C
 D
LR
SI
 Q
QI
LE
HK
NK
ML
KN
HL
RN
DN
QE
 A
AM
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P 
NL
KK
RK
  
  
  
  
  
  
 E
  
C 
  
  
Q 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
F 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
A 
  
 N
ES
FK
TQ
GA
SS
KV
SL
YH
QS
GV
QW
HD
LR
LL
QP
SP
PR
FK
QF
SC
LS
LP
RS
WD
NR
HM
RP
CP
ET
AA
MK
 E
  
  
  
 R
KK
LK
KR
KE
GA
K 
2
9
0
 
 
 
 
 
 
 
3
0
0
 
 
 
 
 
 
 
3
1
0
 
 
 
 
 
 
 
3
2
0
 
 
 
 
 
 
 
3
3
0
 
 
 
 
 
 
 
3
4
0
 
 
 
 
 
 
 
3
5
0
 
 
 
 
 
 
 
3
6
0
 
 
 
 
 
 
 
3
7
0
 
 
 
 
 
 
 
3
8
0
 
 
 
 
 
 
 
3
9
0
 
 
 
 
 
 
 
4
0
0
 
 
 
 
 
 
 
 
 
AN
KR
D1
8A
  
  
 
HN
LK
VA
SE
EK
QE
RL
 R
SE
NK
QP
QD
SQ
SY
GK
KK
D 
M 
GN
FM
LK
 D
IA
ML
KE
EL
YA
IK
ND
SL
RK
EK
KY
IQ
EI
KS
IT
EI
NA
NF
EK
SV
RL
NE
 M
IT
K 
VA
 Y
SQ
QL
ND
LK
AE
NA
RL
NS
 L
EK
EK
  
  
  
  
  
  
  
Q 
  
  
  
  
  
  
  
  
  
 Y
  
  
  
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
R 
  
  
  
  
  
  
  
  
E 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 A
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 T
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
01
1
HN
LK
VA
SE
EK
QE
RL
 R
SE
NK
QP
QD
SQ
SY
GK
KK
D 
M 
GN
FM
LK
 D
IA
ML
KE
EL
YA
IK
ND
SL
RK
EK
KY
IQ
EI
KS
IT
EI
NA
NF
EK
SV
RL
NE
 M
IT
K 
VA
 Y
SQ
QL
ND
LK
AE
NA
RL
NS
 L
EK
EK
  
  
  
  
  
  
  
E 
  
  
  
  
  
  
  
  
  
 F
  
  
  
R 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
E 
  
  
  
Q 
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 E
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 K
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
40
1
HN
LK
VA
SE
EK
QE
RL
 R
SE
NK
QP
QD
SQ
SY
GK
KK
D 
M 
GN
FM
LK
 D
IA
ML
KE
EL
YA
IK
ND
SL
RK
EK
KY
IQ
EI
KS
IT
EI
NA
NF
EK
SV
RL
NE
 M
IT
K 
VA
 Y
SQ
QL
ND
LK
AE
NA
RL
NS
 L
EK
EK
  
  
  
  
  
  
  
E 
  
  
  
  
  
  
  
  
  
 F
  
  
  
R 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
E 
  
  
  
Q 
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 E
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 K
  
  
  
  
  
  
  
  
  
  
  
  
  
4
1
0
 
 
 
 
 
 
 
4
2
0
 
 
 
 
 
 
 
4
3
0
 
 
 
 
 
 
 
4
4
0
 
 
 
 
 
 
 
4
5
0
 
 
 
 
 
 
 
4
6
0
 
 
 
 
 
 
 
4
7
0
 
 
 
 
 
 
 
4
8
0
 
 
 
 
 
 
 
4
9
0
 
 
 
 
 
 
 
5
0
0
 
 
 
 
 
 
 
5
1
0
 
 
 
 
 
 
 
5
2
0
 
 
 
 
 
 
 
 
 
AN
KR
D1
8A
  
  
 
HN
KE
RL
EA
EV
ES
LH
S 
LA
TA
IN
EY
NE
I 
ER
KD
LE
LV
LW
RA
DD
VS
RH
E 
MG
SN
IS
QL
TD
KN
EL
LT
EQ
VH
KA
RV
KF
NT
LK
GK
LR
ET
RD
AL
RE
KT
LA
L 
 V
QL
DL
 Q
AQ
HR
IK
 M
KQ
MH
PN
GE
  
  
  
  
  
  
  
 S
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
R 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 V
  
  
  
  
  
  
  
  
  
 K
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 G
S 
  
  
  
  
  
  
E 
  
  
  
  
AN
KR
D1
8B
_1
01
1
HN
KE
RL
EA
EV
ES
LH
S 
LA
TA
IN
EY
NE
I 
ER
KD
LE
LV
LW
RA
DD
VS
RH
E 
MG
SN
IS
QL
TD
KN
EL
LT
EQ
VH
KA
RV
KF
NT
LK
GK
LR
ET
RD
AL
RE
KT
LA
L 
 V
QL
DL
 Q
AQ
HR
IK
 M
KQ
MH
PN
GE
  
  
  
  
  
  
  
 N
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 L
  
  
  
  
  
  
  
  
  
 T
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 E
S 
  
  
  
  
  
  
E 
  
  
  
  
AN
KR
D1
8B
_1
40
1
HN
KE
RL
EA
EV
ES
LH
S 
LA
TA
IN
EY
NE
I 
ER
KD
LE
LV
LW
RA
DD
VS
RH
E 
MG
SN
IS
QL
TD
KN
EL
LT
EQ
VH
KA
RV
KF
NT
LK
GK
LR
ET
RD
AL
RE
KT
LA
L 
 V
QL
DL
 Q
AQ
HR
IK
 M
KQ
MH
PN
GE
  
  
  
  
  
  
  
 N
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 L
  
  
  
  
  
  
  
  
  
 T
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 E
N 
  
  
  
  
  
  
G 
  
  
  
  
5
3
0
 
 
 
 
 
 
 
5
4
0
 
 
 
 
 
 
 
5
5
0
 
 
 
 
 
 
 
5
6
0
 
 
 
 
 
 
 
5
7
0
 
 
 
 
 
 
 
5
8
0
 
 
 
 
 
 
 
5
9
0
 
 
 
 
 
 
 
6
0
0
 
 
 
 
 
 
 
6
1
0
 
 
 
 
 
 
 
6
2
0
 
 
 
 
 
 
 
6
3
0
 
 
 
 
 
 
 
6
4
0
 
 
 
 
 
 
 
 
 
AN
KR
D1
8A
  
  
 
AK
ES
QS
IG
KQ
 S
 E
ER
IR
Q 
EL
EN
LL
LE
RQ
LE
DA
RK
EG
DN
KE
IV
IN
IH
RD
CL
EN
GK
ED
LL
EE
RN
KE
LM
 E
YN
YL
KE
KL
LQ
 E
KE
KA
ER
EV
IV
RE
FQ
EE
LV
DH
LK
 F
S 
SE
SP
LE
GT
SH
CH
  
  
  
  
  
  
  
  
  
 Q
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 I
  
  
  
  
  
  
  
  
  
  
  
N 
L 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
C 
  
  
  
  
  
  
  
  
  
  
  
T 
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
01
1
AK
ES
QS
IG
KQ
 S
 E
ER
IR
Q 
EL
EN
LL
LE
RQ
LE
DA
RK
EG
DN
KE
IV
IN
IH
RD
CL
EN
GK
ED
LL
EE
RN
KE
LM
 E
YN
YL
KE
KL
LQ
 E
KE
KA
ER
EV
IV
RE
FQ
EE
LV
DH
LK
 F
S 
SE
SP
LE
GT
SH
CH
  
  
  
  
  
  
  
  
  
 R
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 M
  
  
  
  
  
  
  
  
  
  
  
N 
S 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
N 
  
  
  
  
  
Y 
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
40
1
AK
ES
QS
IG
KQ
 S
 E
ER
IR
Q 
EL
EN
LL
LE
RQ
LE
DA
RK
EG
DN
KE
IV
IN
IH
RD
CL
EN
GK
ED
LL
EE
RN
KE
LM
 E
YN
YL
KE
KL
LQ
 E
KE
KA
ER
EV
IV
RE
FQ
EE
LV
DH
LK
 F
S 
SE
SP
LE
GT
SH
CH
  
  
  
  
  
  
  
  
  
 R
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 M
  
  
  
  
  
  
  
  
  
  
  
Y 
S 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
N 
  
  
  
  
  
Y 
  
  
  
  
  
  
  
  
  
  
  
K 
  
  
  
  
  
  
  
6
5
0
 
 
 
 
 
 
 
6
6
0
 
 
 
 
 
 
 
6
7
0
 
 
 
 
 
 
 
6
8
0
 
 
 
 
 
 
 
6
9
0
 
 
 
 
 
 
 
7
0
0
 
 
 
 
 
 
 
7
1
0
 
 
 
 
 
 
 
7
2
0
 
 
 
 
 
 
 
7
3
0
 
 
 
 
 
 
 
7
4
0
 
 
 
 
 
 
 
7
5
0
 
 
 
 
 
 
 
7
6
0
 
 
 
 
 
 
 
 
 
AN
KR
D1
8A
  
  
 
IN
L 
ET
WT
SK
KK
LF
QV
EI
QP
EE
KH
EE
FR
K 
FE
LI
SL
LN
YT
AD
QI
RK
KN
RE
LE
EE
AT
GY
KK
CL
EM
TI
NM
LN
AF
AN
ED
F 
CH
GD
LN
TD
QL
KM
DI
LF
KK
LK
QK
F 
DL
 A
EK
EA
VS
S 
CV
NL
AK
  
 N
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 N
  
V 
  
  
  
 E
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 L
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 N
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
01
1
IN
L 
ET
WT
SK
KK
LF
QV
EI
QP
EE
KH
EE
FR
K 
FE
LI
SL
LN
YT
AD
QI
RK
KN
RE
LE
EE
AT
GY
KK
CL
EM
TI
NM
LN
AF
AN
ED
F 
CH
GD
LN
TD
QL
KM
DI
LF
KK
LK
QK
F 
DL
 A
EK
EA
VS
S 
CV
NL
AK
  
 D
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 D
  
M 
  
  
  
 K
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 V
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 S
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AN
KR
D1
8B
_1
40
1
IN
L 
ET
WT
SK
KK
LF
QV
EI
QP
EE
KH
EE
FR
K 
FE
LI
SL
LN
YT
AD
QI
RK
KN
RE
LE
EE
AT
GY
KK
CL
EM
TI
NM
LN
AF
AN
ED
F 
CH
GD
LN
TD
QL
KM
DI
LF
KK
LK
QK
F 
DL
 A
EK
EA
VS
S 
CV
NL
AK
  
 D
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 D
  
M 
  
  
  
 K
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 V
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 S
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Chapter Seven  Supplementary Data                                                                                                                              
 
 
 
 
 
228 
 
 
Figure S 3 – Sequence alignment of ANKRD18A with two isoforms of 
ANRKD18B. The sequences were aligned using Clustal Omega (McWilliam, Li et 
al. 2013) and the alignment formatted using Espript (Robert and Gouet 2014). 
Identical amino acids are indicated by white type on red background, similar 
residues by red type on white background. Numbers above the aligned 
sequences indicate residue numbers for ANKRD18A. ANKRD18B_1011 and 
ANKRD18B_1401 indicate the 1011-residue and 1401-residue alternative splice 
forms of ANRKD18, respectively. 
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1       10        20        30        40        50        60        70
18A_Hs MRKLFSFGRRLGQALLSSMDQEY GPGY I DWELRKIHRAAIKGDAAEVERCLTRRF  LDARDRKDRT                           D                            RD          A R
18A_Gg MRKLFSFGRRLGQALLSSMDQEY GPGY I DWELRKIHRAAIKGDAAEVERCLTRRF  LDARDRKDRT                           D                            RD          A R
18A_Pg MRKLFSFGRRLGQALLSSMDQEY GPGY I DWELRKIHRAAIKGDAAEVERCLTRRF  LDARDRKDRT                           D                            RD          A R
18A_Nl MRKLFSFGRRLGQALLSSMDQEY GPGY I DWELRKIHRAAIKGDAAEVERCLTRRF  LDARDRKDRT                           H                            QN          P G
        80        90       100       110       120       130       140
18A_Hs  LHLACA GRV VVTLLL   CQID CDRL RTPLMKAVH QEEACAI LL  GANPNI DIYGNTALHY         Q      HR     I    N                V  E       E          V H R S C
18A_Gg  LHLACA GRV VVTLLL   CQID CDRL RTPLMKAVH QEEACAI LL  GANPNI DIYGNTALHY         E      HR     I    N                I  K       K          V R R G H
18A_Pg  LHLACA GRV VVTLLL   CQID CDRL RTPLMKAVH QEEACAI LL  GANPNI DIYGNTALHY         E      HR     I    N                L  E       K          V H R G C
18A_Nl  LHLACA GRV VVTLLL   CQID CDRL RTPLMKAVH QEEACAI LL  GANPNI DIYGNTALHY         E      GK     V    R                I  E       K          A F G C H
       150       160       170       180       190       200       210
18A_Hs AVYN GTSLAE LLSHHAN EA N EGNTP LFAINS RQHMVEFLLKNQAN HAVDNF R ALILAVQ           R          K                         I      K        HK I L L R T
18A_Gg AVYN GTSLAE LLSHHAN EA N EGNTP LFAINS RQHMVEFLLKNQAN HAVDNF R ALILAVQ           R          K                         I      K        HE I L L R I
18A_Pg AVYN GTSLAE LLSHHAN EA N EGNTP LFAINS RQHMVEFLLKNQAN HAVDNF R ALILAVQ           R          K                         I      K        HK I L L R T
18A_Nl AVYN GTSLAE LLSHHAN EA N EGNTP LFAINS RQHMVEFLLKNQAN HAVDNF R ALILAVQ           K          E                         V      R        RQ S R F G T
       220       230       240       250       260       270       280
18A_Hs   SSI  LLLQQNI I SQD FGQTAEDYA C DLRSI QQILEHKNK LKN LRNDNQETA MK  N KN    VT                          R         M   H           P  L L R S M L S A A
18A_Gg   SSI  LLLQQNI I SQD FGQTAEDYA C DLRSI QQILEHKNK LKN LRNDNQETA MK  N KN    VT                          R         M   H           P  L L H S M F S A E
18A_Pg   SSI  LLLQQNI I SQD FGQTAEDYA C DLRSI QQILEHKNK LKN LRNDNQETA MK  N KN    VT                          R         M   H           P  M L R S M F C A A
18A_Nl   SSI  LLLQQNI I SQD FGQTAEDYA C DLRSI QQILEHKNK LKN LRNDNQETA MK  N KS    IS                          E         I   R           S  L S N F T V C T A
       290       300       310       320       330       340       350
18A_Hs KRKE A  E NL VASEEKQERL RSENKQPQDSQS GKKKD M GN M K DIAMLKEELYAIKND LR      H            Q            Y      Y  F  K               S  R KA K A L
18A_Gg KRKE A  E NL VASEEKQERL RSENKQPQDSQS GKKKD M GN M K DIAMLKEELYAIKND LR      H            E            Y      Y  F  R               S  G .K K A L
18A_Pg KRKE A  E NL VASEEKQERL RSENKQPQDSQS GKKKD M GN M K DIAMLKEELYAIKND LR      Q            E            Y      Y  F  R               S  R KA K A L
18A_Nl KRKE A  E NL VASEEKQERL RSENKQPQDSQS GKKKD M GN M K DIAMLKEELYAIKND LR      H            E            C      H  Y  R               N  G KA T V S
       360       370       380       390       400       410       420
18A_Hs KE  YI EIKSITEINA FEKSVRLNE MITK  A YSQ L DLKAEN RLNS LEKEKHNKERLEAEVE  KK  Q          N         K    V R   Q N      A    E                T
18A_Gg KE  YI EIKSITEINA FEKSVRLNE MITK  A YSQ L DLKAEN RLNS LEKEKHNKERLEAEVE  KK  Q          N         E    V R   Q N      A    E                K
18A_Pg KE  YI EIKSITEINA FEKSVRLNE MITK  A YSQ L DLKAEN RLNS LEKEKHNKERLEAEVE  NK  Q          K         E    V Q   Q N      A    E                K
18A_Nl KE  YI EIKSITEINA FEKSVRLNE MITK  A YSQ L DLKAEN RLNS LEKEKHNKERLEAEVE  KE  H          N         E    M Q   E S      S    K                T
       430       440       450       460       470       480       490
18A_Hs SLHS LATA N Y EI ERKDLELVL RAD VSR EKM SNIS LTD NE LT Q  KARVKF TLK KL         E N  V            D   H   G    Q   K    E VH      N   G  S I W L
18A_Gg SLHS LATA N Y EI ERKDLELVL RAD VSR EKM SNIS LTD NE LT Q  KARVKF TLK KL         Q K  V            D   H   D    Q   K    E VH      N   G  S I W L
18A_Pg SLHS LATA N Y EI ERKDLELVL RAD VSR EKM SNIS LTD NE LT Q  KARVKF TLK KL         E N  V            D   H   G    K   K    E VH      N   G  N I R L
18A_Nl SLHS LATA N Y EI ERKDLELVL RAD VSR EKM SNIS LTD NE LT Q  KARVKF TLK KL         E N  L            E   E   G    Q   E    K LS      S   A  R A L F
       500       510       520       530       540       550       560
18A_Hs  ETRDALREKTLAL SVQLDL QAQH IKE KQMHPN EAKESQS GKQNSLEERI Q EL NLLLE  L                   R    R                          R   E      R G M G I Q RQ
18A_Gg  ETRDALREKTLAL SVQLDL QAQH IKE KQMHPN EAKESQS GKQNSLEERI Q EL NLLLE  L                   K    R                          R   E      R G M G I Q RQ
18A_Pg  ETRDALREKTLAL SVQLDL QAQH IKE KQMHPN EAKESQS GKQNSLEERI Q EL NLLLE  L                   R    R                          R   E      R G M G I R RQ
18A_Nl  ETRDALREKTLAL SVQLDL QAQH IKE KQMHPN EAKESQS GKQNSLEERI Q EL NLLLE  L                   K    Q                          H   K      C E T E T E .L
       570       580        590       600       610       620         
18A_Hs  DA KEG NKE VINI   CLENGKEDLL EE NKELM EYNYLKEKLLQ EKE AE EVIVR  QEEL E     D   I    H D            R                C   K       E     R R . K R F V
18A_Gg  DA KEG NKE VINI   CLENGKEDLL EE NKELM EYNYLKEKLLQ EKE AE EVIVR  QEEL E     N   I    H D            R                Y   K       E     R R . N R F V
18A_Pg  DA KEG NKE VINI   CLENGKEDLL EE NKELM EYNYLKEKLLQ EKE AE EVIVR  QEEL E     D   I    H D            R                Y   K       E     R R . K R C V
18A_Nl  DA KEG NKE VINI   CLENGKEDLL EE NKELM EYNYLKEKLLQ EKE AE EVIVR  QEEL K     N   V    Q G            K                Y   E       Q     L G L N G L A
630       640       650       660       670       680       690         
18A_Hs DHLK FS SESPLEGTS CHINL ET TSKKKLFQVE QPEEKHEEFRKLFELIS L Y  DQIRKKN E               H     N  W                            N T        R T I I L A
18A_Gg DHLK FS SESPLEGTS CHINL ET TSKKKLFQVE QPEEKHEEFRKLFELIS L Y  DQIRKKN E               Q     D  W                            N T        R K I I L A
18A_Pg DHLK FS SESPLEGTS CHINL ET TSKKKLFQVE QPEEKHEEFRKLFELIS L Y  DQIRKKN E               H     D  W                            N T        R K N I L A
18A_Nl DHLK FS SESPLEGTS CHINL ET TSKKKLFQVE QPEEKHEEFRKLFELIS L Y  DQIRKKN E               H     D  R                            D N        H K M S S V
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Figure S 4 – Alignment of ANKRD18A sequences from different primates. 
Hs = human, Gg = gorilla, Pg = chimpanzee, Nl = gibbon. The sequences were 
aligned using Clustal Omega (McWilliam, Li et al. 2013) and and the alignment 
formatted using Espript (Robert and Gouet 2014). The EEE motif mutated in the 
thrombocytopenic patients is at residues 799 to 801 (human sequence numbers). 
700       710       720       730       740       750       760         
18A_Hs LEEEA G KKCLEMTINMLNAF NEDF CH DLN DQ KMDILFKKLKQK              C           Y                    G     L            KE  T A S T FNDLVAE AVSSE VNLAK
18A_Gg LEEEA G KKCLEMTINMLNAF NEDF CH DLN DQ KMDILFKKLKQK              C           Y                    G     L            EH  I A G T TPLSYFY ....F R....
18A_Pg LEEEA G KKCLEMTINMLNAF NEDF CH DLN DQ KMDILFKKLKQK              C           S                    G     L            KE  T A S T FNDLVAE AVSSK VNLAK
18A_Nl LEEEA G KKCLEMTINMLNAF NEDF CH DLN DQ KMDILFKKLKQK              C           Y                    A     V            KE  T G S K FDDLMAE AVSSK VNLAK
770       780       790       800       810       820       830         
18A_Hs                   C                                                   DNEVLHQELLSMRNVQEK EKLEKDKKMLEEEVLNLKTHMEKDMVELGKLQEYKSELDERAVQEIEKLEE
18A_Gg                   .                                                   .................. ...................................................
18A_Pg                   C                                                   DNEVLHQELLSMRKVQEK EKLEKDKKMLEEEVLNLKTHMEKDMVELGKLQEYKSELDERAVQEIEKLEE
18A_Nl                   C                                                   DNEVLHQELLSMRKVQEE EKLEKDKKMLEEVVLNLKTHMEKDMVELGKAQEYKLELDEGTRQAIEKSVE
840       850       860       870       880       890       900         
18A_Hs                                    C                                  IHLQKQAEYEKQLEQLNKDNTASLKKKELTLKDVE KFSKMKTAYEEVTTELEEFKEAFAGAVKANNSMS
18A_Gg                                    .                                  ................................... ..................................
18A_Pg                                    C                                  IHLQKQAEYEKQLEQLNKDNTASLKKKELTLKDVE KFSKMKTAYEEVTTELEEFKEAFAAALKANNSMS
18A_Nl                                    C                                  IQSQERAENEKQLEQLNRDNTALLKKKELTLKDVE KFSKMKTAYEEVTTELEEYKEALAITLKANHSMS
910       920       930       940       950       960       970         
18A_Hs                                         C                             KKLMKSDKKIAVISTKLFTEKQRMKYFLSTLPTRPEPELP VENLNSIELNRKYIPKTAIRIPTSNPQTS
18A_Gg                                         .                             ........................................ .............................
18A_Pg                                         C                             KKLTKSDKKIAVISTKLFTEKQRMKYFLSTLPTRPEPELP VENLNSIELNRKYIPKTAIRIPTSNPQTS
18A_Nl                                         C                             KKLMKSDEKIAMISTMLLMEKQQIKYFLSTLPMTPDPELP VXNLNSIGLDRKYSPKTAIRIPTSNPQPS
980       990                                                           
18A_Hs   C                                                                   NN KNFLTEVLLC.........................................................
18A_Gg   .                                                                   .. ...................................................................
18A_Pg   C                                                                   NN KNSLTEVLLC.........................................................
18A_Nl   C                                                                   NN KNSLTEMEPDCVEQIITETKKTFAVLGTCSRLLSSLESTATEEAQASLPITRSLVPNRRTAAASTEM
                                                                      
18A_Hs ..............................................                        
18A_Gg ..............................................                        
18A_Pg ..............................................                        
18A_Nl SQLLYKGVPFQSRTNRPGGVRSPGLQLEGTSTLQWEQGPIAHPRHR                        
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